Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof

ABSTRACT

The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.

This application claims the benefit of U.S. Provisional Application 60/461,787, filed Apr. 10, 2003, and 60/547,265, filed Feb. 24, 2004. These applications are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to a soluble and stable form of human Double Minute 2 protein, Hdm2. The present invention further pertains to nucleic acids encoding these proteins. The present invention also relates to a process of obtaining specific samples of Hdm2 that are amenable to forming homogeneous crystals for X-ray crystallization analysis and the crystals formed thereby. The present invention also pertains to methods of using the X-ray diffractable crystals in structure-based drug design to identify compounds that can modulate the activity of the protein.

BACKGROUND OF THE INVENTION

The most commonly inactivated tumor suppressor gene in human cancer encodes the p53 protein, a transcription factor that is intimately involved in maintaining the integrity of the genome in a cell [Hall and Peters, Adv. Cancer Res., 68:67-108 (1996); Hainaut et al., Nucleic Acid Res., 25:151-157 (1997); Sherr, Cancer Res., 60:3689-95 (2000)]. In response to oncogenic stress signals, the cell triggers the p53 transcription factor to initiate either apoptosis or cell cycle arrest. Apoptosis facilitates the elimination of damaged cells from the organism, while cell cycle arrest enables damaged cells to repair genetic damage [reviewed in Ko et al., Genes & Devel. 10:1054-1072 (1996); Levine, Cell 88:323-331 (1997)]. The loss of the safeguard functions of p53 predisposes damaged cells to progress to a cancerous state. Inactivating p53 in mice consistently leads to an unusually high rate of tumors [Donehower et al., Nature, 356:215-221 (1992)].

The p53 transcription factor promotes the expression of a number of cell cycle regulatory genes, including the gene encoding the Mouse Double Minute (Mdm2) protein [see, Chene, Nature Reviews Cancer 3:102-109 (2003)]. The Mdm2 protein (designated Hdm2 in humans and Mdm2 in mice) acts to down-regulate p53 activity in an auto-regulatory manner [Wu et al, Genes Dev., 7:1126-1132 (1993); Bairak et al., EMBO J, 12:461-468 (1993)]. In the absence of oncogenic stress signals, i.e., under normal cellular conditions, the Mdm2 protein serves to maintain p53 activity at low levels [Wu et al, Genes Dev., 7:1126-1132 (1993); Barak et al., EMBO J, 12:461-468 (1993)].

Interestingly, whereas Mdm2 negative (Mdm2^(−/−)) mice are not viable [Jones et al, Nature, 378:206-208 (1995); Montes de Oca Luna et al., Nature, 378:203-206 (1995)], additional inactivation of the p53 gene rescues Mdm2^(−/−) mice [Jones et al, Nature, 378:206-208 (1995); Montes de Oca Luna et al., Nature, 378:203-206 (1995)]. These results indicate that the misregulation of the p53 transcription factor in the Mdm2 negative mice is the root cause of the observed lethality of the Mdm2^(−/−) genotype, and that the regulation of p53 function relies on an appropriate balance between the two components of this p53-Mdm2 auto-regulatory system. Indeed, this balance appears to be essential for cell survival.

There are at least three ways that Mdm2 acts to downregulate p53 activity. First, Mdm2 can bind to the N-terminal transcriptional activation domain of p53 to block expression of p53-responsive genes [Kussie et al., Science, 274:948-953 (1996); Oliner et al., Nature, 362:857-860 (1993); Momand et al, Cell, 69:1237-1245 (1992)]. Second, Mdm2 shuttles p53 from the nucleus to the cytoplasm to facilitate the proteolytic degradation of p53 [Roth et al, EMBO J, 17:554-564 (1998); Freedman et al., Mol Cell Biol, 18:7288-7293 (1998); Tao and Levine, Proc. Natl. Acad. Sci. 96:3077-3080 (1999)]. Finally, Mdm2 possesses an intrinsic E3 ligase activity for conjugating ubiquitin to p53 within the ubiquitin-dependent 26S proteosome pathway [Honda et al., FEBS Lett, 420:25-27 (1997); Yasuda, Oncogene 19:1473-1476 (2000)]. Thus, Mdm2 impedes the ability of the p53 transcription factor to promote the expression of its target genes through binding p53 in the nucleus.

Attenuating the p53-Mdm2 auto-regulatory system can have a critical effect on cell homeostasis. Consistently, a correlation between the overexpression of Mdm2 and tumor formation has been reported [Chene, Nature 3:102-109 (2003)]. Since Mdm2 acts as a post-translational regulatory effector of the p53 transcription factor, compounds that hinder the ability of Hdm2/Mdm2, to interact with p53 would be anticipated to cause an immediate increase in p53 activity, and thereby rapidly promote either cell cycle arrest or apoptosis in damaged cells. Not surprisingly then, there is currently a substantial effort being made to identify new anticancer agents that hinder the ability of Hdm2 to interact with p53 [Chene, Nature 3:102-109 (2003)]. However, to date, no suitable anticancer agent has been found.

Structure-based drug design is one way to optimize the success of identifying useful antagonists of Hdm2, but use of this powerful methodology requires the three-dimensional structure of the target protein. So far, little information has been provided regarding the three-dimensional structure of Hdm2. Indeed, the only structures of Mdm2 currently available are those of Hdm2 and Xenopus Mdm2 (XMdm2), complexed with a p53 peptide, but neither crystalline form is suitable for structure-based drug design [Kussie, et al. Science, 274(5289): 948-953 (1996)]. Moreover, most of the protein-protein contacts in these crystal lattices are formed through the interaction of the exposed residues in the bound p53 peptide (D21, K24, and L25), making the p53 peptide difficult to displace, which makes it inaccessible to potential inhibitors.

In direct contrast, a successful structure-based drug design program focusing on Hdm2 requires a form of the Hdm2 protein that is amenable to crystallization in the absence of any particular binding partner. Further, the crystal form of the p53-binding pocket of the Hdm2 protein should be accessible to potential inhibitors used for testing binding or for co-structural determination. However, up until now, the solubility and stability of the free Hdm2 protein has been significantly less than that of the Hdm2-p53 peptide complex.

Thus, there is a need to obtain nucleic acids that encode an Hdm2 protein that is soluble and stable at high protein concentrations even when the protein is free of p53 or fragments thereof. In addition, there is a need to design purification procedures that lead to the preparation of an isolated active Hdm2 protein that is soluble and stable when independent of p53 or fragments thereof. In addition, there is a need to obtain reproducible crystals of Hdm2 that are of sufficient quality for X-ray crystallization analyses and structural determinations. There is also a need to provide methods for identifying inhibitors of Hdm2 through structure-based drug design and for combining potential inhibitors with the crystals of Hdm2 and analyzing their binding. Further, there is a need to obtain Hdm2 protein samples that, when combined with potential inhibitors, are amenable to forming homogenous crystals.

SUMMARY OF THE INVENTION

The present invention provides modified Hdm2 proteins that are amenable to crystallization and are soluble in E. coli extracts. The present invention further discloses a set of amino acid substitutions of the Hdm2 protein that improve its solubility and/or stability without compromising its ability to bind p53. It is a further object of the present invention to provide a modified Hdm2 protein having an amino acid substitution at one or more of the seven sites defined in Table 1. In one embodiment, the modified Hdm2 protein comprises the amino acid of SEQ ID NO: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2) or said amino acid sequence comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In other embodiments, the modified Hdm2 protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 6, 8 10 and 12; or said amino acid sequence comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4.

The present invention further provides isolated and/or recombinant nucleic acids that encode the modified Hdm2 proteins of the present invention, as well as specific peptide fragments and fusion proteins thereof. In one embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid of SEQ ID NO: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2) or said amino acid sequence comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In other embodiments, the nucleic acid encodes a modified Hdm2 protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 6, 8 10 and 12; or said amino acid sequence comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In certain embodiments, the nucleic acid may comprise a nucleotide sequence selected from the group consisting of SEQ ID NOS: 5, 7, 9 and 11. The present invention further provides expression vectors that can comprise any of the nucleic acids of the present invention and a transcriptional control sequence. Preferably the nucleic acids of the present invention are operatively linked to a transcriptional control sequence in expression vectors. Host cells comprising the expression vectors are also part of the present invention. In one particular embodiment, the host cell is an E coli, cell.

In addition, the present invention provides methods for producing the above-mentioned modified Hdm2 proteins. One such embodiment comprises culturing a host cell of the present invention that expresses a nucleic acid encoding a modified Hdm2 protein of the present invention, thereby producing the modified Hdm2 protein. Methods for purifying and/or obtaining the resulting recombinant modified Hdm2 proteins are also included in the present invention, as are the purified recombinant modified Hdm2 proteins.

The present invention further provides compounds that bind to Hdm2. In one such embodiment the compound is an acetylated tripeptide. In a particular embodiment of this type the compound is Ac-^(6Cl)WAC_(3c)E. In another embodiment the compound is Ac-^(6Br)WAC_(3c)E.

The present invention further provides protein-ligand complexes between the modified Hdm2 proteins of the present invention and their ligands. Preferred ligands in the complex are Ac-^(6Cl)WAC_(3c)E and Ac-^(6Br)WAC_(3c)E.

Crystals comprising a modified Hdm2 protein, and/or one of the protein-ligand complexes of the present invention, also are part of the present invention. Preferably, such crystals effectively diffract X-rays for the determination of the atomic coordinates of the protein and/or of the protein-ligand complex to a resolution of greater than 5.0 Å (e.g., at least 3.0 Å, at least 2.5 Å, at least 2.0 Å, or at least 1.5 Å).

The invention provides a crystal comprising a polypeptide selected from (a) a modified Hdm2 protein, characterized by structural coordinates comprising a root mean square deviation of conserved residue backbone atoms of less than about 1.5 Å (e.g., less than about 1.0 Å, less than about 0.5 Å, or less than about 0.1 Å) when superimposed on backbone atoms described by structural coordinates of Table 3 or (b) a modified Hdm2 protein characterized by structural coordinates comprising a root mean square deviation of conserved residue backbone atoms of less than about 1.5 Å (e.g., less than about 1.0 Å, less than about 0.5 Å, or less than about 0.1 Å) when superimposed on backbone atoms described by structural coordinates of Table 4. In certain embodiments, the crystal may be complexed with a compound that binds to modified Hdm2 (e.g., SCH549128, Ac-^(6Cl)WAC_(3c)E or Ac-^(6Br)WAC_(3c)E)

The invention also provides the three-dimensional structure of the modified Hdm2 protein. In one embodiment, the three-dimensional structure is characterized by structural coordinates comprising a root mean square deviation of conserved residue backbone atoms of less than about 1.5 Å (e.g., less than about 1.0 Å, less than about 0.5 Å, or less than about 0.1 Å) when superimposed on backbone atoms described by structural coordinates of Table 3 or 4. The present invention further provides methods of using this three-dimensional structural information in drug discovery and/or to solve corresponding structures of Hdm2 homologues, other crystalline forms of Hdm2 mutants, and co-complexes of Hdm2 and its ligands.

In another aspect of the present invention, methods are provided for obtaining a crystal comprising a modified Hdm2 protein. In one embodiment, the crystal is obtained by vapor diffusion.

In another aspect, the present invention provides a crystalline form of Hdm2 protein that is amenable to ligand soaking experiments, which enables X-ray crystallographic structural determinations to be performed on multiple Hdm2-ligand complexes in rapid succession.

The present invention further provides methods of obtaining a crystal comprising a protein-ligand complex between a ligand and a polypeptide comprising a modified Hdm2 protein. The present invention further provides methods for exchanging ligands within a crystal.

In yet another aspect, the present invention provides a method for designing, selecting and/or optimizing a compound and then evaluating it for use as an inhibitor of Hdm2. One such embodiment comprises obtaining a set of atomic coordinates that define the three-dimensional structure of the modified Hdm2 protein from a crystal of the present invention. In a related embodiment, a set of atomic coordinates that define the three-dimensional structure of the protein-ligand binding complex from a crystal of the present invention is obtained. In either case, a potential agent is then designed, selected or optimized by performing structure-based drug design with the atomic coordinates obtained. Preferably, the design or selection is performed in conjunction with computer modeling.

In another aspect, the invention provides a method for evaluating the ability of a potential inhibitor to associate with Hdm2 comprising employing computational means to perform a fitting operation between the potential inhibitor and the structure coordinates of Hdm2 and quantitating the association between the potential inhibitor and Hdm2.

A compound that is predicted to inhibit Hdm2 can be synthesized, if necessary, and subsequently contacted with Hdm2 or an active fragment thereof. The activity of the compound is then determined by an assay that measures one or more of Hdm2's activities, as described above. A compound that is predicted to inhibit Hdm2 is identified as an inhibitor of Hdm2 when there is a decrease in the activity of Hdm2 in the presence of the agent relative to in its absence.

In a related aspect of the present invention, a computer is provided that comprises a three-dimensional representation of a modified Hdm2 protein in computer memory. One such computer comprises a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, comprising the atomic coordinates of Table 3 or 4. In another embodiment, the computer comprises a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, comprising the atomic coordinates of Table 3 or 4. In yet another embodiment, the computer comprises a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, comprising the atomic coordinates of Table 3 or 4. Preferably, the computer further comprises a working memory for storing instructions for processing the machine-readable data, a central-processing unit coupled to the working memory and to the machine-readable data storage medium for processing the machine readable data into a three-dimensional representation of the modified Hdm2 protein and/or Hdm2 protein-ligand complex. More preferably, the computer includes a display coupled to the central-processing unit for displaying the three-dimensional representation.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides stable modified Hdm2 proteins produced by introducing an amino acid substitution into one or more of a unique set of amino acid residues of Hdm2. The modified Hdm2 proteins of the present invention have an improved solubility and form novel crystals that heretofore were unattainable with the wild-type Hdm2 protein. The present invention further provides methods for generating and purifying these modified Hdm2 proteins. The modified Hdm2 proteins of the present invention may be used for the structural determination of Hdm2 by X-ray crystallography and/or NMR.

Crystals of the modified Hdm2 protein and their resulting structures can be used to design high affinity inhibitors of Hdm2 that may be used in the treatment of cancer. Such drugs may be particularly useful to treat soft-tissue tumors, osteosarcomas and oesophageal carcinomas.

Structure-based drug design is the most efficient method for such drug development. In one common paradigm, a three dimensional structure is determined for a protein, e.g., the modified Hdm2, and/or a corresponding protein-ligand complex. Potential antagonists (e.g., inhibitors and/or potential drugs) of the protein are then identified and/or designed with the aid of computer modeling [Bugg et al., Scientific American, December: 92-98 (1993); West et al., TIPS, 16:67-74 (1995); Dunbrack et al., Folding & Design, 2:27-42 (1997)]. The drug candidates are then selected and tested. The most promising drug candidates are identified and then combined with the protein in a crystalline protein-ligand complex. The three-dimensional structure of the protein-ligand complex is then determined, and new potential antagonists of the protein are identified and/or designed with the aid of computer modeling. This process can then be continued in successive iterations until a lead drug candidate is identified.

Heretofore, the ability to perform structure based drug design with Hdm2 was severely hampered due to the lack of a crystalline form of the Hdm2 that is conducive for such studies. The expression and purification of a modified Hdm2 protein that when placed in a protein-ligand complex can form a monodisperse preparation, as disclosed herein, is therefore critical for the initiation of a structure based drug design program.

In addition, the present invention provides two specific ligands for Hdm2, the acetylated tripeptides, Ac-^(6Cl)WAC_(3c)E and Ac-^(6Br)WAC_(3c)E. Their precise chemical structures are provided below. These tripeptides can be used to bind the modified Hdm2 proteins of the present invention to form a protein-ligand complex that is then crystallized. Such X-ray diffractable crystals can be used for structure based drug design to identify anti-tumor drugs.

Patches of hydrophobic amino acid residues on the surface of the Hdm2 protein were initially determined to be a critical factor leading to the relative insolubility of the wild-type Hdm2 protein. Interrupting these hydrophobic patches by replacing selected surface hydrophobic amino acid residues with hydrophilic amino acid alternatives were found to increase the solubility of the ensuing modified Hdm2 protein, as well as create new crystal contact sites.

The present invention therefore provides several approaches for identifying appropriate hydrophobic amino acid residues to be replaced by more hydrophilic alternatives. One such approach entails employing the Clustalw program to align the amino acid sequences of Hdm2 and Hdm4 analogs from a number of species to identify natural amino acid variations. In one particular alignment, protocol Hdm2 or Hdm4 sequences from the following species were used: Brachydanio rerio (Zebrafish), Canis familiaris (Dog), Equus caballus (Horse), Homo sapiens (Human), Mesocricetus auratus (Golden Hamster), Mus musculus (Mouse), Xenopus laevis (African Clawed Frog) and Gallus gallus (Chicken). Seven Hdm2 surface amino acid residues in the hydrophobic patches of Hdm2 were identified and the preferred alternative amino acids at those sites noted, see Table 1 below. In a related approach, the seven amino acid substitutions were selected to specifically increase Hdm2 solubility, see modified Hdm2 (HK₅) having the amino acid sequence of SEQ ID NO: 12.

In still another approach, the amino acid sequences of Hdm2 and XMdm2 were compared to identify the positions of surface, solvent exposed, hydrophobic amino acid residues of the human protein that were occupied by more hydrophilic residues in the corresponding Xenopus laevis amino acid sequence. From this protein surface analysis, four potential amino acid substitutions were chosen: Human: Xenopus laevis: F55Y, Y76H, Y104S, V109S.

In accordance with the present invention, there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein “Sambrook et al., 1989”); DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization [B. D. Hames & S. J. Higgins eds. (1985)]; Transcription And Translation [B. D. Hames & S. J. Higgins, eds. (1984)]; Animal Cell Culture [R. I. Freshney, ed. (1986)]; Immobilized Cells And Enzymes [IRL Press, (1986)]; B. Perbal, A Practical Guide To Molecular Cloning (1984); F. M. Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1996) (herein “Ausubel et al., 1996”).

As used herein the following terms shall have the definitions set out below:

As used herein the term “polypeptide” is used interchangeably with the term “protein” and is further meant to encompass peptides. Therefore, as used herein, a polypeptide is a polymer of two or more amino acids joined together by peptide linkages. Preferably, a polypeptide is a polymer comprising twenty or more amino acid residues joined together by peptide linkages, whereas a peptide comprises five to twenty amino acid residues joined together by peptide linkages.

As used herein a polypeptide “consisting essentially of” or that “consists essentially of” a specified amino acid sequence is a polypeptide that

-   -   (i) retains an important characteristic of the polypeptide         comprising that amino acid sequence, e.g., the ability to bind         p53 and/or act as a ligase for conjugating ubiquitin to p53, and     -   (ii) further comprises the identical amino acid sequence, except         it consists of plus or minus 10% (or a lower percentage), and         preferably plus or minus 5% (or a lower percentage) of the amino         acid residues. In a particular embodiment, additional amino acid         residues included as part of the polypeptide are part of a         linked Tag, such as a C-terminal His₆ Tag.

The term “generic Mdm2” is used herein to refer to the double minute 2 polypeptide from any species. When used by itself, Mdm2 refers to mouse Mdm2. When used with another species name appended to it, it refers to the Mdm2 ortholog from the named species, e.g., Xenopus Mdm2 refers to the Mdm2 ortholog from Xenopus. “Mdm2” also encompass modified forms thereof.

As used herein the terms “human Mdm2” and “Hdm2” are used interchangeably to denote the human ortholog of Mdm2. “Hdm2” also encompass modified forms thereof. Hdm2 has the GenBank accession number of M92424. Mouse Mdm2 has the GenBank accession number of X58876 [see also, published U.S. patent application 2002/0045192, published Apr. 18, 2002, the contents of which are hereby incorporated by reference in their entirety.] The amino acid sequences provided herein correspond to amino acid residues 17-125 of the full-length Hdm2 protein and retain their numerical designation from that full-length sequence. Therefore, the first amino acid residue of the wild-type Hdm2(17-125) sequence, SEQ ID NO: 2, corresponds to amino acid 17 of the full-length Hdm2 protein.

As used herein a “modified Hdm2” is identical to the wild-type Hdm2(17-125) except it has at least one amino acid substitution, i.e., it has one or more amino acid substitutions. Furthermore, a modified Hmd2 of the present invention comprises an amino acid substitution at one or more of the seven positions listed in Table 1 and denoted in SEQ ID NO: 4. Preferably, that amino acid substitution is one that is specifically defined in Table 1 (and denoted in SEQ ID NO: 4). It is also preferable that a modified Hdm2 protein of the present invention comprises 109 amino acid residues and that the positions of these 109 residues correspond to amino acid residues 17-125 of the full-length wild-type Hdm2 protein.

As used herein, a “conservative amino acid substitution” is the substitution of a functionally equivalent amino acid for an amino acid within the sequence of Hdm2. The conservative amino acid substitution can be at any position in the Hdm2 sequence except for the seven positions identified in Table 1, for which the alternatives are specifically defined. In general, a functionally equivalent amino acid is one having a similar polarity and/or molecular properties for the amino acid within the sequence. Specifically, an amino acid substitute may be selected from other members of the class to which the amino acid belongs. The class of nonpolar amino acids includes alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The class of polar neutral amino acids includes glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The class of positively charged (basic) amino acids includes arginine, and lysine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Particularly preferred conserved amino acid exchanges are:

-   -   (a) Lys for Arg or vice versa such that a positive charge may be         maintained;     -   (b) Glu for Asp or vice versa such that a negative charge may be         maintained;     -   (c) Ser for Thr or vice versa such that a free —OH can be         maintained;     -   (d) Gin for Asn or vice versa such that a free NH₂ can be         maintained; and     -   (e) Ile for Leu or for Val or vice versa as roughly equivalent         hydrophobic amino acids.

As used herein the term “specific peptide fragment” is a peptide that comprises at least six amino acid residues, and preferably at least twelve amino acid residues of a modified Hdm2 protein that differs from the corresponding fragment of the wild-type Hdm2 by at least one amino acid residue. Furthermore, the different amino acid residue (or different residues) is located at a position that corresponds to one (or more) of the seven variable sites denoted in SEQ ID NO: 4 and listed Table 1 below.

As used herein the term “chimeric” protein is meant to include fusion proteins. “Chimeric” proteins of the present invention comprise at least a portion of a non-Hdm2 protein or peptide joined via a peptide bond to at least a portion of an Hdm2 protein, preferably a modified Hdm2. Chimeric proteins can have additional structural, regulatory, and/or catalytic properties. As used herein a chimeric protein can contain multiple additions to at least a portion of a modified Hdm2 protein, e.g., it can comprise both a His₆Tag and a signal sequence. In a particular embodiment the chimeric protein functions as a means of detecting and/or isolating the polypeptide or fragment thereof after a recombinant nucleic acid encoding the modified Hdm2 protein or fragment thereof is expressed. Non-Hdm2 amino acid sequences are preferably either amino- or carboxy-terminal to the modified Hdm2 sequence.

As used herein, DNA and protein sequence percent identity can be determined using C, MacVector 6.0.1, Vector NTI (Informax, Inc. MD), Oxford Molecular Group PLC (1996) and the Clustal W algorithm with the alignment default parameters, and default parameters for identity. These commercially available programs can also be used to determine sequence similarity using the same or analogous default parameters. Alternatively, an Advanced Blast search under the default filter conditions can be used, e.g., using the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wis.) pileup program using the default parameters.

As used herein a “nucleic acid” refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; “RNA molecules”) or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; “DNA molecules”), or any phosphoester analogs thereof, such as phosphorothioates and thioesters, in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. When referring to a nucleic acid that is double stranded both the “sense” strand and the complementary “antisense” strand are intended to be included. Thus a nucleic acid that is hybridizable to SEQ ID NO: 1, for example, can be either hybridizable to the “sense” strand of SEQ ID NO: 1, which is particularly listed in the SEQUENCE LISTING, or to the “antisense” strand which can be readily determined from that SEQUENCE LISTING.

A DNA “coding sequence” is a double-stranded DNA sequence that is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3′ to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. In eukaryotic cells, polyadenylation signals are control sequences.

A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.

A coding sequence is “under the control” of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which can then be trans-RNA spliced and translated into the protein encoded by the coding sequence.

A nucleic acid sequence is “operatively linked” to an expression control sequence when the expression control sequence controls or regulates the transcription and translation of that nucleic acid sequence. The term operatively linked includes having an appropriate start signal.

A “heterologous nucleotide sequence” as used herein is a nucleotide sequence that is added by recombinant methods to a nucleotide sequence encoding a modified Hdm2 of the present invention or encoding a fragment thereof, to form a nucleic acid that is not naturally formed in nature. Such nucleic acids can encode chimeric proteins. In addition, as used herein, a heterologous nucleotide sequence need not be a single contiguous nucleotide sequence, but can include multiple non-contiguous nucleotide sequences that have been combined with a nucleotide sequence encoding a modified Hdm2 protein of the present invention, or a portion thereof. A heterologous nucleotide sequence can comprise non-coding sequences including restriction sites, regulatory sites, promoters and the like. In still another embodiment the heterologous nucleotide can function as a means of detecting a nucleotide sequence of the present invention. The present invention provides heterologous nucleotide sequences that, when combined with nucleotide sequences encoding a modified Hdm2 protein or a fragment thereof, are necessary and sufficient to encode all of the chimeric proteins of the present invention.

The phrase “binding to” in regard to a ligand binding to a polypeptide is used herein to include any or all such specific interactions that lead to a protein-ligand binding complex. This can include processes such as covalent, ionic (electrostatic and/or charged), hydrophobic and hydrogen bonding, but does not include non-specific associations such solvent preferences.

As used herein a “ligand” of a Mdm2 protein, e.g., a modified Hdm2 protein, is a compound that binds to the polypeptide in a protein-ligand binding complex. In a specific embodiment of the present invention the ligand inhibits the ability of the Mdm2 protein to bind p53 when the ligand is bound to the Mdm2 protein in a protein-ligand binding complex. In another embodiment, the ligand inhibits the ability of Mdm2 to act as an E3 ligase for conjugating ubiquitin to p53 when the ligand is bound to the Mdm2 protein in a protein-ligand binding complex. Such ligands may also be termed an “inhibitor”.

As used herein, a “protein-ligand binding complex” or polypeptide-compound complex” is a specific association between a polypeptide and the compound that binds to it. In a preferred embodiment of the present invention, the ligand or compound is an inhibitor of the polypeptide. In a particular embodiment of this type, the binding of the inhibitor to the polypeptide occurs at the active site of the polypeptide.

As used herein “incubating a ligand with a crystal” is used interchangeably with “soaking a crystal with a ligand”. Incubating a ligand with a crystal is the contacting of a ligand with a crystal of a polypeptide under the appropriate conditions and for a sufficient time period (e.g., hours to several days) for the ligand to bind to the crystalline polypeptide and form a crystalline protein-ligand complex. Such incubating can further include contacting an excess of a substitute ligand with a crystal of a protein-ligand complex under the appropriate conditions and for a sufficient time period (e.g., hours to several days) for the substitute ligand to replace the initial ligand and form the new crystalline protein-ligand complex.

As used herein the terms “displacing”, “replacing”, and “exchanging” are used interchangeably in regard to the substitution of one ligand in a protein-ligand complex for another.

As used herein an “excess of a substitute ligand” is an amount of that ligand that is sufficient to replace 80% or more, and preferably 90% or more, of the initial ligand in a protein-ligand complex. In a particular embodiment of this type, the concentration of the substitute ligand is about ten-fold higher than the concentration of the protein-ligand complex. In a preferred embodiment, the concentration of the substitute ligand is about one hundred-fold higher than the concentration of the protein-ligand complex.

As used herein the term “X-ray diffractable crystal” is a crystal of a compound, e.g., a protein that yields a discernable diffraction pattern when subjected to 0.5 to 2.5 Å incident X-ray radiation.

As used herein an “X-ray quality crystal” is an X-ray diffractable crystal that can yield meaningful structural data of its crystalline composition when subjected to X-ray crystallographic analysis.

As used herein, and unless otherwise specified, the terms “agent”, “potential drug”, “compound”, or “test compound” are used interchangeably, and refer to chemicals that have or potentially have a use as a modulator of the activity of Mdm2. Preferably the modulator is an inhibitor of the binding complex formed between p53 and Mdm2. Preferably such agents include drugs for the treatment or prevention of a disease and/or condition involving the p53 transcription factor, e.g., cancer. Therefore, such agents may be used, as described herein, in drug assays and drug screens and the like.

As used herein a “small organic molecule” is an organic compound [or organic compound complexed with an inorganic compound (e.g., metal)] that has a molecular weight of less than 3 Kd.

As used herein the terms “approximately” and “about” are used to signify that a value is within twenty percent of the indicated value i.e., an amino acid sequence containing “approximately” 110 amino acid residues can contain between 88 and 132 amino acid residues.

As used herein the phrases “structure based rational drug design”, “structure based drug design” and “structure assisted drug design” are used interchangeably. These phrases are meant to convey a particular method of identifying and/or designing a ligand (preferably an inhibitor) for a specific target protein that includes the use of the three-dimensional structure of that protein and/or its corresponding protein-ligand complex.

Nucleic Acids Encoding Mdm2 Proteins

The nucleic acids can further comprise heterologous nucleotide sequences. In one embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid of SEQ ID NO: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2). In a particular embodiment of this type the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 3, wherein at least one nucleotide of one of the codons encoding one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from the nucleic acid sequence of wild-type Hdm2(17-125) (SEQ ID NO: 1) and wherein said codon encodes a different amino acid from that of wild-type Hdm2(17-125) (SEQ ID NO: 2).

In one embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid sequence of SEQ ID NO: 6. In a particular embodiment of this type, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 5. In another embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid sequence of SEQ ID NO: 8. In a particular embodiment of this type, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 7. In still another embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid sequence of SEQ ID NO: 10. In a particular embodiment of this type, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 9. In yet another embodiment, the nucleic acid encodes a modified Hdm2 protein comprising the amino acid sequence of SEQ ID NO: 12. In a particular embodiment of this type, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 11. Nucleic acids that consist of the nucleotide sequences that encode the modified Hdm2 proteins of the present invention or that consist of nucleotide sequences that encode specific peptide fragments of those proteins are also provided. The present invention also includes those nucleic acids that encode a modified Hdm2 comprising one or more conservative amino acid substitutions. In certain embodiments, there may be 1-11 conservative amino acid substitutions, preferably 1, 2 or 3 conservative amino acid substitutions. In a related embodiment, the present invention provides nucleic acids that further comprise a heterologous nucleotide sequence.

Obtaining and/or constructing a cDNA that encodes a Mdm2 protein, including Hdm2 proteins and the modified Hdm2 proteins of the present invention, facilitates the production of the large quantities of protein required to perform standard enzyme assays and/or X-ray crystallographic analysis.

The present invention provides specific nucleic acid constructs that allow for the expression and isolation of large quantities of stable and active modified Hmd2 proteins. These nucleic acids can further contain heterologous nucleotide sequences. To express a recombinant protein of the present invention in a host cell, an expression vector can be constructed comprising the corresponding cDNA. The present invention therefore, provides expression vectors containing nucleic acids encoding the modified Hmd2 proteins of the present invention. Due to the degeneracy of nucleotide coding sequences, other DNA sequences that encode the same or substantially the same amino acid sequence as a nucleic acid encoding a modified Hmd2 protein of the present invention may be used in the practice of the present invention. These include, but are not limited to, allelic genes, homologous genes from other species, which are altered by the substitution of different codons that encode the same amino acid residue within the sequence, thus producing a silent change. Host cells comprising the expression vectors of the present invention are also provided. One particular host cell, an E. coli cell, is specifically exemplified below.

General methods for the cloning of cDNAs and expression of their corresponding recombinant proteins have been described [see Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3 edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor L.I. (2000)]. The particular methodology used herein is described in Example 1 below. Preferably, all of the nucleic acid constructs of the present invention are sequence confirmed.

Any technique for mutagenesis known in the art can be used to convert the native (wild-type) Hdm2 to a modified Hdm2 of the present invention, including but not limited to, in vitro site-directed mutagenesis [Hutchinson et al., J. Biol. Chem., 253:6551 (1978); Zoller and Smith, DNA, 3:479-488 (1984); Oliphant et al., Gene, 44:177 (1986); Hutchinson et al., Proc. Natl. Acad. Sci. U.S.A., 83:710 (1986)]. The use of TAB@ linkers (Pharmacia), etc. and PCR techniques also can be employed for site directed mutagenesis [see Higuchi, “Using PCR to Engineer DNA”, in PCR Technology: Principles and Applications for DNA Amplification, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70 (1989)].

Preferably mutagenesis (i.e., modification) of an Hdm2 transcript is performed in a two step process [Wang and Malcolm, BioTechniques 26:680-682 (1999)]. In Examples 2 and 3 below, two extension reactions were performed in separate tubes in the first stage: (i) one containing the forward primer, and (ii) the other containing the reverse primer. After two cycles, the two reactions are mixed and the standard QuickChange mutagenesis procedure was carried out for an additional 18 cycles. Following amplification, the parental strand was digested with 1 Unit of Dpn1 for 2 hours and an aliquot was transformed into DH5-alpha cells [GeneWiz, New York, N.Y.]. The pET32 Xa/LIC-hdm2 (17-125) vector was used as a template.

When the modified Hdm2 has three amino acid substitutions, as described in the Example 1 below, the GENETAILOR Site-directed Mutagenesis system (Invitrogen, Carlsbad, Calif., USA) was used with the pET32 Xa/LIC-hdm2 (17-125) as the template. In this case the GENETAILOR mutagenesis was performed according to the manufacture's instruction manual, with the lone exception being the use of the pfu turbo DNA polymerase.

The Modified Hdm2 Proteins

In one embodiment, the modified Hdm2 polypeptide of the invention comprises the amino acid sequence SEQ ID NO: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2). In another embodiment, the modified Hdm2 polypeptide comprises one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In certain embodiments, there may be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 conservative amino acid substitutions in the sequence at sites other than those indicated in Table 1. In preferred embodiments, there may be 1, 2 or 3 conservative amino acid substitutions at sites other than those indicated in Table 1.

In particular embodiments, the amino acid residues at all seven of the variable positions in the amino acid sequence of SEQ ID NO: 4 are different than that of SEQ ID NO: 2. In a specific embodiment of this type, the modified Hdm2 protein is the Hdm2(HK5) comprising the amino acid sequence of SEQ ID NO: 12 or said modified Hdm2 protein comprising the amino acid sequence of SEQ ID NO: 12 comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4 as described above. In other embodiments, the modified Hdm2 protein comprises the amino acid sequence SEQ ID NO: 4 wherein the amino acid residues at six, five, four or three of the seven variable positions (X₁-X₇) in the amino acid sequence of SEQ ID NO: 4 are different than that of SEQ ID NO: 2. In certain embodiments, the modified Hdm2 protein comprises one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4.

In yet another embodiment, the amino acid residues at two of the seven variable positions in the amino acid sequence of SEQ ID NO: 4 are different than that of SEQ ID NO: 2. In a particular embodiment of this type the modified Hdm2 protein is Hdm2(F55Y/Y76H) protein comprising the amino acid sequence of SEQ ID NO: 10 or said modified Hdm2 protein comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In another embodiment, only one of the amino acid residues at the seven variable positions in the amino acid sequence of SEQ ID NO: 4 is different than that of SEQ ID NO: 2. In a particular embodiment of this type, the modified Hdm2 protein is the Hdm2(F55Y) protein comprising the amino acid sequence of SEQ ID NO: 8 or said modified Hdm2 protein comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. In another particular embodiment, the modified Hdm2 protein is Hdm2(Y76H) protein comprising the amino acid sequence of SEQ ID NO: 6 or said modified Hdm2 protein comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4.

The present invention further provides a modified Hdm2 protein consisting of, or consisting essentially of, SEQ ID NOs: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2). In certain embodiments, said modified Hdm2 protein comprises one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. A modified Hdm2 protein is further provided that consists of, or consists essentially of, SEQ ID NOs: 6, 8, 10 or 12, or said modified Hdm2 protein comprising one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4.

Fusion proteins that comprise the modified Hdm2 proteins of the present invention are also provided, as well as specific peptide fragments of those proteins.

In one such embodiment, the modified Hdm2 protein comprises the amino acid sequence of SEQ ID NO: 4. In a preferred embodiment, the modified Hdm2 protein comprises the amino acid sequence of SEQ ID NO: 6. In one embodiment the compound is Ac-^(6Br)WAC_(3c)E. In a preferred embodiment, the compound is AC-^(6Cl)WAC_(3c)E.

The amino acid sequences of the wild-type (WT) Hdm2 and the following modified Hdm2 proteins corresponding to amino acid residues 17-125 of the full-length wild-type Hdm2 are provided below: WT Hdm2(17-125): SEQ ID NO: 2      SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRL YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGT SVSEN Modified Hdm2 (X₁-X₇): SEQ ID NO: 4      SQIPASEQETX ₁VRPKPX ₂LLKLLKSVGAQKDTYTMKEVLX ₃YLGQYIMTK RLYDEKQQHIVX ₄CSNDX ₅LGDLFGVX ₆SFSVKEHRKIYTMIX ₇RNLVVVNQQES SDSGTSVSEN Modified Hdm2 (Y76H): SEQ ID NO: 6      SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRL YDEKQQHIVHCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSG TSVSEN Modified Hdm2 (F55Y): SEQ ID NO: 8      SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLYYLGQYIMTKRL YDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGT SVSEN Modified Hdm2 (F55Y/Y76H): SEQ ID NO: 10      SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLYYLGQYIMTKRL YDEKQQHIVHCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSG TSVSEN Modified Hdm2 (HK₅): SEQ ID NO: 12      SQIPASEQETKVRPKPKLLKLLKSVGAQKDTYTMKEVLHYLGQYIMTKR LYDEKQQHIVKCSNDKLGDLFGVKSFSVKEHRKIYTMIYRNLVVVNQQESSDS GTSVSEN

Modified Hdm2 (HK₅) as indicated above has six amino acid substitutions (L27K, L33K, F55H, Y76K, L81 K, and P89K) selected to specifically increase Hdm2 solubility; only two are derived from natural variants.

Column 1 of Table 1 denotes the seven variable amino acid positions in the sequence of SEQ ID NO: 4, and presents the numbering of the amino acid positions in relation to both the full-length wild-type Hdm2 and the corresponding numbering of the wild-type Hdm2(17-125) having the amino acid sequence of SEQ ID NO: 2 (in parentheses). The seven defined positions in SEQ ID NO: 4 in which the amino acid residue can specifically vary are denoted as X₁-X₇ (column 2). The amino acid residues in the full-length wild-type Hmd2 occupying those seven positions are listed in column 3. All of the natural variants identified by the Clustalw alignment of the amino acid sequences of Hdm2 and Hdm4 analogs using Brachydanio rerio (Zebrafish), Canis familiaris (Dog), Equus caballus (Horse), Homo sapiens (Human), Mesocricetus auratus (Golden Hamster), Mus musculus (Mouse), Xenopus laevis (African Clawed Frog) and Gallus gallus (Chicken) are provided in column 4. All acceptable amino acids are listed in Column 5, including the amino acid residues for the seven respective positions of the wild-type Hmd2, which are in bold. TABLE 1 Amino Acid Substitutions for SEQ ID NO: 4 A.A. A.A. Species Position Name Hdm2 Variants Acceptable Variants  27 (11) X₁ L27 Q L, K, R, Q, E, D, S  33 (17) X₂ L33 Q L, K, R, Q, E, D, S  55 (39) X₃ F55 L, Y, H F, H, Y, K, R, Q, E, D, S  76 (60) X₄ Y76 H Y, H, K, R, Q, E, D, S  81 (65) X₅ L81 A, P, C L, K, R, Q, E, D, S, P, A  89 (73) X₆ P89 K, V, Q, T P, K, R, Q, E, D, S 104 (88) X₇ Y104 I, N, R, S Y, K, R, Q, E, D, S, N

In addition, the modified Hdm2 proteins of the present invention may include conservative amino acid substitutions relative to the wild type sequence of Hdm2 (other than those at the seven positions identified in Table 1, for which the alternatives are specifically defined). In general, there are no more than 11 conservative amino acid substitutions (e.g., no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 conservative amino acid substitutions). In a preferred embodiment, there are no more than 3 conservative amino acid substitutions (0, 1, 2 or 3).

All of the modified Hdm2 proteins of the present invention also can be part of a chimeric protein. In a specific embodiment, a chimeric modified Hdm2 protein is expressed in a prokaryotic cell. Such a chimeric protein can be a fusion protein used to isolate a modified Hdm2 protein of the present invention, through the use of an affinity column that is specific for the protein fused to the modified Hdm2 protein. Examples of such fusion proteins include: a glutathione-S-transferase (GST) fusion protein, a maltose-binding protein (MBP) fusion protein, a FLAG-tagged fusion protein, or a poly-histidine-tagged fusion protein. Specific linker sequences such as a Ser-Gly linker can also be part of such a fusion protein. A chimeric modified Hdm2 protein of the present invention also can be expressed in a eukaryotic cell.

Expression of a chimeric, modified Hdm2 protein, or fragment thereof, as a fusion protein can facilitate stable expression, and/or allow for purification based on the properties of the fusion partner. Thus the purification of the recombinant polypeptides of the present invention can be simplified through the use of fusion proteins having affinity Tags. For example, GST binds glutathione conjugated to a solid support matrix, MBP binds to a maltose matrix, and poly-histidine chelates to a Ni-chelation support matrix [see Hochuli et al., Biotechnology 6:1321-1325 (1998)]. The fusion protein can be eluted from the specific matrix with appropriate buffers, or by treating with a protease that is specific for a cleavage site that has been genetically engineered in between the modified Hdm2 protein and its fusion partner. Alternatively, a modified Hdm2 protein can be combined with a marker protein such as green fluorescent protein [Waldo et al., Nature Biotech. 17:691-695 (1999); U.S. Pat. No. 5,625,048 and WO 97/26333].

Alternatively or in addition, other column chromatography steps (e.g., gel filtration, ion exchange, affinity chromatography etc.) can be used to purify the recombinant modified Hdm2 proteins of the present invention. In many cases, such column chromatography steps employ high performance liquid chromatography or analogous methods in place of the more classical gravity-based procedures. The specific details for the preferred purification procedure of the modified Hdm2 proteins of the present invention are provided in Example 1 below.

In addition, the modified Hdm2 proteins of the present invention and proteins thereof including, specific peptide fragment thereof can be chemically synthesized [see e.g., Synthetic Peptides: A User's Guide, W.H.Freeman & Co., New York, N.Y., pp. 382, Grant, ed. (1992)].

Crystallization of Protein

The modified Hdm2 proteins result in novel crystal forms not obtained with the wild-type protein. In one embodiment, the modified Hdm2 protein may be crystallized in the presence of one of a variety of different compounds (e.g., an small molecule inhibitor or a peptide from p53). Further, a compound complexed to modified Hdm2 may be exchanged in the crystal by a second compound (e.g., a potential inhibitor) by soaking the crystal in a solution containing the second compound. These crystals and the resulting structures can be used to obtain a detailed view of various inhibitors that bind to Hdm2, providing a basis for further design of potent inhibitors of Hdm2 to be used as anticancer agents.

Crystallization may be accomplished by using any of the known methods in the art (Giegé, et al., (1994) Acta Crystallogr. D50: 339-350; McPherson, (1990) Eur. J. Biochem. 189: 1-23). Such techniques include microbatch, hanging drop, seeding and dialysis. Preferably, hanging-drop vapor diffusion (McPherson, (1976) J. Biol. Chem. 251: 6300-6303) or microbatch methods (Chayen (1997) Structure 5: 1269-1274) are used. In each of these methods, it is important to promote continued crystal growth after nucleation by maintaining a supersaturated solution. In the microbatch method, polypeptide is mixed with precipitants to achieve supersaturation, the vessel is sealed and set aside until crystals appear. In the dialysis method, polypeptide is retained in a sealed dialysis membrane that is placed into a solution containing precipitant. Equilibration across the membrane increases the precipitant concentration thereby causing the polypeptide to reach supersaturation levels. It is desirable to use a modified Hdm2 protein preparation having a concentration of at least about 1 mg/mL and preferably about 5 mg/mL to about 60 mg/mL, more preferably about 20 mg/mL to about 50 mg/mL, even more preferably about 30 mg/mL to about 40 mg/mL. Crystallization may be achieved in precipitant solutions containing polyethylene glycol 1000-20,000 (PEG; average molecular weight ranging from about 1000 to about 20,000 Da), preferably about 2000 to about 6000 Da, more preferably about 5000 Da, with concentrations ranging from about 10% to about 50% (w/v). It may also be desirable to include a protein stabilizing agent. If glycerol is chosen as the protein stabilizing agent, it is preferably provided at a concentration ranging from about 0.5% to about 20%. A suitable salt, such as magnesium chloride, potassium chloride, sodium chloride, lithium chloride or sodium citrate may also be desirable in the precipitant solution, preferably in a concentration ranging from about 1 mM to about 2000 mM. The precipitant is preferably buffered to a pH of from about 6.5 to about 9.5, preferably about 7.5-8.5. Specific buffers useful in the precipitant solution may vary and are well-known in the art (Scopes, Protein Purification: Principles and Practice, Third ed., (1994) Springer-Verlag, New York). Examples of useful buffers include, but are not limited to, Hepes, Tris, MES and acetate. Crystals routinely grow at a wide range of temperatures. It is, however, preferred that crystals form at temperatures between about 2° C. and about 26° C.

The crystals of the present invention have a wide range of uses. For example, high quality crystals are suitable for X-ray or neutron diffraction analysis to determine the three dimensional structure of Hdm2 and in particular to assist in the identification of the protein's effector sites. Knowledge of these sites and solvent accessible residues allow structure-based design and construction of agonists and antagonists for Hdm2.

In addition, crystallization itself can be used as a purification method. In some instances, a polypeptide or protein crystallizes from a heterogeneous mixture into crystals. Isolation of such crystals by filtration and/or centrifugation, followed by redissolving the polypeptide affords a purified solution suitable for use in growing high-quality crystals that are preferred for diffraction analysis.

Once a crystal of the present invention is grown, X-ray diffraction data can be collected. One method for determining structure with X-ray diffraction data includes use of synchrotron radiation, under standard cryogenic condition; however, alternative methods may also be used. For example, crystals can be characterized by using X-rays produced by a conventional source, such as a sealed tube or a rotating anode. Methods of characterization include, but are not limited to, precession photography, oscillation photography and diffractometer data collection.

The crystallizable compositions provided by this invention may be amenable to X-ray crystallography for providing the three-dimensional structure of a Hdm2 polypeptide. The present invention includes crystals which effectively diffract X-rays for the determination of the atomic coordinates of Hdm2 to a resolution of greater than about 5.0 Angstroms (e.g., about 4.5 Å, about 4.0 Å, about 3 Å, about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å, about 0.1 Å), preferably greater than about 4.0 Angströms (e.g., about 3 Å, about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å, about 0.1 Å), more preferably greater than about 2.8 Angströms (e.g., about 2.5 Å, about 2 Å, about 1 Å, about 0.5 Å, about 0.1 Å) and most preferably greater than about 2.0 Angströms (e.g., about 1.5 Å, about 1.0 Å, about 0.5 Å, about 0.1 Å).

The present invention includes Hdm2 crystals whose three-dimensional structure is described by the structure coordinates set forth in Table 3 or 4. The scope of the present invention also includes crystals which possess structural coordinates which are similar to those set forth in Table 3 or 4; preferably, the crystals or the soluble polypeptides which are used to form the crystals exhibit Hdm2 catalytic activity and/or p53 binding (see above). In some embodiments, the crystal comprises a polypeptide that comprises the amino acid sequence of SEQ ID NO: 4, wherein one or more of the seven specific amino acid residues denoted as X₁-X₇ of SEQ ID NO: 4 differs from that of wild-type Hdm2(17-125) (SEQ ID NO: 2). In other embodiments, the crystal comprises a polypeptide that comprises the amino acid sequence selected from the group consisting of SEQ ID NOS: 8 and 12. In another embodiment, the modified Hdm2 polypeptide comprises one or more conservative amino acid substitutions at sites other than that of X₁-X₇ of SEQ ID NO: 4. Structural similarity between crystals is discussed in detail below.

The term “structure coordinates” refers to Cartesian coordinates derived from mathematical equations related to the patterns obtained on diffraction of a beam of X-rays by the atoms (scattering centers) of a molecule. The diffraction data are used to calculate electron density maps and to establish the positions of the individual atoms of the molecule.

Those of skill in the art will understand that a set of structure coordinates for a protein or a protein complex or a portion thereof, is a relative set of points that define a shape in three dimensions. Thus, it is possible that an entirely different set of coordinates could define a similar or identical shape. Moreover, slight variations in the individual coordinates will have little effect on overall shape.

The present invention includes crystals exhibiting structure coordinates which are similar to those set forth in Table 3 or 4 but for crystallographic permutations of the structure coordinates, fractionalization of the structure coordinates, additions, subtractions, rotations or translations to sets of the structure coordinates or any combinations of the above.

Alternatively, modifications in the crystal structure due to mutations, additions, substitutions, and/or deletions of amino acids, or other changes in any of the components that make up the crystal may also account for variations in structure coordinates. If such variations are within an acceptable standard error as compared to the coordinates of Table 3 or 4, the resulting three-dimensional shape is considered to be the same and, accordingly, the modified crystal is considered to be within the scope of the present invention.

Various computational analyses may be necessary to determine whether a crystal is sufficiently similar to the crystals whose structural coordinates are set forth in Table 3 or 4 as to be considered the same. Such analyses may be carried out in current software applications, such as the Molecular Similarity application of QUANTA (Molecular Simulations Inc., San Diego, Calif.) version 4.1, and as described in the accompanying User's Guide.

The Molecular Similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure. In general, the procedure used in Molecular Similarity to compare structures is divided into four steps: 1) input the structures to be compared; 2) define the atom equivalences in these structures; 3) perform a fitting operation; and 4) analyze the results.

Each structure is identified by a name. One structure is identified as the target (i.e., the fixed structure); all remaining structures are working structures (i.e., moving structures). Since atom equivalency within QUANTA is defined by user input, for the purpose of this invention we will define equivalent atoms as protein backbone atoms (N, CA, C and O) for all conserved residues between the two structures being compared.

When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure. The fitting operation uses a least squares fitting algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atom is an absolute minimum. This number, given in Angströms, is reported by QUANTA.

The term “root mean square deviation” (RMSD) is a commonly known term in the art which, in general, means the square root of the arithmetic mean of the squares of the deviations from the mean distance of corresponding atoms. It is a way to express the deviation or variation from a trend or object.

For the purpose of this invention, any set of structure coordinates of a molecule that has a RMSD of conserved residue backbone atoms (N, CA, C, O) of less than about 2.0 Å when superimposed—using backbone atoms—on the relevant structure coordinates of Table 3 or 4 are considered identical and are within the scope of the present invention. Preferably the crystal is a modified Hdm2 protein as defined above. Preferably, the root mean square deviation is less than about 1.5 Å, more preferably less than 1.0 Å, even more preferably, the root mean square deviation is less than about 0.5 Å and most preferably, the root mean square deviation is less than about 0.1 Å.

The term “least squares” refers to a method based on the principle that the best estimate of a value is that in which the sum of the squares of the deviations of observed values is a minimum.

In one embodiment, the modified Hdm2 protein comprises the amino acid sequence of SEQ ID NO: 6. In a particular embodiment of this type, the crystal has the space group of P2₁2₁2₁, having unit cell dimensions of: a=41.1, b=66.1, c=96.1 Angstroms. In a particular embodiment of this type, the modified Hdm2 protein comprises the amino acid sequence of SEQ ID NO: 10. In a particular embodiment of this type, the crystal has the space group of P2₁2₁2₁, having unit cell dimensions of: a=38.0, b=45.3, c=64.0 Angstroms. In a related embodiment, the crystal comprises a protein-ligand binding complex with the modified Hdm2 protein.

In accordance with the present invention, the structure coordinates of the Hdm2 polypeptide and portions thereof may be stored in a machine-readable storage medium. Such data may be used for a variety of purposes, such as drug discovery and X-ray crystallographic analysis of a protein crystal (e.g., for producing a three-dimensional representation of Hdm2). Accordingly, one aspect of this invention provides a machine-readable data storage medium comprising a data storage material encoded with the structure coordinates set forth in Table 3 or 4. The machine-readable data storage medium may also include any set of structure coordinates of a molecule that has a root mean square deviation of conserved residue backbone atoms (N, CA, C, O) of less than about 1.5 Å, preferably, less than about 1.0 Å, more preferably less than about 0.5 Å and even more preferably less than about 0.1 Å when superimposed—using backbone atoms—on the relevant structure coordinates of Table 3 or 4.

A computer system, useful in reading the machine readable data storage medium, includes a computer comprising a central processing unit (“CPU”) and a memory storage device and is also within the scope of the present invention. In general, the computer system may be any computer with an operating system such as MS-DOS, PC-DOS, Windows, OS/2, Unix, Unix variant or MaCOS. Particularly preferred computer systems are the Silicon Graphics Octane workstation or Compaq AlphaServer DS20. Other hardware systems and software packages will be known to those skilled in the art.

Input hardware coupled to the computer system by input line, may be implemented in a variety of ways. Machine-readable data of this invention may be input via the use of a modem or modems connected by a telephone line or a dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. A keyboard may also be used as an input device.

Output hardware, coupled to the computer system by output lines, may similarly be implemented by conventional devices. By way of example, output hardware may include a display terminal (e.g., a cathode ray tube (CRT)) for displaying a graphical representation of the three dimensional structure of Hdm2 or a portion thereof using a program such as INSIGHT (Molecular Simulations Inc., San Diego, Calif.) or QUANTA as described herein. Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use. In preferred embodiments, the computer possesses a display which is displaying a three dimensional representation of Hdm2 or a fragment or homologue thereof.

In operation, the central processing unit (CPU) coordinates the use of the various input and output devices, coordinates data accesses from mass storage and accesses to and from working memory, and determines the sequence of data processing steps. A number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein. Specific references to components of the computer system are included as appropriate throughout the following description of the data storage medium.

A magnetic data storage medium can be encoded with a machine-readable data by a computer system as described above. Storage medium may be, for example, a conventional floppy diskette or hard disk, having a suitable substrate, which may be conventional, and a suitable coating, which may be conventional, on one or both sides, containing magnetic domains whose polarity or orientation can be altered magnetically. The magnetic domains of the coating of medium may be polarized or oriented so as to encode, in a manner which may be conventional, machine readable data, such as that described herein, for execution by a system as described herein. Storage medium may also have an opening for receiving the spindle of a disk drive or other data storage device. Alternatively, an optically-readable data storage medium can be encoded with such machine-readable data, or a set of instructions. Medium can be a conventional compact disk read only memory (CD-ROM) or a rewritable medium such as a magneto-optical disk which is optically readable and magneto-optically writable.

In general, in the case of CD-ROM, as is well known, disk coating is reflective and is impressed with a plurality of pits to encode the machine-readable data. The arrangement of the pits is read by reflecting laser light off the surface of the coating. A protective coating, which preferably is substantially transparent, is provided on top of the coating.

In general, in the case of a magneto-optical disk, as is well known, disk coating has no pits, but has a plurality of magnetic domains whose polarity or orientation can be changed magnetically when heated above a certain temperature, as by a laser. The orientation of the domains can be read by measuring the polarization of laser light reflected from the coating. The arrangement of the domains encodes the data as described above.

Structure Based Drug Design

The present invention permits the use of structure-based drug design techniques to design, select, and synthesize chemical entities, including inhibitory compounds that are capable of binding to a Hdm2 polypeptide. Also, de novo and iterative drug design methods can be used to develop drugs from the structure of the Hdm2 crystals of this invention.

One particularly useful drug design technique enabled by this invention is structure-based drug design. Structure-based drug design is a method for optimizing associations between a protein and a compound by determining and evaluating the three-dimensional structures of successive sets of protein/compound complexes.

Those skilled in the art will appreciate that association of natural ligands or substrates with the binding pockets of their corresponding receptors, enzymes or specific binding proteins is the basis of many biological mechanisms of action. The term “binding pocket”, as used herein, may refer to any region of a molecule or molecular complex, that, as a result of its shape, favorably associates with another chemical entity or compound. Similarly, drugs may exert their biological effects through association with the binding pockets of receptors and/or specific binding proteins. Such association may occur with all or any part of the binding pockets. An understanding of such associations will help lead to the design of drugs having more favorable associations with the target protein, and thus, improved biological effects. Therefore, this information is valuable in designing potential protein inhibitors, such as inhibitors of Hdm2.

In iterative structure-based drug design, crystals of a series of protein/compound complexes are obtained and then the three-dimensional structure of each complex is solved. Such an approach provides insight into the association between the proteins and compounds of each complex. This is accomplished by selecting compounds with inhibitory activity, obtaining crystals of a new polypeptide, solving the three-dimensional structure of the polypeptide, and comparing the associations between the new protein and previously solved protein. By observing how changes in the compound affected the protein/compound associations, these associations may be optimized.

In some cases, iterative structure-based drug design is carried out by forming successive protein-compound complexes and then crystallizing each new complex. Alternatively, a pre-formed protein crystal is soaked in the presence of an inhibitor or other binding compound, thereby forming a protein/compound complex and obviating the need to crystallize each individual protein/compound complex. Advantageously, the modified Hdm2 crystals provided by this invention may be soaked in the presence of compounds, such as Hdm2 inhibitors, substrates or other ligands to provide novel Hdm2/compound crystal complexes. In one embodiment, the complexes may be produced and screened using high throughput methods to quickly identify or design potential inhibitors of Hdm2.

The structure coordinates set forth in Table 3 or 4 can also be used to aid in obtaining structural information about another crystallized molecule or molecular complex. This may be achieved by any of a number of well-known techniques, including molecular replacement.

The structure coordinates set forth in Table 3 or 4 can also be used for determining at least a portion of the three-dimensional structure of molecules or molecular complexes which contain at least some structurally similar features to Hdm2. In particular, structural information about another crystallized molecule or molecular complex may be obtained by well-known techniques, including molecular replacement.

Therefore, another aspect of this invention provides a method of utilizing molecular replacement to obtain structural information about a crystallized molecule or molecular complex, whose structure is unknown, comprising the steps of generating an X-ray diffraction pattern from said crystallized molecule or molecular complex and applying crystallographic phases derived from at least a portion of the structure coordinates set forth in Table 3 or 4 to the X-ray diffraction pattern to generate a three-dimensional electron density map of the molecule or molecular complex whose structure is unknown.

Once the structure coordinates of a protein crystal have been determined, they are useful in solving the structures of other crystals. In addition, the structure of Hdm2 homologues may be determined from the structural coordinates of the present invention. For example, polypeptides may be crystallized and their structures elucidated by, for example, difference Fourier techniques and molecular replacement.

By using molecular replacement, all or part of the structure coordinates of the Hdm2 polypeptide provided by this invention (and set forth in Table 3 or 4) can be used to determine the previously unknown structure of a crystallized molecule or molecular complex more quickly and efficiently than attempting to determine such information ab initio.

Molecular replacement provides an accurate estimation of the phases for an unknown structure. Phases are a factor in equations used to solve crystal structures that cannot be measured experimentally. Obtaining accurate values for the phases, by methods other than molecular replacement, is a time-consuming process. However, when the crystal structure of a protein containing a homologous portion has been solved, the phases from the known structure may provide a satisfactory estimate of the phases for the unknown structure.

Thus, this method involves generating a preliminary model of a molecule or molecular complex whose structure coordinates are unknown, by orienting and positioning the relevant portion of the modified Hdm2 crystal according to Table 3 or 4 within the unit cell of the crystal of the unknown molecule or molecular complex so as best to account for the observed X-ray diffraction pattern amplitudes to generate an election density map of the structure whose coordinates are unknown. This, in turn, can be subjected to any well-known model building and structure refinement techniques to provide a final, accurate structure of the unknown crystallized molecule or molecular complex (Lattman, “Use of the Rotation and Translation Functions”, in Meth. Enzymol., 115: 55-77 (1985); Rossman, ed., “The Molecular Replacement Method”, Int. Sci. Rev. Ser., No. 13, Gordon & Breach, New York (1972)).

Phase information from the structure coordinates of the present invention may be used to elucidate the structure of other crystals. For example, the structure of Hdm2 in complex with other atoms or molecules may be elucidated. Such complexes include, for example, those containing atoms soaked into or cocrystallized within the crystal lattice. Other structures which can be elucidated using the phase information of the present invention include for example other proteases or homologues or mutants thereof having sufficient three-dimensional structure similarity to Hdm2 complex as to be solved using molecular replacement. Also, these protein molecules in a complex with a small molecule substrate(s), inhibitor(s), transition state analog(s), product(s) or analog(s) of any of these may also be solved using the phase information of the present invention. Other complexes whose structure can be elucidated from the phase information of the present invention include a modified Hdm2 complexed with an inhibitor other than those presented herein. Complexes containing a combination of the above molecules may also be solved using the phase information of the present invention.

The structure of any portion of any crystallized molecule or molecular complex that is sufficiently homologous to any portion of the modified Hdm2 protein can be solved by this method. The difference Fourier method simply calculates an electron density map using phases calculated from the structure coordinates and observed diffraction amplitudes from a crystal of an unknown structure. This method is often used to solve structures of protein/ligand complexes where the ligand is small and does not affect the crystal form significantly.

In a preferred embodiment, the method of molecular replacement is utilized to obtain structural information about a molecule wherein the molecule comprises a Hdm2 polypeptide complex. The structure coordinates of modified Hdm2 provided by this invention are particularly useful in solving the structure of other crystal forms of Hdm2 polypeptide complexes. This approach enables the determination of the optimal sites for interaction between chemical entities, including interaction of candidate inhibitors with Hdm2.

Modified Hdm2 crystals may be studied using well-known X-ray diffraction techniques and may be refined versus X-ray data to 3 Å resolution or better to an R_(free) value of about 0.40 or less using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see e.g., Blundell & Johnson, supra; Meth. Enzymol., vol. 114 & 115, H. W. Wyckoff et al., eds., Academic Press (1985)). This information may be used to optimize known Hdm2 inhibitors and to design new Hdm2 inhibitors.

Once a three-dimensional structure of a crystal comprising a modified Hdm2 protein in a protein-ligand complex is determined, the potential inhibitor of Hdm2 can be examined through the use of computer modeling using a docking program such as GRAM, DOCK, or AUTODOCK [Dunbrack et al., Folding & Design, 2:27-42 (1997)]. This procedure can include computer fitting of potential inhibitors to the modified Hdm2 protein to ascertain how well the shape and the chemical structure of the potential modulator will interact with the modified Hdm2 protein [Bugg et al., Scientific American, December:92-98 (1993); West et al., TIBS, 16:67-74 (1995)]. Computer programs can also be employed to estimate the attraction, repulsion, and steric hindrance of the modified Hdm2 protein with an inhibitor.

Generally the tighter the fit, the lower the steric hindrances, and the greater the attractive forces, the more potent the inhibitor, since these properties are consistent with a tighter binding constant. Furthermore, the more specificity in the design of a potential drug the more likely that the drug will not interact as well with other proteins. This will minimize potential side-effects due to unwanted interactions with other proteins.

Compounds that may be used initially have been discussed by Chene [Nature 3:102-109 (2003)]. In addition, the present invention discloses the acetylated tripeptides, (a) Ac-^(6Cl)WAC_(3c)E and (b) Ac-^(6Br)WAC_(3c)E, as shown respectively below, which can individually bind a modified Hmd2 protein in protein-ligand complex and form an X-ray diffractable crystal.

These ligands then can be systematically modified by computer modeling programs until one or more promising potential analogs are identified. Such analysis has been shown to be effective in the development of HIV protease inhibitors [Lam et al., Science 263:380-384 (1994); Wlodawer et al., Ann. Rev. Biochem. 62:543-585 (1993); Appelt, Perspectives in Drug Discovery and Design 1:23-48 (1993); Erickson, Perspectives in Drug Discovery and Design 1:109-128 (1993)]. Alternatively, a potential inhibitor initially can be obtained by screening a random peptide library or a chemical library. In the former case, a random peptide library can be produced by recombinant bacteriophage, for example, [Scott and Smith, Science, 249:386-390 (1990); Cwirla et al., Proc. Natl. Acad. Sci., 87:6378-6382 (1990); Devlin et al., Science, 249:404-406 (1990)]. This approach may be particularly useful in this case since the natural binding partner for Mdm2 is the p53 protein. In any case, a peptide selected in this manner could then be systematically modified by computer modeling programs, as described above.

If a potential inhibitor is a small organic compound, it can be selected from a library of chemicals, as are commercially available. Alternatively, the small organic compound may be synthesized de novo. Once obtained, the potential inhibitor can be further tested in a standard binding and/or functional assay with Hdm2, a modified Hdm2 protein or active fragments thereof.

For example, a binding assay can be performed following the attachment of the Hdm2 protein to a solid support. Methods for placing Hdm2 protein on the solid support are well known in the art and include such things as linking biotin to the Hdm2 protein and linking avidin to the solid support. The solid support can be washed to remove unbound protein. A solution of a labeled potential inhibitor can be contacted with the solid support. The solid support is washed again to remove the potential inhibitor not bound to the support. The amount of labeled potential inhibitor remaining with the solid support, and thereby bound to the Hdm2 protein can be determined. Alternatively, or in addition, the dissociation constant between the labeled potential inhibitor and the Hdm2 protein, for example, can be determined. Suitable labels for either the Hdm2 protein or the potential inhibitor include, radioactive labels (e.g., ¹⁴C, ¹H,) and fluorescent labels such as fluorescein isothiocyanate (FITC).

In another embodiment, a Biacore machine can be used to determine the binding constant of the Hdm2 protein with a potential inhibitor [O'Shannessy et al. Anal. Biochem. 212:457-468 (1993); Schuster et al., Nature 365:343-347 (1993)].

In addition, an inhibitor can be identified using an ELISA-based competition assay [Bottger et al., Oncogene 13:2141-2147 (1996); Bottger et al., J. Miol. Biol. 269:744-756 (1997)]. For example, the p53 protein or Hdm2-binding fragment thereof can be biotinylated and immobilized on a streptavidin-coated ELISA plate. Hdm2 is then incubated alone (in a control) or in the presence of a potential inhibitor. The Hdm2 solutions are then individually contacted with the immobilized p53 protein or Hdm2-binding fragment thereof. The binding of the Hdm2 is then determined, e.g., with a detectable anti-Hdm2 antibody. When the amount of Hdm2 detected is lower in the sample incubated with the potential inhibitor relative to the control, the potential inhibitor is identified as an inhibitor.

When a promising inhibitor is identified, a crystal comprising a protein-ligand complex of the inhibitor and a modified Hdm2 protein can be prepared. The three-dimensional structure of the resulting crystalline protein-ligand complex can then be determined by molecular replacement analysis, for example.

Molecular replacement involves the use of a known three-dimensional structure as a search model to determine the structure of a closely related molecule or protein-ligand complex in a different crystalline form. The measured X-ray diffraction properties of the new crystal are compared with the search model structure to compute the position and orientation of the protein in the new crystal. Computer programs that can be used include: X-PLOR [Brunger et al., Acta Crystallogr. A 46:585-593 (1990); Brunger et al., Acta Crystallogr. D Biol Crystallogr., 54:905-921 (1998)], CNS, (Crystallography and NMR System, a next level of XPLOR), and AMORE [Navaza, Acta Crystallographics ASO, 157-163 (1994)]. Once the position and orientation are known, an electron density map can be calculated using the search model to provide X-ray phases. Thereafter, the electron density is inspected for structural differences and the search model is modified to conform to the new structure. Using this approach, it is possible to solve the three-dimensional structures of crystals of any protein-ligand complex of the modified Hdm2 protein.

For all of the drug screening assays described herein, further refinements to the structure of the drug will generally be necessary and can be made by the successive iterations of any and/or all of the steps provided by the particular drug screening assay and/or in combination with other such drug screening assays.

A candidate drug selected by performing structure based drug design can then be assayed in situ and/or in vivo. For example, a candidate drug can be evaluated for cellular activity by incubating the candidate drug in cell cultures, e.g. using HCT-116 cells or OSA-CL cells, and then measuring its effect on cellular proliferation and expression levels of proteins that are transcriptionally regulated by p53 such as p21waf1 and Hdm2 [Chene et al., J. Mol. Biol. 299:245-256 (2000)]. A candidate drug is identified as a drug if in the presence of the drug relative to in its absence, the amount of cellular proliferation decreases and/or the amount of a protein that is transcriptionally regulated by p53 increases.

Indeed, methods of testing such potential candidate drugs in animal models are well known in the art. The potential drugs can be administered by a variety of ways including topically, orally, subcutaneously, or intraperitoneally depending on the proposed use. Generally, at least two groups of animals are used in the assay, with at least one group being a control group that is administered the administration vehicle without the potential drug. TABLE 2 TABLE OF SEQUENCES SEQ ID NO: Type Description 1 N.A. WT Hdm2 (17-125) 2 A.A. WT Hdm2 (17-125) 3 N.A. modified Hdm2 (X₁-X₇) 4 A.A. modified Hdm2 (X₁-X₇) 5 N.A. modified Hdm2 (Y76H) 6 A.A. modified Hdm2 (Y76H) 7 N.A. modified Hdm2 (F55Y) 8 A.A. modified Hdm2 (F55Y) 9 N.A. modified Hdm2 (F55Y/Y76H) 10 A.A. modified Hdm2 (F55Y/Y76H) 11 N.A. modified Hdm2 (HK₅) 12 A.A. modified Hdm2 (HK₅) 13 N.A. Hdm2 (F55Y) Primer 14 N.A. RChdm2 (F55Y) Primer 15 N.A. Hdm2 (Y76H) Primer 16 N.A. RChdm2 (Y76H) 17 N.A. Y104S-GTAILOR-F Primer 18 N.A. Y104-GTAILOR-R Primer

The present invention may be better understood by reference to the following non-limiting examples, which are provided as exemplary of the invention. The following examples are presented in order to more fully illustrate certain embodiments of the invention. They should in no way be construed as limiting the broad scope of the invention.

EXAMPLES Example 1 Preparation of Modified Hdm2

Preparation of Hdm2 Constructs

Hdm2 was either modified with a single amino acid change, or with a double amino acid change using the QuickChange kit (Stratagene, La Jolla, Calif., USA) and the pET32-Xa/LIC-hdm2 (17-125) vector as a template. The pET32-Xa/LIC parental vector was obtained from Novagen (San Diego, Calif.). Hdm2(F55Y), Hdm2(Y76H) and Hdm2(F55Y/Y76H) were constructed in this manner.

A modified Hdm2 having three amino acid substitutions, Hdm2(F55Y/Y76H/Y104S) was generated using GENETAILOR Site-directed Mutagenesis system (Invitrogen, Carlsbad, Calif., USA) with the vector indicated above as the template. The following primers were used to generate the above-identified modified Hdm2 proteins: (1) Hdm2(F55Y) Primer: SEQ ID NO:13 5′ CTATGAAAGAGGTTCTTTATTATCTTGGCCAGTATATTATGAC 3′ (2) RChdm2(F55Y) Primer: SEQ ID NO:14 5′ GTCATAATATACTGGCCAAGATAATAAAGAACCTCTTTCATAG 3′ (3) Hdm2(Y76H) Primer: SEQ ID NO:15 5′ GAGAAGCAACAACATATTGTACATTGTTCAAATGATCTTCTAGG 3′ (4) RChdm2(Y76H) Primer: SEQ ID NO:16 5′ CCTAGAAGATCATTTGAACAATGTACAATATGTTGTTGCTTCTC 3′ (5) Y104S-GTAILOR-F Primer: SEQ ID NO:17 5′ CAGGAACTTGGTAGTAGTCAATCAGCAGG 3′ (6) Y104-GTAILOR-R Primer: SEQ ID NO:18 5′ GACTACTACCAAGTTCCTGGAGATCATGGT 3′

QuickChange mutagenesis was performed in two steps as previously described [Wang et al., BioTechniques 26:680-682(1999)]. In the first stage two extension reactions were performed in separate tubes; one containing the forward primer and the other containing the reverse primer. After two cycles, the two reactions were mixed and the standard QuickChange mutagenesis procedure was carried out for an additional 18 cycles. Following amplification, the parental strand was digested with 1U of Dpn1 for 2 hours and an aliquot was transformed into DH5-α cells. The GENETAILOR mutagenesis was performed according to the manufacturer's instructions except that pfu turbo DNA polymerase was used instead of the polymerase recommended by manufacture. All constructs were confirmed by sequencing (GeneWiz, New York, N.Y.).

Expression of Modified Hdm2

A colony from freshly transformed cells was grown at 37° C. to an optical density (OD) of 2.0 in 10 ml TERRIFIC broth (Mediatech, Inc.) containing 100 μg/ml carbenicilin and 1% glucose. This 10 ml culture was then used to inoculate a 1 liter culture having the same medium composition. The 1 liter culture was grown at 37° C. to an OD of 2.0, stored at 4° C. overnight, and then used to inoculate a 10 liter tank containing TERRIFIC broth and 100 μg/ml carbenicilin. The 10 liter culture was grown at 37° C. to an OD of 1.5-2.0 before lowering the temperature to 16° C. The 10 liter culture was then induced with 1 mM IPTG, and the cells were harvested 18 hours post-induction.

Purification of Modified Hdm-2 Proteins

The purification protocol as exemplified herein for Hdm2(F55Y/Y76H) is applicable for all of the modified Hdm2 proteins of the present invention.

IPTG-induced cells containing Hdm2(F55Y/Y76H) were harvested from the 10 liter fermentation, as described above. The cells were suspended in 500 ml of 50 mM Tris-Cl Buffer, pH 8.0_(rt) (room temperature), 0.3 M NaCl, 10% (v/v) glycerol, 5 mM β-mercaptoethanol, 25 mM imidazole, 18,000 Units/liter endonuclease (ultrapure benzonase; SIGMA), and 6 ml/liter of CALBIOCHEM Protease Inhibitor Cocktail III. (All processing was performed at 4° C.) To homogenize the resulting cell suspension, it was passed through a large OMNI Mixer probe for 45 seconds, three times. The cell suspension was kept on ice for 2 minutes between each 45 second passage. The cells were then broken by three passages of the homogenized cell suspension through a Microfluidizer. The extract was recovered by centrifugation at 205,000×g for 80 minutes at 4° C.

The resulting 645 ml extract was mixed end over end for 50 minutes with 28 ml of QIAGEN Ni-NTA SUPERFLOW resin, which had been equilibrated with the equilibration buffer [50 mM Tris-Cl, pH 8.0_(rt), 0.3 M NaCl, 5 mM 1-mercaptoethanol and 25 mM imidazole]. The supernatant was decanted, and the resin was then washed with 600 ml of the equilibration buffer. The resin was poured into a 2.6×5.3 cm column, washed with an additional 200 ml of equilibration buffer at 3.6 ml/min, and finally eluted with 50 mM Tris-Cl, pH 8.0_(rt), 0.1 M NaCl, 250 mM imidazole, 5 mM β-mercaptoethanol and 20% glycerol.

A 0.64 ml volume of 0.5 M CaCl₂ was added to the eluted fusion protein pool (195 mg of protein in 63 ml of elution buffer). The pooled protein was then diluted to 1 mg/ml with 50 mM Tris-Cl, pH 8.0_(rt), 0.1 M NaCl, 10% glycerol, 5 mM CaCl₂ and 5 mM β-mercaptoethanol. A 1.95 ml volume of 2000 Units/ml Factor Xa protease (NOVAGEN) was added, and the pooled protein was dialyzed overnight versus 3.87 liters of the same buffer.

A 4.33 ml volume of 1 M imidazole, pH 8.0, was added to the 200 ml of cleaved, pooled fusion protein, to bring the imidazole concentration to 24 mM. The pooled protein was then applied at a rate of 3.6 m/min to a 50 ml (2.6×9.4 cm) column of QIAGEN Ni-NTA SUPERFLOW resin that had been equilibrated with equilibration buffer. The column was then washed with the equilibration buffer.

The 230 ml flow-through was dialyzed versus three changes (6 liters, 5 liters and 5 liters) of Buffer A [25 mM Hepes-KOH, pH 7.5, 0.15 M KCl, 1 mM Na₂-EDTA, 0.03% sodium azide and 5 mM dithiothreitol]. All manipulations of the modified Hdm2 were in Buffer A from this point on. The dialyzed pooled protein was concentrated to 8.5 ml with an AMICON YM10 membrane, centrifuged at 205,000×g for 15 minutes, and then applied to a 2.6×60 cm column of PHARMACIA SUPERDEX-75 at a flow rate of 0.8 ml/min. The resulting eluant was collected in 3.2 ml fractions.

Fractions 66-75 contained the purified, modified Hdm2 monomer. These fractions were pooled and a protein concentration of 3.6 mg/ml was determined using ε₂₇₆=10,150 M⁻¹ cm⁻¹ in 20 mM sodium phosphate, pH 6.5, with 6 M guanidine hydrochloride (ExPASy-ProtParam Tool). This determination correlated with that determined by the Bradford dye binding assay (BIORAD), using bovine serum albumin as the protein standard.

EXAMPLE 2 Preparation and Crystallization of Hdm2 F55Y/Y76H-Tripeptide Complex

The modified Hdm2 (F55Y/Y76H) protein was prepared by means of QuickChange mutagenesis as disclosed in Example 1 using the appropriate primers. A small scale expression study was carried out to evaluate the solubility and expression level of this construct. The expression level of the soluble Hdm2(F55Y/Y76H) protein is 2 to 3 fold higher than wild type. 110 mgs of the Hdm2(F55Y/Y76H) was purified from a 10 L culture through the four-step purification protocol described above.

A 13 ml aliquot of the 3.6 mg/ml pool was concentrated to a 1.25 mM concentration (in 3 ml), on an AMICON 5000 mwco Ultrafree membrane. A 3 ml aliquot of 8.5 mM SCH549128 (MW=535) in Buffer A was added to the concentrated aliquot. The complex was incubated at room temperature for 10 minutes, and then concentrated as above, to a final volume of 1.3 ml.

The HDM2(F55Y/Y76H) protein-tripeptide complex was crystallized using a hanging-drop vapor diffusion method. The protein (0.5 μl; 34 mg/ml) in 25 mM Hepes-potassium hydroxide, pH7.5, 0.15 M potassium chloride, 1 mM EDTA, 0.03% sodium azide and 5 mM DTT buffer was mixed with an equal volume of precipitant solution [1.4 M tri sodium citrate, 0.1 M sodium Hepes, pH 7.5] placed on the underside of a siliconized glass coverslip and sealed in close proximity to 1 ml of the precipitant solution. Crystallization plates were incubated at 22° C.; rectangular rod crystals (0.02×0.2 mm) grew over 2-30 days.

Prior to data collection, crystals were washed with the reservoir solution of the crystallization setup and transferred into the same solution with 20% glycerol added. The crystals were then flash-cooled in a nitrogen stream at 95 K. X-ray diffraction was collected using a Rigaku generator equipped with a Raxis 4++ detector. Data were integrated and scaled using the HKL package.

Data Collection Statistics: Resolution 50.0-1.70 Å No. of collected reflections 135908 No. of unique reflections (F >= 0)  12484 R-sym  6.7% Percent of theoretical (I/s >= 1) 98.7% Unit Cell a = 37.999 Å, b = 45.333 Å, c = 63.999 Å, α = β = γ = 90° Space Group P2₁2₁2₁ Asymmetric unit 1 molecule

The crystal structure was solved using molecular replacement using the search models 1YCQ and 1YCR from the PDB. Refinement was done using the program CNX.

Theoretical Number of Reflections 9121 Resolution Limits 50.0-1.90 Å Number of unobserved reflections  106 (1.2%) Number of reflections in working set 8592 (98.8%) Number of reflections in test set  423 (4.6%) Number of protein residues 87 Number of solvent atoms 44 R-factor  0.223 R-free  0.243 RMSD bond length     0.0083 Å RMSD bond angles 1.46°

The structural coordinates for the above-described Hdm2 crystal are set forth below in Table 3, which is in Protein Data Bank (PDB) file format. The numbered columns refer to the following: Col. # Reference 1 Atomic coordinate records for standard groups 2 Atom serial number 3 Atom name 4 Residue name 5 Residue sequence number 6 Orthogonal coordinates for X in Angstroms 7 Orthogonal coordinates for Y in Angstroms 8 Orthogonal coordinates for Z in Angstroms 9 Occupancy 10 Temperature factor 11 Element symbol

TABLE 3 1 2 3 4 5 6 7 8 9 10 11 ATOM 1 CB GLU 25 8.599 29.031 2.725 1.00 52.10 C ATOM 2 CG GLU 25 7.336 29.192 3.556 1.00 55.02 C ATOM 3 CD GLU 25 6.648 27.844 3.697 1.00 57.01 C ATOM 4 OE1 GLU 25 5.517 27.697 3.186 1.00 58.12 O ATOM 5 OE2 GLU 25 7.235 26.932 4.322 1.00 57.62 O ATOM 6 C GLU 25 10.683 30.035 1.753 1.00 47.48 C ATOM 7 O GLU 25 10.654 29.682 0.574 1.00 48.97 O ATOM 8 N GLU 25 8.564 31.353 1.814 1.00 50.30 N ATOM 9 CA GLU 25 9.389 30.323 2.511 1.00 49.61 C ATOM 10 N THR 26 11.816 30.195 2.431 1.00 43.07 N ATOM 11 CA THR 26 13.119 29.941 1.824 1.00 37.71 C ATOM 12 CB THR 26 14.267 30.244 2.807 1.00 38.14 C ATOM 13 OG1 THR 26 14.227 31.628 3.174 1.00 38.51 O ATOM 14 CG2 THR 26 15.613 29.942 2.163 1.00 37.88 C ATOM 15 C THR 26 13.216 28.482 1.385 1.00 34.76 C ATOM 16 O THR 26 12.823 27.579 2.120 1.00 34.28 O ATOM 17 N LEU 27 13.730 28.261 0.179 1.00 29.30 N ATOM 18 CA LEU 27 13.872 26.915 −0.365 1.00 28.75 C ATOM 19 CB LEU 27 13.479 26.866 −1.842 1.00 28.72 C ATOM 20 CG LEU 27 12.043 27.255 −2.190 1.00 29.98 C ATOM 21 CD1 LEU 27 11.823 27.208 −3.696 1.00 30.85 C ATOM 22 CD2 LEU 27 11.037 26.358 −1.482 1.00 30.07 C ATOM 23 C LEU 27 15.240 26.271 −0.161 1.00 26.20 C ATOM 24 O LEU 27 16.270 26.922 −0.316 1.00 26.92 O ATOM 25 N VAL 28 15.234 24.989 0.196 1.00 24.29 N ATOM 26 CA VAL 28 16.465 24.230 0.402 1.00 22.04 C ATOM 27 CB VAL 28 16.566 23.684 1.845 1.00 21.66 C ATOM 28 CG1 VAL 28 16.716 24.839 2.822 1.00 20.57 C ATOM 29 CG2 VAL 28 15.337 22.849 2.180 1.00 18.74 C ATOM 30 C VAL 28 16.549 23.066 −0.585 1.00 22.51 C ATOM 31 O VAL 28 15.526 22.500 −0.979 1.00 20.60 O ATOM 32 N ARG 29 17.770 22.733 −0.996 1.00 21.42 N ATOM 33 CA ARG 29 18.010 21.641 −1.937 1.00 23.64 C ATOM 34 CB ARG 29 18.869 22.116 −3.107 1.00 27.62 C ATOM 35 CG ARG 29 19.162 21.053 −4.151 1.00 33.83 C ATOM 36 CD ARG 29 20.043 21.611 −5.267 1.00 38.61 C ATOM 37 NE ARG 29 19.435 22.740 −5.965 1.00 42.13 N ATOM 38 CZ ARG 29 18.360 22.653 −6.742 1.00 45.54 C ATOM 39 NH1 ARG 29 17.763 21.483 −6.929 1.00 47.02 N ATOM 40 NH2 ARG 29 17.882 23.740 −7.337 1.00 46.93 N ATOM 41 C ARG 29 18.696 20.470 −1.227 1.00 20.05 C ATOM 42 O ARG 29 19.851 20.573 −0.819 1.00 18.84 O ATOM 43 N PRO 30 17.988 19.343 −1.078 1.00 19.58 N ATOM 44 CD PRO 30 16.511 19.312 −1.031 1.00 21.57 C ATOM 45 CA PRO 30 18.498 18.137 −0.425 1.00 20.02 C ATOM 46 CB PRO 30 17.278 17.234 −0.444 1.00 22.34 C ATOM 47 CG PRO 30 16.234 18.184 0.016 1.00 21.93 C ATOM 48 C PRO 30 19.678 17.493 −1.160 1.00 19.19 C ATOM 49 O PRO 30 19.624 17.323 −2.379 1.00 18.14 O ATOM 50 N LYS 31 20.737 17.144 −0.433 1.00 17.57 N ATOM 51 CA LYS 31 21.870 16.450 −1.044 1.00 17.54 C ATOM 52 CB LYS 31 23.083 16.416 −0.110 1.00 17.17 C ATOM 53 CG LYS 31 23.588 17.814 0.242 1.00 21.31 C ATOM 54 CD LYS 31 24.792 17.784 1.175 1.00 24.34 C ATOM 55 CE LYS 31 25.250 19.198 1.499 1.00 27.70 C ATOM 56 NZ LYS 31 26.424 19.216 2.411 1.00 30.99 N ATOM 57 C LYS 31 21.367 15.049 −1.436 1.00 18.76 C ATOM 58 O LYS 31 20.316 14.612 −0.961 1.00 17.24 O ATOM 59 N PRO 32 22.093 14.338 −2.319 1.00 18.30 N ATOM 60 CD PRO 32 23.329 14.791 −2.991 1.00 21.43 C ATOM 61 CA PRO 32 21.764 13.000 −2.820 1.00 19.62 C ATOM 62 CB PRO 32 23.111 12.503 −3.293 1.00 22.05 C ATOM 63 CG PRO 32 23.536 13.680 −4.080 1.00 21.40 C ATOM 64 C PRO 32 21.004 11.990 −1.947 1.00 19.34 C ATOM 65 O PRO 32 19.883 11.591 −2.299 1.00 17.19 O ATOM 66 N LEU 33 21.594 11.559 −0.833 1.00 18.45 N ATOM 67 CA LEU 33 20.911 10.581 0.017 1.00 18.88 C ATOM 68 CB LEU 33 21.788 10.020 1.142 1.00 21.73 C ATOM 69 CG LEU 33 23.050 9.209 0.871 1.00 28.04 C ATOM 70 CD1 LEU 33 24.067 9.989 0.052 1.00 29.17 C ATOM 71 CD2 LEU 33 23.663 8.738 2.191 1.00 29.05 C ATOM 72 C LEU 33 19.597 11.062 0.602 1.00 17.92 C ATOM 73 O LEU 33 18.603 10.340 0.565 1.00 16.48 O ATOM 74 N LEU 34 19.588 12.277 1.140 1.00 17.19 N ATOM 75 CA LEU 34 18.365 12.817 1.719 1.00 15.57 C ATOM 76 CB LEU 34 18.632 14.142 2.431 1.00 17.51 C ATOM 77 CG LEU 34 17.436 14.863 3.052 1.00 18.19 C ATOM 78 CD1 LEU 34 16.656 13.966 4.007 1.00 16.62 C ATOM 79 CD2 LEU 34 17.885 16.147 3.738 1.00 16.73 C ATOM 80 C LEU 34 17.316 12.995 0.638 1.00 17.16 C ATOM 81 O LEU 34 16.128 12.769 0.870 1.00 16.85 O ATOM 82 N LEU 35 17.755 13.385 −0.553 1.00 15.69 N ATOM 83 CA LEU 35 16.814 13.578 −1.644 1.00 18.62 C ATOM 84 CB LEU 35 17.508 14.148 −2.885 1.00 20.48 C ATOM 85 CG LEU 35 16.605 14.406 −4.097 1.00 23.23 C ATOM 86 CD1 LEU 35 15.470 15.356 −3.733 1.00 23.45 C ATOM 87 CD2 LEU 35 17.389 14.944 −5.293 1.00 23.24 C ATOM 88 C LEU 35 16.160 12.238 −1.966 1.00 19.55 C ATOM 89 O LEU 35 14.951 12.155 −2.195 1.00 17.74 O ATOM 90 N LYS 36 16.964 11.181 −1.955 1.00 18.27 N ATOM 91 CA LYS 36 16.453 9.859 −2.271 1.00 22.37 C ATOM 92 CB LYS 36 17.610 8.864 −2.413 1.00 24.10 C ATOM 93 CG LYS 36 17.212 7.444 −2.785 1.00 30.65 C ATOM 94 CD LYS 36 18.461 6.576 −2.920 1.00 32.62 C ATOM 95 CE LYS 36 18.128 5.145 −3.307 1.00 36.89 C ATOM 96 NZ LYS 36 19.362 4.312 −3.442 1.00 37.42 N ATOM 97 C LYS 36 15.413 9.413 −1.246 1.00 22.40 C ATOM 98 O LYS 36 14.435 8.751 −1.597 1.00 22.93 O ATOM 99 N LEU 37 15.605 9.802 0.013 1.00 22.25 N ATOM 100 CA LEU 37 14.659 9.432 1.065 1.00 21.53 C ATOM 101 CB LEU 37 15.231 9.702 2.453 1.00 24.79 C ATOM 102 CG LEU 37 16.511 8.980 2.865 1.00 27.14 C ATOM 103 CD1 LEU 37 16.996 9.454 4.226 1.00 29.28 C ATOM 104 CD2 LEU 37 16.317 7.474 2.855 1.00 29.24 C ATOM 105 C LEU 37 13.355 10.197 0.894 1.00 22.46 C ATOM 106 O LEU 37 12.269 9.636 1.053 1.00 19.80 O ATOM 107 N LEU 38 13.470 11.479 0.557 1.00 21.33 N ATOM 108 CA LEU 38 12.296 12.322 0.369 1.00 21.81 C ATOM 109 CB LEU 38 12.693 13.794 0.252 1.00 22.60 C ATOM 110 CG LEU 38 13.394 14.398 1.467 1.00 23.43 C ATOM 111 CD1 LEU 38 13.905 15.806 1.185 1.00 24.29 C ATOM 112 CD2 LEU 38 12.491 14.362 2.685 1.00 24.94 C ATOM 113 C LEU 38 11.483 11.884 −0.836 1.00 24.00 C ATOM 114 O LEU 38 10.254 11.986 −0.830 1.00 25.09 O ATOM 115 N LYS 39 12.160 11.381 −1.865 1.00 24.12 N ATOM 116 CA LYS 39 11.442 10.928 −3.045 1.00 28.66 C ATOM 117 CB LYS 39 12.339 10.855 −4.282 1.00 29.59 C ATOM 118 CG LYS 39 12.939 12.179 −4.728 1.00 30.58 C ATOM 119 CD LYS 39 13.798 11.969 −5.968 1.00 34.21 C ATOM 120 CE LYS 39 14.414 13.266 −6.459 1.00 35.99 C ATOM 121 NZ LYS 39 13.376 14.268 −6.818 1.00 37.93 N ATOM 122 C LYS 39 10.766 9.588 −2.803 1.00 29.02 C ATOM 123 O LYS 39 9.784 9.256 −3.468 1.00 30.57 O ATOM 124 N SER 40 11.270 8.823 −1.839 1.00 27.39 N ATOM 125 CA SER 40 10.671 7.526 −1.557 1.00 27.21 C ATOM 126 CB SER 40 11.619 6.625 −0.768 1.00 29.11 C ATOM 127 OG SER 40 11.934 7.200 0.484 1.00 31.61 O ATOM 128 C SER 40 9.371 7.739 −0.791 1.00 26.87 C ATOM 129 O SER 40 8.522 6.850 −0.731 1.00 24.88 O ATOM 130 N VAL 41 9.217 8.931 −0.222 1.00 23.16 N ATOM 131 CA VAL 41 8.020 9.265 0.534 1.00 24.52 C ATOM 132 CB VAL 41 8.321 10.392 1.553 1.00 25.80 C ATOM 133 CG1 VAL 41 7.053 10.879 2.197 1.00 27.99 C ATOM 134 CG2 VAL 41 9.271 9.873 2.620 1.00 25.81 C ATOM 135 C VAL 41 6.933 9.718 −0.436 1.00 24.07 C ATOM 136 O VAL 41 5.750 9.780 −0.083 1.00 22.91 O ATOM 137 N GLY 42 7.343 10.018 −1.665 1.00 23.67 N ATOM 138 CA GLY 42 6.394 10.446 −2.678 1.00 23.84 C ATOM 139 C GLY 42 6.685 11.764 −3.373 1.00 22.51 C ATOM 140 O GLY 42 6.165 12.010 −4.461 1.00 21.84 O ATOM 141 N ALA 43 7.508 12.616 −2.767 1.00 22.69 N ATOM 142 CA ALA 43 7.817 13.916 −3.361 1.00 23.42 C ATOM 143 CB ALA 43 8.331 14.868 −2.287 1.00 26.17 C ATOM 144 C ALA 43 8.830 13.811 −4.497 1.00 23.99 C ATOM 145 O ALA 43 9.996 13.496 −4.270 1.00 23.65 O ATOM 146 N GLN 44 8.369 14.091 −5.715 1.00 23.66 N ATOM 147 CA GLN 44 9.194 14.028 −6.925 1.00 26.00 C ATOM 148 CB GLN 44 8.416 13.405 −8.091 1.00 27.49 C ATOM 149 CG GLN 44 7.957 11.970 −7.853 1.00 29.74 C ATOM 150 CD GLN 44 9.160 11.066 −7.633 1.00 33.73 C ATOM 151 OE1 GLN 44 10.295 11.436 −7.932 1.00 36.21 O ATOM 152 NE2 GLN 44 8.915 9.878 −7.092 1.00 35.39 N ATOM 153 C GLN 44 9.814 15.363 −7.344 1.00 28.84 C ATOM 154 O GLN 44 9.895 15.669 −8.532 1.00 33.20 O ATOM 155 N LYS 45 10.239 16.162 −6.373 1.00 26.37 N ATOM 156 CA LYS 45 10.849 17.453 −6.676 1.00 26.53 C ATOM 157 CB LYS 45 9.937 18.606 −6.267 1.00 26.39 C ATOM 158 CG LYS 45 9.609 18.638 −4.794 1.00 26.84 C ATOM 159 CD LYS 45 8.700 19.806 −4.469 1.00 28.76 C ATOM 160 CE LYS 45 8.370 19.843 −2.986 1.00 27.65 C ATOM 161 NZ LYS 45 7.477 20.988 −2.669 1.00 30.55 N ATOM 162 C LYS 45 12.229 17.574 −6.037 1.00 25.49 C ATOM 163 O LYS 45 12.575 16.786 −5.161 1.00 24.24 O ATOM 164 N ASP 46 13.020 18.548 −6.480 1.00 26.71 N ATOM 165 CA ASP 46 14.360 18.726 −5.925 1.00 28.66 C ATOM 166 CB ASP 46 15.403 18.827 −7.040 1.00 35.21 C ATOM 167 CG ASP 46 15.144 19.991 −7.980 1.00 40.54 C ATOM 168 OD1 ASP 46 14.152 20.724 −7.771 1.00 42.44 O ATOM 169 OD2 ASP 46 15.936 20.172 −8.932 1.00 45.73 O ATOM 170 C ASP 46 14.534 19.865 −4.913 1.00 25.87 C ATOM 171 O ASP 46 15.587 19.975 −4.286 1.00 24.85 O ATOM 172 N THR 47 13.513 20.703 −4.747 1.00 23.77 N ATOM 173 CA THR 47 13.586 21.811 −3.788 1.00 23.33 C ATOM 174 CB THR 47 13.618 23.193 −4.476 1.00 25.02 C ATOM 175 OG1 THR 47 12.413 23.394 −5.219 1.00 27.77 O ATOM 176 CG2 THR 47 14.814 23.291 −5.398 1.00 26.67 C ATOM 177 C THR 47 12.398 21.764 −2.843 1.00 21.70 C ATOM 178 O THR 47 11.266 21.522 −3.263 1.00 21.88 O ATOM 179 N TYR 48 12.670 21.995 −1.563 1.00 19.26 N ATOM 180 CA TYR 48 11.649 21.927 −0.524 1.00 19.39 C ATOM 181 CB TYR 48 11.819 20.647 0.286 1.00 20.20 C ATOM 182 CG TYR 48 11.751 19.375 −0.517 1.00 20.69 C ATOM 183 CD1 TYR 48 10.643 18.539 −0.433 1.00 20.32 C ATOM 184 CE1 TYR 48 10.577 17.366 −1.170 1.00 23.35 C ATOM 185 CD2 TYR 48 12.799 19.007 −1.362 1.00 20.03 C ATOM 186 CE2 TYR 48 12.744 17.836 −2.107 1.00 22.54 C ATOM 187 CZ TYR 48 11.631 17.021 −2.007 1.00 21.66 C ATOM 188 OH TYR 48 11.564 15.867 −2.747 1.00 24.12 O ATOM 189 C TYR 48 11.761 23.093 0.444 1.00 18.48 C ATOM 190 O TYR 48 12.732 23.838 0.420 1.00 18.96 O ATOM 191 N THR 49 10.747 23.246 1.286 1.00 18.95 N ATOM 192 CA THR 49 10.792 24.247 2.344 1.00 19.64 C ATOM 193 CB THR 49 9.398 24.779 2.729 1.00 20.36 C ATOM 194 OG1 THR 49 8.595 23.704 3.229 1.00 18.68 O ATOM 195 CG2 THR 49 8.720 25.421 1.531 1.00 21.70 C ATOM 196 C THR 49 11.332 23.403 3.503 1.00 19.26 C ATOM 197 O THR 49 11.187 22.177 3.491 1.00 16.72 O ATOM 198 N MET 50 11.971 24.033 4.482 1.00 19.49 N ATOM 199 CA MET 50 12.496 23.287 5.621 1.00 19.92 C ATOM 200 CB MET 50 13.164 24.227 6.623 1.00 19.27 C ATOM 201 CG MET 50 13.752 23.549 7.857 1.00 21.93 C ATOM 202 SD MET 50 15.038 22.346 7.482 1.00 22.54 S ATOM 203 CE MET 50 16.405 23.430 7.220 1.00 21.56 C ATOM 204 C MET 50 11.366 22.505 6.292 1.00 20.51 C ATOM 205 O MET 50 11.556 21.358 6.717 1.00 19.62 O ATOM 206 N LYS 51 10.184 23.113 6.370 1.00 20.47 N ATOM 207 CA LYS 51 9.055 22.446 7.008 1.00 21.99 C ATOM 208 CB LYS 51 7.860 23.388 7.165 1.00 26.64 C ATOM 209 CG LYS 51 6.659 22.735 7.834 1.00 33.29 C ATOM 210 CD LYS 51 5.483 23.695 7.983 1.00 38.26 C ATOM 211 CE LYS 51 4.301 23.005 8.660 1.00 40.81 C ATOM 212 NZ LYS 51 3.128 23.912 8.828 1.00 42.40 N ATOM 213 C LYS 51 8.650 21.172 6.273 1.00 19.90 C ATOM 214 O LYS 51 8.205 20.210 6.898 1.00 19.38 O ATOM 215 N GLU 52 8.817 21.149 4.953 1.00 18.87 N ATOM 216 CA GLU 52 8.464 19.944 4.205 1.00 17.93 C ATOM 217 CB GLU 52 8.382 20.189 2.699 1.00 18.18 C ATOM 218 CG GLU 52 7.344 21.203 2.247 1.00 23.24 C ATOM 219 CD GLU 52 7.396 21.313 0.732 1.00 25.60 C ATOM 220 OE1 GLU 52 8.396 21.846 0.213 1.00 23.72 O ATOM 221 OE2 GLU 52 6.438 20.874 0.057 1.00 26.89 O ATOM 222 C GLU 52 9.486 18.855 4.482 1.00 15.85 C ATOM 223 O GLU 52 9.135 17.685 4.619 1.00 16.69 O ATOM 224 N VAL 53 10.753 19.250 4.568 1.00 16.93 N ATOM 225 CA VAL 53 11.825 18.293 4.825 1.00 17.04 C ATOM 226 CB VAL 53 13.203 18.995 4.855 1.00 16.03 C ATOM 227 CG1 VAL 53 14.280 18.019 5.304 1.00 16.51 C ATOM 228 CG2 VAL 53 13.534 19.547 3.467 1.00 17.18 C ATOM 229 C VAL 53 11.596 17.602 6.166 1.00 15.46 C ATOM 230 O VAL 53 11.612 16.371 6.254 1.00 15.66 O ATOM 231 N LEU 54 11.368 18.401 7.203 1.00 15.11 N ATOM 232 CA LEU 54 11.136 17.868 8.539 1.00 18.02 C ATOM 233 CB LEU 54 11.038 19.004 9.564 1.00 18.06 C ATOM 234 CG LEU 54 12.275 19.897 9.715 1.00 19.94 C ATOM 235 CD1 LEU 54 12.017 21.075 10.651 1.00 21.06 C ATOM 236 CD2 LEU 54 13.484 19.088 10.172 1.00 19.37 C ATOM 237 C LEU 54 9.887 16.989 8.551 1.00 17.44 C ATOM 238 O LEU 54 9.890 15.901 9.132 1.00 17.96 O ATOM 239 N TYR 55 8.824 17.456 7.900 1.00 19.29 N ATOM 240 CA TYR 55 7.582 16.686 7.826 1.00 19.06 C ATOM 241 CB TYR 55 6.476 17.462 7.107 1.00 21.67 C ATOM 242 CG TYR 55 5.208 16.659 6.914 1.00 24.34 C ATOM 243 CD1 TYR 55 4.331 16.414 7.970 1.00 27.75 C ATOM 244 CE1 TYR 55 3.185 15.626 7.788 1.00 28.11 C ATOM 245 CD2 TYR 55 4.910 16.100 5.671 1.00 26.71 C ATOM 246 CE2 TYR 55 3.778 15.316 5.479 1.00 27.50 C ATOM 247 CZ TYR 55 2.920 15.082 6.537 1.00 29.01 C ATOM 248 OH TYR 55 1.802 14.302 6.332 1.00 31.62 O ATOM 249 C TYR 55 7.778 15.329 7.162 1.00 17.61 C ATOM 250 O TYR 55 7.450 14.295 7.742 1.00 18.75 O ATOM 251 N TYR 56 8.314 15.332 5.943 1.00 17.90 N ATOM 252 CA TYR 56 8.537 14.079 5.228 1.00 15.80 C ATOM 253 CB TYR 56 8.959 14.322 3.781 1.00 16.36 C ATOM 254 CG TYR 56 7.897 14.995 2.944 1.00 19.38 C ATOM 255 CD1 TYR 56 6.589 14.508 2.934 1.00 18.67 C ATOM 256 CE1 TYR 56 5.610 15.083 2.132 1.00 21.66 C ATOM 257 CD2 TYR 56 8.201 16.083 2.125 1.00 19.49 C ATOM 258 CE2 TYR 56 7.225 16.667 1.315 1.00 20.60 C ATOM 259 CZ TYR 56 5.935 16.160 1.325 1.00 22.09 C ATOM 260 OH TYR 56 4.967 16.724 0.524 1.00 24.00 O ATOM 261 C TYR 56 9.463 13.067 5.893 1.00 16.42 C ATOM 262 O TYR 56 9.247 11.863 5.759 1.00 16.20 O ATOM 263 N LEU 57 10.484 13.531 6.609 1.00 17.70 N ATOM 264 CA LEU 57 11.362 12.579 7.283 1.00 18.25 C ATOM 265 CB LEU 57 12.629 13.232 7.836 1.00 22.32 C ATOM 266 CG LEU 57 13.582 13.831 6.810 1.00 26.55 C ATOM 267 CD1 LEU 57 14.757 14.543 7.473 1.00 27.16 C ATOM 268 CD2 LEU 57 14.073 12.746 5.861 1.00 29.77 C ATOM 269 C LEU 57 10.588 11.891 8.385 1.00 18.46 C ATOM 270 O LEU 57 10.782 10.704 8.641 1.00 19.38 O ATOM 271 N GLY 58 9.693 12.639 9.023 1.00 16.71 N ATOM 272 CA GLY 58 8.883 12.060 10.077 1.00 18.09 C ATOM 273 C CLY 58 7.958 11.030 9.458 1.00 18.69 C ATOM 274 O GLY 58 7.750 9.948 10.012 1.00 17.12 O ATOM 275 N CLN 59 7.402 11.370 8.297 1.00 18.56 N ATOM 276 CA GLN 59 6.494 10.470 7.585 1.00 19.64 C ATOM 277 CB GLN 59 5.787 11.209 6.448 1.00 21.81 C ATOM 278 CG GLN 59 4.918 12.363 6.913 1.00 25.45 C ATOM 279 CD GLN 59 3.842 11.829 7.830 1.00 29.94 C ATOM 280 OE1 GLN 59 3.753 12.211 9.000 1.00 32.36 O ATOM 281 NE2 GLN 59 3.015 10.934 7.304 1.00 31.47 N ATOM 282 C GLN 59 7.212 9.228 7.062 1.00 18.28 C ATOM 283 O GLN 59 6.624 8.150 6.977 1.00 18.50 O ATOM 284 N TYR 60 8.488 9.391 6.725 1.00 17.72 N ATOM 285 CA TYR 60 9.322 8.294 6.237 1.00 19.36 C ATOM 286 CB TYR 60 10.699 8.816 5.829 1.00 19.10 C ATOM 287 CG TYR 60 11.675 7.746 5.386 1.00 21.10 C ATOM 288 CD1 TYR 60 11.634 7.221 4.095 1.00 22.00 C ATOM 289 CE1 TYR 60 12.526 6.224 3.691 1.00 20.83 C ATOM 290 CD2 TYR 60 12.635 7.247 6.269 1.00 21.10 C ATOM 291 CE2 TYR 60 13.532 6.245 5.876 1.00 20.35 C ATOM 292 CZ TYR 60 13.469 5.740 4.585 1.00 20.69 C ATOM 293 OH TYR 60 14.329 4.746 4.187 1.00 20.09 O ATOM 294 C TYR 60 9.474 7.246 7.335 1.00 19.51 C ATOM 295 O TYR 60 9.283 6.046 7.113 1.00 18.29 O ATOM 296 N ILE 61 9.812 7.722 8.527 1.00 17.99 N ATOM 297 CA ILE 61 10.012 6.851 9.675 1.00 19.08 C ATOM 298 CB ILE 61 10.521 7.687 10.878 1.00 20.08 C ATOM 299 CG2 ILE 61 10.452 6.869 12.164 1.00 20.84 C ATOM 300 CG1 ILE 61 11.945 8.179 10.586 1.00 18.04 C ATOM 301 CD1 ILE 61 12.547 9.033 11.670 1.00 20.08 C ATOM 302 C ILE 61 8.709 6.155 10.049 1.00 20.09 C ATOM 303 O ILE 61 8.692 4.975 10.406 1.00 19.98 O ATOM 304 N MET 62 7.606 6.879 9.933 1.00 20.53 N ATOM 305 CA MET 62 6.330 6.303 10.301 1.00 25.34 C ATOM 306 CB MET 62 5.305 7.398 10.599 1.00 28.26 C ATOM 307 CG MET 62 3.943 6.874 11.011 1.00 34.36 C ATOM 308 SD MET 62 2.800 8.211 11.360 1.00 41.93 S ATOM 309 CE MET 62 2.064 8.447 9.727 1.00 41.20 C ATOM 310 C MET 62 5.800 5.313 9.277 1.00 25.27 C ATOM 311 O MET 62 5.281 4.257 9.648 1.00 24.70 O ATOM 312 N THR 63 5.951 5.635 7.997 1.00 25.57 N ATOM 313 CA THR 63 5.441 4.755 6.954 1.00 28.86 C ATOM 314 CB THR 63 5.393 5.479 5.599 1.00 29.41 C ATOM 315 OG1 THR 63 4.566 6.641 5.722 1.00 33.31 O ATOM 316 CG2 THR 63 4.809 4.574 4.526 1.00 28.44 C ATOM 317 C THR 63 6.247 3.473 6.810 1.00 27.27 C ATOM 318 O THR 63 5.711 2.449 6.383 1.00 27.48 O ATOM 319 N LYS 64 7.526 3.510 7.168 1.00 26.66 N ATOM 320 CA LYS 64 8.324 2.295 7.087 1.00 26.49 C ATOM 321 CB LYS 64 9.730 2.517 6.523 1.00 26.55 C ATOM 322 CG LYS 64 9.740 3.088 5.117 1.00 29.11 C ATOM 323 CD LYS 64 11.150 3.247 4.571 1.00 28.43 C ATOM 324 CE LYS 64 11.850 1.886 4.510 1.00 29.76 C ATOM 325 NZ LYS 64 13.237 1.959 3.969 1.00 29.61 N ATOM 326 C LYS 64 8.375 1.642 8.453 1.00 25.50 C ATOM 327 O LYS 64 9.026 0.617 8.639 1.00 26.13 O ATOM 328 N ARG 65 7.678 2.255 9.403 1.00 24.76 N ATOM 329 CA ARG 65 7.607 1.754 10.765 1.00 25.45 C ATOM 330 CB ARG 65 6.672 0.542 10.843 1.00 31.11 C ATOM 331 CG ARG 65 5.246 0.879 10.397 1.00 35.38 C ATOM 332 CD ARG 65 4.303 −0.309 10.470 1.00 41.28 C ATOM 333 NE ARG 65 2.954 0.053 10.034 1.00 46.30 N ATOM 334 CZ ARG 65 1.897 −0.754 10.104 1.00 48.44 C ATOM 335 NH1 ARG 65 2.023 −1.978 10.598 1.00 49.25 N ATOM 336 NH2 ARG 65 0.712 −0.338 9.674 1.00 48.82 N ATOM 337 C ARG 65 8.979 1.472 11.378 1.00 25.07 C ATOM 338 O ARG 65 9.193 0.425 11.990 1.00 23.46 O ATOM 339 N LEU 66 9.910 2.409 11.202 1.00 22.51 N ATOM 340 CA LEU 66 11.259 2.246 11.745 1.00 21.93 C ATOM 341 CB LEU 66 12.251 3.184 11.063 1.00 21.83 C ATOM 342 CG LEU 66 12.406 3.035 9.552 1.00 21.63 C ATOM 343 CD1 LEU 66 13.391 4.062 9.015 1.00 20.95 C ATOM 344 CD2 LEU 66 12.838 1.634 9.170 1.00 20.51 C ATOM 345 C LEU 66 11.322 2.436 13.259 1.00 22.70 C ATOM 346 O LEU 66 12.325 2.115 13.893 1.00 22.69 O ATOM 347 N TYR 67 10.246 2.962 13.833 1.00 23.65 N ATOM 348 CA TYR 67 10.174 3.180 15.273 1.00 23.29 C ATOM 349 CB TYR 67 9.091 4.197 15.622 1.00 24.97 C ATOM 350 CG TYR 67 7.703 3.781 15.182 1.00 25.97 C ATOM 351 CD1 TYR 67 6.928 2.923 15.966 1.00 27.64 C ATOM 352 CE1 TYR 67 5.656 2.522 15.554 1.00 27.94 C ATOM 353 CD2 TYR 67 7.172 4.227 13.972 1.00 27.22 C ATOM 354 CE2 TYR 67 5.905 3.830 13.549 1.00 28.73 C ATOM 355 CZ TYR 67 5.153 2.980 14.345 1.00 29.04 C ATOM 356 OH TYR 67 3.899 2.594 13.930 1.00 29.83 O ATOM 357 C TYR 67 9.917 1.838 15.951 1.00 24.96 C ATOM 358 O TYR 67 9.215 0.992 15.404 1.00 26.17 O ATOM 359 N ASP 68 10.500 1.629 17.124 1.00 25.95 N ATOM 360 CA ASP 68 10.282 0.376 17.835 1.00 28.28 C ATOM 361 CB ASP 68 11.205 0.225 19.038 1.00 31.87 C ATOM 362 CG ASP 68 10.969 −1.082 19.781 1.00 35.20 C ATOM 363 OD1 ASP 68 10.683 −1.042 20.994 1.00 36.44 O ATOM 364 OD2 ASP 68 11.061 −2.149 19.141 1.00 36.99 O ATOM 365 C ASP 68 8.827 0.260 18.262 1.00 28.80 C ATOM 366 O ASP 68 8.286 1.157 18.907 1.00 23.20 O ATOM 367 N GLU 69 8.200 −0.851 17.898 1.00 32.27 N ATOM 368 CA GLU 69 6.799 −1.073 18.224 1.00 36.70 C ATOM 369 CB GLU 69 6.336 −2.428 17.684 1.00 40.26 C ATOM 370 CG GLU 69 4.873 −2.762 17.936 1.00 44.82 C ATOM 371 CD GLU 69 3.981 −1.727 17.266 1.00 48.03 C ATOM 372 OE1 GLU 69 3.189 −2.115 16.380 1.00 50.17 O ATOM 373 OE2 GLU 69 4.064 −0.532 17.621 1.00 50.09 O ATOM 374 C GLU 69 6.490 −0.956 19.719 1.00 36.29 C ATOM 375 O GLU 69 5.376 −0.587 20.089 1.00 35.50 O ATOM 376 N LYS 70 7.471 −1.245 20.574 1.00 36.45 N ATOM 377 CA LYS 70 7.246 −1.173 22.018 1.00 37.74 C ATOM 378 CB LYS 70 7.591 −2.501 22.694 1.00 40.70 C ATOM 379 CG LYS 70 6.766 −3.677 22.186 1.00 43.93 C ATOM 380 CD LYS 70 7.137 −4.979 22.889 1.00 46.97 C ATOM 381 CE LYS 70 6.298 −6.143 22.369 1.00 47.54 C ATOM 382 NZ LYS 70 6.634 −7.434 23.042 1.00 48.98 N ATOM 383 C LYS 70 7.928 −0.005 22.730 1.00 37.66 C ATOM 384 O LYS 70 7.557 0.348 23.852 1.00 39.60 O ATOM 385 N GLN 71 8.918 0.595 22.080 1.00 33.78 N ATOM 386 CA GLN 71 9.615 1.749 22.643 1.00 31.65 C ATOM 387 CB GLN 71 11.073 1.425 22.967 1.00 33.12 C ATOM 388 CG GLN 71 11.259 0.266 23.920 1.00 35.60 C ATOM 389 CD GLN 71 12.739 0.054 24.162 1.00 36.23 C ATOM 390 OE1 GLN 71 13.361 −0.811 23.548 1.00 35.70 O ATOM 391 NE2 GLN 71 13.305 0.826 25.081 1.00 35.71 N ATOM 392 C GLN 71 9.530 2.706 21.466 1.00 29.31 C ATOM 393 O GLN 71 10.488 2.864 20.713 1.00 23.70 O ATOM 394 N GLN 72 8.378 3.349 21.322 1.00 27.87 N ATOM 395 CA GLN 72 8.142 4.223 20.185 1.00 29.09 C ATOM 396 CB GLN 72 6.650 4.530 20.041 1.00 32.14 C ATOM 397 CG GLN 72 5.800 3.283 19.830 1.00 35.48 C ATOM 398 CD GLN 72 4.345 3.680 19.685 1.00 37.97 C ATOM 399 OE1 GLN 72 3.689 3.324 18.707 1.00 40.02 O ATOM 400 NE2 GLN 72 3.836 4.431 20.654 1.00 39.88 N ATOM 401 C GLN 72 8.975 5.480 20.002 1.00 27.04 C ATOM 402 O GLN 72 8.862 6.134 18.968 1.00 28.04 O ATOM 403 N HIS 73 9.814 5.823 20.973 1.00 25.52 N ATOM 404 CA HIS 73 10.638 7.017 20.817 1.00 26.50 C ATOM 405 CB HIS 73 10.876 7.728 22.155 1.00 29.45 C ATOM 406 CG HIS 73 11.649 6.914 23.147 1.00 33.08 C ATOM 407 CD2 HIS 73 11.240 6.122 24.167 1.00 34.44 C ATOM 408 ND1 HIS 73 13.025 6.847 23.136 1.00 34.94 N ATOM 409 CE1 HIS 73 13.432 6.048 24.109 1.00 35.16 C ATOM 410 NE2 HIS 73 12.369 5.596 24.748 1.00 34.82 N ATOM 411 C HIS 73 11.968 6.628 20.170 1.00 25.41 C ATOM 412 O HIS 73 12.763 7.494 19.797 1.00 24.29 O ATOM 413 N ILE 74 12.200 5.322 20.031 1.00 22.09 N ATOM 414 CA ILE 74 13.439 4.827 19.433 1.00 19.61 C ATOM 415 CB ILE 74 13.967 3.575 20.159 1.00 19.95 C ATOM 416 CG2 ILE 74 15.274 3.118 19.517 1.00 20.34 C ATOM 417 CG1 ILE 74 14.185 3.888 21.640 1.00 15.63 C ATOM 418 CD1 ILE 74 14.696 2.712 22.442 1.00 20.76 C ATOM 419 C ILE 74 13.275 4.472 17.966 1.00 20.12 C ATOM 420 O ILE 74 12.440 3.642 17.593 1.00 19.78 O ATOM 421 N VAL 75 14.083 5.107 17.131 1.00 18.20 N ATOM 422 CA VAL 75 14.034 4.856 15.703 1.00 17.89 C ATOM 423 CB VAL 75 14.193 6.171 14.901 1.00 17.74 C ATOM 424 CG1 VAL 75 14.278 5.862 13.413 1.00 20.35 C ATOM 425 CG2 VAL 75 13.025 7.106 15.185 1.00 19.50 C ATOM 426 C VAL 75 15.152 3.909 15.297 1.00 18.16 C ATOM 427 O VAL 75 16.326 4.218 15.493 1.00 18.79 O ATOM 428 N HIS 76 14.788 2.754 14.745 1.00 18.90 N ATOM 429 CA HIS 76 15.775 1.785 14.271 1.00 20.21 C ATOM 430 CB HIS 76 15.334 0.332 14.487 1.00 19.35 C ATOM 431 CG HIS 76 15.229 −0.064 15.924 1.00 18.87 C ATOM 432 CD2 HIS 76 14.203 0.011 16.804 1.00 20.15 C ATOM 433 ND1 HIS 76 16.292 −0.602 16.618 1.00 17.09 N ATOM 434 CE1 HIS 76 15.924 −0.841 17.864 1.00 18.81 C ATOM 435 NE2 HIS 76 14.661 −0.478 18.003 1.00 18.94 N ATOM 436 C HIS 76 16.102 2.027 12.810 1.00 21.94 C ATOM 437 O HIS 76 15.285 1.781 11.923 1.00 21.85 O ATOM 438 N CYS 77 17.314 2.496 12.567 1.00 19.97 N ATOM 439 CA CYS 77 17.743 2.787 11.217 1.00 22.10 C ATOM 440 CB CYS 77 17.956 4.292 11.050 1.00 21.37 C ATOM 441 SG CYS 77 19.086 4.999 12.249 1.00 23.82 S ATOM 442 C CYS 77 18.889 1.937 10.685 1.00 22.14 C ATOM 443 O CYS 77 19.434 2.212 9.619 1.00 21.97 O ATOM 444 N SER 78 19.251 0.899 11.434 1.00 22.19 N ATOM 445 CA SER 78 20.304 −0.010 11.000 1.00 24.97 C ATOM 446 CB SER 78 20.689 −1.008 12.098 1.00 24.27 C ATOM 447 OG SER 78 19.588 −1.819 12.475 1.00 23.96 O ATOM 448 C SER 78 19.746 −0.727 9.772 1.00 27.08 C ATOM 449 O SER 78 18.578 −1.098 9.752 1.00 29.90 O ATOM 450 N ASN 79 20.562 −0.896 8.739 1.00 31.08 N ATOM 451 CA ASN 79 20.102 −1.579 7.530 1.00 33.84 C ATOM 452 CB ASN 79 19.475 −2.939 7.856 1.00 37.91 C ATOM 453 CG ASN 79 20.430 −3.867 8.583 1.00 40.98 C ATOM 454 OD1 ASN 79 20.087 −4.436 9.623 1.00 44.02 O ATOM 455 ND2 ASN 79 21.639 −4.014 8.050 1.00 41.58 N ATOM 456 C ASN 79 19.130 −0.741 6.688 1.00 33.03 C ATOM 457 O ASN 79 18.500 −1.260 5.765 1.00 31.20 O ATOM 458 N ASP 80 18.995 0.543 7.013 1.00 28.81 N ATOM 459 CA ASP 80 18.098 1.425 6.263 1.00 24.65 C ATOM 460 CB ASP 80 16.875 1.821 7.091 1.00 23.49 C ATOM 461 CG ASP 80 15.880 2.662 6.307 1.00 24.25 C ATOM 462 OD1 ASP 80 14.807 2.115 5.975 1.00 23.20 O ATOM 463 OD2 ASP 80 16.143 3.855 6.033 1.00 22.88 O ATOM 464 C ASP 80 18.890 2.645 5.811 1.00 24.06 C ATOM 465 O ASP 80 19.814 3.078 6.505 1.00 21.20 O ATOM 466 N LEU 81 18.546 3.188 4.647 1.00 21.17 N ATOM 467 CA LEU 81 19.257 4.354 4.131 1.00 23.85 C ATOM 468 CB LEU 81 18.638 4.843 2.819 1.00 27.45 C ATOM 469 CG LEU 81 19.280 6.057 2.138 1.00 29.98 C ATOM 470 CD1 LEU 81 20.759 5.822 1.861 1.00 32.81 C ATOM 471 CD2 LEU 81 18.548 6.421 0.845 1.00 32.11 C ATOM 472 C LEU 81 19.313 5.486 5.155 1.00 21.14 C ATOM 473 O LEU 81 20.249 6.285 5.156 1.00 18.90 O ATOM 474 N LEU 82 18.325 5.546 6.042 1.00 18.54 N ATOM 475 CA LEU 82 18.318 6.598 7.052 1.00 15.44 C ATOM 476 CB LEU 82 17.019 6.590 7.857 1.00 16.76 C ATOM 477 CG LEU 82 16.897 7.650 8.953 1.00 16.50 C ATOM 478 CD1 LEU 82 17.090 9.052 8.382 1.00 17.63 C ATOM 479 CD2 LEU 82 15.559 7.538 9.694 1.00 17.39 C ATOM 480 C LEU 82 19.516 6.405 7.969 1.00 15.53 C ATOM 481 O LEU 82 20.070 7.373 8.495 1.00 15.91 O ATOM 482 N GLY 83 19.916 5.145 8.139 1.00 14.77 N ATOM 483 CA GLY 83 21.058 4.824 8.978 1.00 16.75 C ATOM 484 C GLY 83 22.341 5.353 8.365 1.00 19.93 C ATOM 485 O GLY 83 23.236 5.824 9.075 1.00 19.30 O ATOM 486 N ASP 84 22.445 5.278 7.042 1.00 20.23 N ATOM 487 CA ASP 84 23.640 5.790 6.376 1.00 19.77 C ATOM 488 CB ASP 84 23.694 5.372 4.903 1.00 22.40 C ATOM 489 CG ASP 84 23.784 3.865 4.712 1.00 24.25 C ATOM 490 OD1 ASP 84 24.006 3.137 5.700 1.00 24.82 O ATOM 491 OD2 ASP 84 23.627 3.407 3.562 1.00 25.98 O ATOM 492 C ASP 84 23.670 7.314 6.487 1.00 20.03 C ATOM 493 O ASP 84 24.739 7.919 6.577 1.00 19.62 O ATOM 494 N LEU 85 22.488 7.925 6.511 1.00 16.11 N ATOM 495 CA LEU 85 22.385 9.377 6.578 1.00 17.87 C ATOM 496 CB LEU 85 20.972 9.827 6.194 1.00 19.94 C ATOM 497 CG LEU 85 20.673 11.320 6.099 1.00 24.54 C ATOM 498 CD1 LEU 85 21.547 11.960 5.019 1.00 24.28 C ATOM 499 CD2 LEU 85 19.205 11.575 5.770 1.00 24.55 C ATOM 500 C LEU 85 22.779 9.897 7.965 1.00 18.33 C ATOM 501 O LEU 85 23.522 10.875 8.078 1.00 18.30 O ATOM 502 N PHE 86 22.297 9.247 9.022 1.00 18.48 N ATOM 503 CA PHE 86 22.646 9.686 10.372 1.00 19.70 C ATOM 504 CB PHE 86 21.491 9.506 11.370 1.00 22.89 C ATOM 505 CG PHE 86 20.283 10.375 11.092 1.00 25.20 C ATOM 506 CD1 PHE 86 19.282 10.504 12.051 1.00 29.11 C ATOM 507 CD2 PHE 86 20.175 11.114 9.915 1.00 26.71 C ATOM 508 CE1 PHE 86 18.195 11.359 11.850 1.00 26.77 C ATOM 509 CE2 PHE 86 19.091 11.972 9.702 1.00 28.12 C ATOM 510 CZ PHE 86 18.100 12.095 10.673 1.00 28.90 C ATOM 511 C PHE 86 23.943 9.104 10.927 1.00 19.63 C ATOM 512 O PHE 86 24.464 9.594 11.927 1.00 21.85 O ATOM 513 N GLY 87 24.468 8.074 10.272 1.00 18.21 N ATOM 514 CA GLY 87 25.713 7.467 10.715 1.00 20.13 C ATOM 515 C GLY 87 25.620 6.699 12.021 1.00 22.27 C ATOM 516 O GLY 87 26.612 6.552 12.737 1.00 21.79 O ATOM 517 N VAL 88 24.425 6.210 12.332 1.00 21.59 N ATOM 518 CA VAL 88 24.186 5.448 13.555 1.00 22.13 C ATOM 519 CB VAL 88 23.716 6.351 14.724 1.00 22.68 C ATOM 520 CG1 VAL 88 24.830 7.306 15.130 1.00 24.59 C ATOM 521 CG2 VAL 88 22.463 7.117 14.324 1.00 23.26 C ATOM 522 C VAL 88 23.105 4.408 13.305 1.00 21.88 C ATOM 523 O VAL 88 22.271 4.576 12.417 1.00 21.47 O ATOM 524 N PRO 89 23.116 3.307 14.074 1.00 22.24 N ATOM 525 CD PRO 89 23.982 2.960 15.221 1.00 23.24 C ATOM 526 CA PRO 89 22.110 2.267 13.901 1.00 20.32 C ATOM 527 CB PRO 89 22.807 1.064 14.503 1.00 23.05 C ATOM 528 CG PRO 89 23.286 1.669 15.787 1.00 22.08 C ATOM 529 C PRO 89 20.770 2.609 14.559 1.00 20.59 C ATOM 530 O PRO 89 19.775 1.912 14.343 1.00 21.33 O ATOM 531 N SER 90 20.743 3.688 15.341 1.00 18.62 N ATOM 532 CA SER 90 19.520 4.097 16.035 1.00 17.25 C ATOM 533 CB SER 90 19.109 3.069 17.085 1.00 18.96 C ATOM 534 OG SER 90 20.118 2.972 18.080 1.00 16.15 O ATOM 535 C SER 90 19.640 5.447 16.724 1.00 17.40 C ATOM 536 O SER 90 20.742 5.937 16.990 1.00 17.90 O ATOM 537 N PHE 91 18.486 6.040 17.013 1.00 15.60 N ATOM 538 CA PHE 91 18.422 7.308 17.718 1.00 16.44 C ATOM 539 CB PHE 91 18.750 8.512 16.828 1.00 19.56 C ATOM 540 CG PHE 91 17.793 8.708 15.682 1.00 19.09 C ATOM 541 CD1 PHE 91 17.923 7.972 14.512 1.00 19.65 C ATOM 542 CD2 PHE 91 16.756 9.634 15.783 1.00 21.34 C ATOM 543 CE1 PHE 91 17.033 8.153 13.450 1.00 20.79 C ATOM 544 CE2 PHE 91 15.858 9.824 14.728 1.00 20.20 C ATOM 545 CZ PHE 91 15.999 9.083 13.561 1.00 20.92 C ATOM 546 C PHE 91 17.043 7.491 18.334 1.00 18.30 C ATOM 547 O PHE 91 16.058 6.939 17.846 1.00 17.76 O ATOM 548 N SER 92 16.992 8.248 19.422 1.00 18.06 N ATOM 549 CA SER 92 15.737 8.575 20.083 1.00 20.21 C ATOM 550 CB SER 92 15.913 8.741 21.587 1.00 20.33 C ATOM 551 OG SER 92 14.676 9.099 22.181 1.00 22.41 O ATOM 552 C SER 92 15.224 9.875 19.468 1.00 20.17 C ATOM 553 O SER 92 16.010 10.786 19.203 1.00 19.59 O ATOM 554 N VAL 93 13.920 9.970 19.226 1.00 20.06 N ATOM 555 CA VAL 93 13.381 11.198 18.647 1.00 22.08 C ATOM 556 CB VAL 93 11.867 11.074 18.371 1.00 21.37 C ATOM 557 CG1 VAL 93 11.608 9.904 17.429 1.00 22.86 C ATOM 558 CG2 VAL 93 11.114 10.891 19.681 1.00 22.21 C ATOM 559 C VAL 93 13.614 12.384 19.583 1.00 22.18 C ATOM 560 O VAL 93 13.425 13.538 19.197 1.00 20.43 O ATOM 561 N LYS 94 14.038 12.098 20.811 1.00 24.14 N ATOM 562 CA LYS 94 14.298 13.153 21.784 1.00 25.77 C ATOM 563 CB LYS 94 14.142 12.620 23.213 1.00 30.87 C ATOM 564 CG LYS 94 15.094 11.484 23.557 1.00 36.14 C ATOM 565 CD LYS 94 14.888 10.965 24.976 1.00 40.51 C ATOM 566 CE LYS 94 13.467 10.431 25.164 1.00 42.75 C ATOM 567 NZ LYS 94 13.224 9.907 26.539 1.00 45.31 N ATOM 568 C LYS 94 15.677 13.781 21.558 1.00 24.88 C ATOM 569 O LYS 94 15.992 14.825 22.129 1.00 24.06 O ATOM 570 N GLU 95 16.488 13.144 20.715 1.00 23.25 N ATOM 571 CA GLU 95 17.823 13.653 20.393 1.00 22.14 C ATOM 572 CB GLU 95 18.761 12.526 19.940 1.00 24.17 C ATOM 573 CG GLU 95 19.031 11.470 21.011 1.00 28.59 C ATOM 574 CD GLU 95 19.963 10.399 20.463 1.00 31.12 C ATOM 575 OE1 GLU 95 21.188 10.511 20.674 1.00 33.36 O ATOM 576 OE2 GLU 95 19.473 9.430 19.847 1.00 32.84 O ATOM 577 C GLU 95 17.733 14.757 19.346 1.00 20.96 C ATOM 578 O GLU 95 18.275 14.639 18.245 1.00 18.40 O ATOM 579 N HIS 96 17.049 15.839 19.702 1.00 20.19 N ATOM 580 CA HIS 96 16.860 16.952 18.782 1.00 20.60 C ATOM 581 CB HIS 96 16.067 18.089 19.431 1.00 19.83 C ATOM 582 CG HIS 96 14.680 17.702 19.844 1.00 21.58 C ATOM 583 CD2 HIS 96 13.987 16.552 19.675 1.00 22.20 C ATOM 584 ND1 HIS 96 13.827 18.572 20.490 1.00 24.09 N ATOM 585 CE1 HIS 96 12.667 17.975 20.700 1.00 23.77 C ATOM 586 NE2 HIS 96 12.737 16.748 20.215 1.00 24.59 N ATOM 587 C HIS 96 18.105 17.502 18.110 1.00 19.96 C ATOM 588 O HIS 96 18.112 17.693 16.897 1.00 18.54 O ATOM 589 N ARG 97 19.163 17.750 18.873 1.00 19.16 N ATOM 590 CA ARG 97 20.343 18.309 18.241 1.00 21.59 C ATOM 591 CB ARG 97 21.402 18.733 19.254 1.00 23.22 C ATOM 592 CG ARG 97 22.605 19.332 18.560 1.00 26.59 C ATOM 593 CD ARG 97 23.697 19.791 19.503 1.00 29.57 C ATOM 594 NE ARG 97 24.804 20.353 18.733 1.00 30.13 N ATOM 595 CZ ARG 97 25.877 20.930 19.263 1.00 31.77 C ATOM 596 NH1 ARG 97 25.998 21.028 20.581 1.00 30.89 N ATOM 597 NH2 ARG 97 26.825 21.417 18.470 1.00 30.56 N ATOM 598 C ARG 97 20.927 17.382 17.187 1.00 20.19 C ATOM 599 O ARG 97 21.341 17.836 16.124 1.00 18.40 O ATOM 600 N LYS 98 20.945 16.083 17.472 1.00 20.40 N ATOM 601 CA LYS 98 21.462 15.113 16.512 1.00 22.67 C ATOM 602 CB LYS 98 21.499 13.710 17.125 1.00 25.02 C ATOM 603 CG LYS 98 21.910 12.590 16.172 1.00 28.25 C ATOM 604 CD LYS 98 23.290 12.753 15.572 1.00 32.85 C ATOM 605 CE LYS 98 23.591 11.577 14.640 1.00 35.25 C ATOM 606 NZ LYS 98 24.936 11.653 13.997 1.00 38.28 N ATOM 607 C LYS 98 20.636 15.113 15.232 1.00 21.36 C ATOM 608 O LYS 98 21.177 15.067 14.124 1.00 20.55 O ATOM 609 N ILE 99 19.322 15.183 15.395 1.00 17.78 N ATOM 610 CA ILE 99 18.409 15.168 14.261 1.00 16.72 C ATOM 611 CB ILE 99 16.962 15.036 14.757 1.00 18.32 C ATOM 612 CG2 ILE 99 15.999 15.108 13.577 1.00 18.94 C ATOM 613 CG1 ILE 99 16.813 13.713 15.522 1.00 18.48 C ATOM 614 CD1 ILE 99 15.432 13.460 16.100 1.00 20.38 C ATOM 615 C ILE 99 18.556 16.406 13.379 1.00 15.71 C ATOM 616 O ILE 99 18.745 16.289 12.166 1.00 16.59 O ATOM 617 N TYR 100 18.473 17.594 13.970 1.00 16.29 N ATOM 618 CA TYR 100 18.649 18.801 13.168 1.00 15.73 C ATOM 619 CB TYR 100 18.384 20.081 13.959 1.00 17.85 C ATOM 620 CG TYR 100 16.958 20.305 14.383 1.00 18.03 C ATOM 621 CD1 TYR 100 15.989 20.628 13.433 1.00 18.59 C ATOM 622 CE1 TYR 100 14.686 20.920 13.805 1.00 19.33 C ATOM 623 CD2 TYR 100 16.585 20.272 15.724 1.00 19.08 C ATOM 624 CE2 TYR 100 15.277 20.564 16.108 1.00 20.31 C ATOM 625 CZ TYR 100 14.337 20.889 15.142 1.00 20.85 C ATOM 626 OH TYR 100 13.047 21.200 15.505 1.00 20.48 O ATOM 627 C TYR 100 20.028 18.898 12.547 1.00 17.08 C ATOM 628 O TYR 100 20.177 19.362 11.417 1.00 17.10 O ATOM 629 N THR 101 21.038 18.455 13.282 1.00 17.01 N ATOM 630 CA THR 101 22.395 18.547 12.771 1.00 18.10 C ATOM 631 CB THR 101 23.421 18.061 13.818 1.00 19.38 C ATOM 632 OG1 THR 101 23.409 18.950 14.944 1.00 19.40 O ATOM 633 CG2 THR 101 24.827 18.023 13.219 1.00 21.23 C ATOM 634 C THR 101 22.563 17.729 11.509 1.00 17.82 C ATOM 635 O THR 101 23.123 18.207 10.523 1.00 18.96 O ATOM 636 N MET 102 22.055 16.503 11.515 1.00 14.87 N ATOM 637 CA MET 102 22.241 15.673 10.345 1.00 18.86 C ATOM 638 CB MET 102 22.051 14.200 10.687 1.00 22.58 C ATOM 639 CG MET 102 22.968 13.769 11.831 1.00 25.73 C ATOM 640 SD MET 102 24.729 14.046 11.491 1.00 29.72 S ATOM 641 CE MET 102 25.017 12.908 10.134 1.00 26.51 C ATOM 642 C MET 102 21.366 16.115 9.181 1.00 17.36 C ATOM 643 O MET 102 21.716 15.918 8.019 1.00 17.66 O ATOM 644 N ILE 103 20.242 16.746 9.488 1.00 17.10 N ATOM 645 CA ILE 103 19.360 17.217 8.432 1.00 18.31 C ATOM 646 CB ILE 103 17.971 17.598 9.004 1.00 18.43 C ATOM 647 CG2 ILE 103 17.137 18.308 7.942 1.00 19.89 C ATOM 648 CG1 ILE 103 17.261 16.336 9.503 1.00 21.17 C ATOM 649 CD1 ILE 103 15.895 16.591 10.129 1.00 21.70 C ATOM 650 C ILE 103 19.997 18.442 7.778 1.00 18.58 C ATOM 651 O ILE 103 20.091 18.521 6.552 1.00 18.12 O ATOM 652 N TYR 104 20.461 19.384 8.598 1.00 17.58 N ATOM 653 CA TYR 104 21.063 20.600 8.065 1.00 19.92 C ATOM 654 CB TYR 104 21.408 21.597 9.171 1.00 17.24 C ATOM 655 CG TYR 104 20.245 22.073 10.015 1.00 19.35 C ATOM 656 CD1 TYR 104 18.920 21.924 9.590 1.00 17.10 C ATOM 657 CE1 TYR 104 17.861 22.409 10.365 1.00 19.27 C ATOM 658 CD2 TYR 104 20.479 22.714 11.227 1.00 17.95 C ATOM 659 CE2 TYR 104 19.439 23.196 12.001 1.00 19.03 C ATOM 660 CZ TYR 104 18.137 23.044 11.571 1.00 18.59 C ATOM 661 OH TYR 104 17.125 23.531 12.363 1.00 18.75 O ATOM 662 C TYR 104 22.308 20.332 7.224 1.00 18.77 C ATOM 663 O TYR 104 22.544 21.020 6.234 1.00 17.01 O ATOM 664 N ARG 105 23.095 19.332 7.608 1.00 19.90 N ATOM 665 CA ARG 105 24.303 19.019 6.850 1.00 22.21 C ATOM 666 CB ARG 105 25.252 18.112 7.634 1.00 23.00 C ATOM 667 CG ARG 105 25.786 18.721 8.916 1.00 25.04 C ATOM 668 CD ARG 105 26.724 17.753 9.616 1.00 27.11 C ATOM 669 NE ARG 105 27.269 18.306 10.853 1.00 27.31 N ATOM 670 CZ ARG 105 27.986 17.604 11.724 1.00 28.44 C ATOM 671 NH1 ARG 105 28.241 16.324 11.488 1.00 27.73 N ATOM 672 NH2 ARG 105 28.442 18.175 12.831 1.00 28.80 N ATOM 673 C ARG 105 24.007 18.433 5.479 1.00 22.30 C ATOM 674 O ARG 105 24.893 18.333 4.632 1.00 24.22 O ATOM 675 N ASN 106 22.752 18.054 5.267 1.00 20.53 N ATOM 676 CA ASN 106 22.317 17.497 3.993 1.00 21.19 C ATOM 677 CB ASN 106 21.721 16.097 4.143 1.00 19.77 C ATOM 678 CG ASN 106 22.744 15.084 4.612 1.00 22.79 C ATOM 679 OD1 ASN 106 23.423 14.470 3.788 1.00 23.07 O ATOM 680 ND2 ASN 106 22.843 14.879 5.924 1.00 19.66 N ATOM 681 C ASN 106 21.414 18.414 3.191 1.00 20.46 C ATOM 682 O ASN 106 20.657 17.967 2.324 1.00 19.35 O ATOM 683 N LEU 107 21.510 19.703 3.497 1.00 20.37 N ATOM 684 CA LEU 107 20.722 20.740 2.845 1.00 22.38 C ATOM 685 CB LEU 107 19.663 21.303 3.791 1.00 21.77 C ATOM 686 CG LEU 107 18.618 20.323 4.316 1.00 23.03 C ATOM 687 CD1 LEU 107 17.706 20.996 5.334 1.00 21.74 C ATOM 688 CD2 LEU 107 17.816 19.716 3.169 1.00 22.14 C ATOM 689 C LEU 107 21.586 21.872 2.306 1.00 23.14 C ATOM 690 O LEU 107 22.618 22.205 2.884 1.00 22.39 O ATOM 691 N VAL 108 21.158 22.445 1.189 1.00 23.48 N ATOM 692 CA VAL 108 21.846 23.569 0.566 1.00 26.51 C ATOM 693 CB VAL 108 22.484 23.158 −0.776 1.00 28.25 C ATOM 694 CG1 VAL 108 23.128 24.364 −1.432 1.00 31.06 C ATOM 695 CG2 VAL 108 23.511 22.064 −0.543 1.00 30.49 C ATOM 696 C VAL 108 20.795 24.647 0.304 1.00 25.74 C ATOM 697 O VAL 108 19.766 24.363 −0.301 1.00 24.47 O ATOM 698 N VAL 109 21.042 25.871 0.767 1.00 25.08 N ATOM 699 CA VAL 109 20.096 26.958 0.548 1.00 28.59 C ATOM 700 CB VAL 109 20.491 28.224 1.325 1.00 30.38 C ATOM 701 CG1 VAL 109 19.457 29.320 1.088 1.00 30.40 C ATOM 702 CG2 VAL 109 20.600 27.907 2.809 1.00 30.06 C ATOM 703 C VAL 109 20.007 27.285 −0.942 1.00 31.09 C ATOM 704 O VAL 109 21.017 27.538 −1.600 1.00 30.68 O ATOM 705 N VAL 110 18.784 27.273 −1.457 1.00 34.26 N ATOM 706 CA VAL 110 18.497 27.512 −2.869 1.00 40.68 C ATOM 707 CB VAL 110 17.092 26.951 −3.231 1.00 41.37 C ATOM 708 CG1 VAL 110 16.776 27.222 −4.691 1.00 42.09 C ATOM 709 CG2 VAL 110 17.046 25.456 −2.948 1.00 41.30 C ATOM 710 C VAL 110 18.586 28.950 −3.376 1.00 45.42 C ATOM 711 O VAL 110 18.320 29.904 −2.643 1.00 45.46 O ATOM 712 N ASN 111 18.980 29.063 −4.644 1.00 50.62 N ATOM 713 CA ASN 111 19.090 30.319 −5.380 1.00 54.41 C ATOM 714 CB ASN 111 18.454 30.130 −6.764 1.00 57.01 C ATOM 715 CG ASN 111 18.469 31.386 −7.600 1.00 59.53 C ATOM 716 OD1 ASN 111 17.413 31.886 −7.991 1.00 60.59 O ATOM 717 ND2 ASN 111 19.660 31.900 −7.891 1.00 60.11 N ATOM 718 C ASN 111 18.521 31.547 −4.662 1.00 54.78 C ATOM 719 O ASN 111 17.400 31.982 −4.938 1.00 56.01 O ATOM 720 C1 SCH 996 −1.000 8.674 15.423 1.00 58.94 ATOM 721 C2 SCH 996 0.074 7.820 16.068 1.00 58.85 ATOM 722 O1 SCH 996 −0.100 7.261 17.153 1.00 59.47 ATOM 723 N1 SCH 996 1.202 7.745 15.337 1.00 57.09 ATOM 724 C3 SCH 996 2.471 7.578 16.042 1.00 55.53 ATOM 725 C4 SCH 996 3.102 8.922 16.429 1.00 58.30 ATOM 726 O2 SCH 996 3.020 9.892 15.673 1.00 59.95 ATOM 727 N2 SCH 996 3.724 8.908 17.631 1.00 61.62 ATOM 728 C5 SCH 996 4.020 10.154 18.329 1.00 63.29 ATOM 729 C6 SCH 996 2.706 10.796 18.790 1.00 65.39 ATOM 730 O3 SCH 996 2.516 12.011 18.716 1.00 65.59 ATOM 731 N3 SCH 996 1.822 9.901 19.269 1.00 67.92 ATOM 732 C7 SCH 996 0.554 10.407 19.793 1.00 70.11 ATOM 733 C8 SCH 996 0.346 9.699 20.930 1.00 70.97 ATOM 734 O4 SCH 996 0.223 10.153 22.077 1.00 71.51 ATOM 735 O5 SCH 996 0.325 8.321 20.830 1.00 71.56 ATOM 736 C9 SCH 996 3.406 6.688 15.192 1.00 49.97 ATOM 737 C10 SCH 996 −0.504 10.428 18.687 1.00 70.56 ATOM 738 C11 SCH 996 −0.315 11.537 17.664 1.00 71.51 ATOM 739 C12 SCH 996 −1.305 12.653 17.941 1.00 72.44 ATOM 740 O6 SCH 996 −0.991 13.651 18.515 1.00 72.59 ATOM 741 O7 SCH 996 −2.556 12.416 17.482 1.00 72.61 ATOM 742 C13 SCH 996 4.852 6.796 15.638 1.00 44.76 ATOM 743 C14 SCH 996 5.890 7.608 15.051 1.00 41.72 ATOM 744 C15 SCH 996 7.096 7.390 15.825 1.00 40.91 ATOM 745 N4 SCH 996 6.776 6.472 16.833 1.00 40.79 ATOM 746 C16 SCH 996 5.458 6.131 16.715 1.00 43.06 ATOM 747 C17 SCH 996 5.912 8.510 13.946 1.00 40.02 ATOM 748 C18 SCH 996 7.115 9.193 13.606 1.00 37.25 ATOM 749 C19 SCH 996 8.298 8.983 14.370 1.00 36.32 ATOM 750 C20 SCH 996 8.295 8.082 15.474 1.00 37.47 ATOM 751 CL1 SCH 996 9.737 9.840 13.965 1.00 29.32 ATOM 752 C21 SCH 996 4.747 11.137 17.396 1.00 62.87 ATOM 753 C22 SCH 996 4.877 9.854 19.566 1.00 62.94 ATOM 754 C23 SCH 996 6.279 9.364 19.188 1.00 62.44 ATOM 755 C24 SCH 996 6.166 10.673 17.043 1.00 62.33 ATOM 756 C25 SCH 996 7.006 10.356 18.280 1.00 62.08 ATOM 757 C1 SCH 998 7.020 14.306 19.529 1.00 32.04 ATOM 758 C2 SCH 998 8.132 14.220 18.499 1.00 30.99 ATOM 759 O1 SCH 998 9.294 13.953 18.813 1.00 31.33 ATOM 760 N1 SCH 998 7.711 14.463 17.243 1.00 28.90 ATOM 761 C3 SCH 998 8.715 14.626 16.190 1.00 28.20 ATOM 762 C4 SCH 998 9.050 16.095 15.923 1.00 28.60 ATOM 763 O2 SCH 998 8.184 16.880 15.527 1.00 28.06 ATOM 764 N2 SCH 998 10.342 16.402 16.159 1.00 26.21 ATOM 765 C5 SCH 998 10.807 17.775 16.036 1.00 28.33 ATOM 766 C6 SCH 998 9.978 18.673 16.963 1.00 33.18 ATOM 767 O3 SCH 998 9.634 19.808 16.630 1.00 35.64 ATOM 768 N3 SCH 998 9.686 18.088 18.140 1.00 37.61 ATOM 769 C7 SCH 998 8.697 18.731 19.006 1.00 42.54 ATOM 770 C8 SCH 998 9.245 18.545 20.404 1.00 42.96 ATOM 771 O4 SCH 998 9.535 19.446 21.049 1.00 44.48 ATOM 772 O5 SCH 998 9.382 17.262 20.693 1.00 43.12 ATOM 773 C9 SCH 998 8.244 13.892 14.923 1.00 27.77 ATOM 774 C10 SCH 998 7.290 18.240 18.661 1.00 44.92 ATOM 775 C11 SCH 998 6.730 18.812 17.368 1.00 48.30 ATOM 776 C12 SCH 998 5.583 19.752 17.684 1.00 49.87 ATOM 777 O6 SCH 998 5.601 20.902 17.365 1.00 51.11 ATOM 778 O7 SCH 998 4.554 19.175 18.348 1.00 50.51 ATOM 779 C13 SCH 998 9.158 14.149 13.740 1.00 25.37 ATOM 780 C14 SCH 998 10.480 13.618 13.499 1.00 25.02 ATOM 781 C15 SCH 998 10.902 14.099 12.199 1.00 25.73 ATOM 782 N4 SCH 998 9.868 14.895 11.699 1.00 25.53 ATOM 783 C16 SCH 998 8.852 14.918 12.609 1.00 25.55 ATOM 784 C17 SCH 998 11.350 12.777 14.254 1.00 25.02 ATOM 785 C18 SCH 998 12.617 12.399 13.724 1.00 25.30 ATOM 786 C19 SCH 998 13.020 12.858 12.437 1.00 26.55 ATOM 787 C20 SCH 998 12.171 13.711 11.677 1.00 24.81 ATOM 788 CL1 SCH 998 14.529 12.355 11.778 1.00 26.71 ATOM 789 C21 SCH 998 10.639 18.264 14.593 1.00 26.42 ATOM 790 C22 SCH 998 12.279 17.852 16.457 1.00 26.82 ATOM 791 C23 SCH 998 13.181 17.061 15.496 1.00 25.79 ATOM 792 C24 SCH 998 11.554 17.510 13.617 1.00 24.84 ATOM 793 C25 SCH 998 13.025 17.532 14.048 1.00 24.21 ATOM 794 C1 SCH 999 14.304 27.533 13.501 1.00 20.77 ATOM 795 C2 SCH 999 14.911 27.965 12.179 1.00 20.52 ATOM 796 O1 SCH 999 14.277 28.618 11.350 1.00 21.90 ATOM 797 N1 SCH 999 16.183 27.557 12.024 1.00 19.32 ATOM 798 C3 SCH 999 16.883 27.892 10.787 1.00 20.88 ATOM 799 C4 SCH 999 16.080 27.517 9.526 1.00 22.08 ATOM 800 O2 SCH 999 15.657 26.372 9.370 1.00 21.93 ATOM 801 N2 SCH 999 15.894 28.551 8.669 1.00 22.51 ATOM 802 C5 SCH 999 15.213 28.377 7.382 1.00 24.88 ATOM 803 C6 SCH 999 13.709 28.188 7.602 1.00 26.16 ATOM 804 O3 SCH 999 12.953 27.935 6.665 1.00 27.24 ATOM 805 N3 SCH 999 13.318 28.331 8.879 1.00 27.90 ATOM 806 C7 SCH 999 11.886 28.201 9.143 1.00 31.35 ATOM 807 C8 SCH 999 11.241 29.583 9.052 1.00 34.43 ATOM 808 O4 SCH 999 10.006 29.558 9.037 1.00 35.86 ATOM 809 O5 SCH 999 11.994 30.531 8.919 1.00 36.30 ATOM 810 C9 SCH 999 18.277 27.245 10.824 1.00 20.43 ATOM 811 C10 SCH 999 11.653 27.295 10.349 1.00 31.35 ATOM 812 C11 SCH 999 12.066 25.844 10.129 1.00 29.83 ATOM 813 C12 SCH 999 11.716 25.026 11.360 1.00 32.05 ATOM 814 O6 SCH 999 12.531 24.381 11.942 1.00 31.48 ATOM 815 O7 SCH 999 10.416 25.092 11.730 1.00 32.95 ATOM 816 C13 SCH 999 19.093 27.591 9.595 1.00 21.99 ATOM 817 C14 SCH 999 19.603 26.675 8.606 1.00 21.11 ATOM 818 C15 SCH 999 20.326 27.456 7.626 1.00 22.79 ATOM 819 N4 SCH 999 20.243 28.793 8.029 1.00 23.21 ATOM 820 C16 SCH 999 19.518 28.863 9.184 1.00 22.90 ATOM 821 C17 SCH 999 19.512 25.260 8.455 1.00 21.66 ATOM 822 C18 SCH 999 20.126 24.621 7.341 1.00 23.05 ATOM 823 C19 SCH 999 20.833 25.388 6.371 1.00 22.06 ATOM 824 C20 SCH 999 20.937 26.803 6.511 1.00 22.85 ATOM 825 CL1 SCH 999 21.550 24.594 5.014 1.00 26.59 ATOM 826 C21 SCH 999 15.747 27.140 6.639 1.00 23.66 ATOM 827 C22 SCH 999 15.409 29.639 6.533 1.00 24.90 ATOM 828 C23 SCH 999 16.867 29.820 6.129 1.00 24.75 ATOM 829 C24 SCH 999 17.176 27.321 6.103 1.00 23.22 ATOM 830 C25 SCH 999 17.379 28.625 5.329 1.00 23.88 ATOM 831 OH2 WAT 1001 3.395 9.112 −1.435 1.00 16.59 O ATOM 839 OH2 WAT 1002 24.775 12.618 6.376 1.00 17.52 O ATOM 832 OH2 WAT 1003 18.514 −0.561 14.622 1.00 18.25 O ATOM 835 OH2 WAT 1004 15.044 24.301 11.181 1.00 18.80 O ATOM 856 OH2 WAT 1005 20.867 15.283 20.436 1.00 24.20 O ATOM 842 OH2 WAT 1006 9.724 26.049 6.031 1.00 24.72 O ATOM 860 OH2 WAT 1007 6.074 13.931 10.197 1.00 24.81 O ATOM 857 OH2 WAT 1008 21.757 8.195 18.608 1.00 25.80 O ATOM 833 OH2 WAT 1009 12.107 26.746 4.500 1.00 25.85 O ATOM 843 OH2 WAT 1010 16.620 1.807 2.942 1.00 26.33 O ATOM 870 OH2 WAT 1011 7.466 20.307 9.569 1.00 26.55 O ATOM 848 OH2 WAT 1012 11.574 22.642 13.779 1.00 26.80 O ATOM 834 OH2 WAT 1013 13.759 −1.012 20.605 1.00 28.49 O ATOM 840 OH2 WAT 1014 25.743 20.101 15.817 1.00 28.57 O ATOM 855 OH2 WAT 1015 0.544 11.546 5.002 1.00 29.35 O ATOM 844 OH2 WAT 1016 21.356 8.460 22.469 1.00 30.69 O ATOM 836 OH2 WAT 1017 14.502 −0.707 6.212 1.00 31.40 O ATOM 841 OH2 WAT 1018 11.775 14.532 17.517 1.00 31.42 O ATOM 851 OH2 WAT 1019 22.475 1.722 7.609 1.00 31.99 O ATOM 859 OH2 WAT 1020 5.732 18.551 −1.162 1.00 32.12 O ATOM 872 OH2 WAT 1021 23.725 20.929 22.606 1.00 34.79 O ATOM 862 OH2 WAT 1022 23.860 26.433 1.644 1.00 34.96 O ATOM 863 OH2 WAT 1023 5.394 16.356 11.571 1.00 35.71 O ATOM 861 OH2 WAT 1024 21.332 30.796 5.811 1.00 36.70 O ATOM 847 OH2 WAT 1025 9.148 −2.863 15.900 1.00 37.64 O ATOM 858 OH2 WAT 1026 14.166 16.525 23.729 1.00 37.84 O ATOM 866 OH2 WAT 1027 11.334 30.280 5.618 1.00 38.35 O ATOM 864 OH2 WAT 1028 18.007 18.195 −4.362 1.00 40.37 O ATOM 871 OH2 WAT 1029 11.860 21.767 17.854 1.00 40.71 O ATOM 874 OH2 WAT 1030 8.276 27.446 8.045 1.00 41.07 O ATOM 846 OH2 WAT 1031 7.632 18.152 11.360 1.00 42.63 O ATOM 865 OH2 WAT 1032 25.898 10.512 16.626 1.00 43.37 O ATOM 854 OH2 WAT 1033 8.159 −1.042 14.070 1.00 44.00 O ATOM 852 OH2 WAT 1034 28.464 14.740 9.077 1.00 46.88 O ATOM 845 OH2 WAT 1035 2.078 6.181 4.658 1.00 47.60 O ATOM 838 OH2 WAT 1036 26.484 15.271 4.182 1.00 47.99 O ATOM 867 OH2 WAT 1037 23.657 28.439 −1.144 1.00 50.33 O ATOM 837 OH2 WAT 1038 13.538 21.361 20.180 1.00 54.13 O ATOM 869 OH2 WAT 1039 25.590 16.309 16.444 1.00 54.19 O ATOM 850 OH2 WAT 1040 26.845 13.685 16.859 1.00 55.86 O ATOM 873 OH2 WAT 1041 27.978 4.166 14.080 1.00 55.87 O ATOM 868 OH2 WAT 1042 20.489 1.898 −2.662 1.00 56.16 O ATOM 853 OH2 WAT 1043 17.178 10.875 −6.741 1.00 59.20 O ATOM 849 OH2 WAT 1044 25.481 2.906 8.796 1.00 63.46 O END

EXAMPLE 3 Preparation and Crystallization of Hdm2 Y76H-Tripeptide Complex

Production and Crystallization of Modified Hdm2(Y76H):

The modified Hdm2(Y76H) protein was produced using the QuickChange site-directed mutagenesis method as discussed in Example 1 except that only the primers for Y76H were used in mutagenesis. The p53 peptide analog, Ac-^(6Cl)WAC_(3c)E, disclosed and defined above, was dissolved in the same buffer and added to the Hdm2(Y76H) protein solution.

The single mutant HDM2 (17-125) Y76H-tripeptide complex was crystallized using a hanging-drop vapor diffusion method. The protein-peptide solution (1 μl; 6-10 mg/ml) in buffer A was mixed with an equal volume of precipitant [0.1 M Tris, pH 8-9, 35% PEG 4000, and 0.0 to 0.2 M magnesium chloride], placed on the underside of a siliconized glass coverslip and sealed in close proximity to 1 ml of the precipitant solution. Vapor diffusion crystallization experiments were conducted using the hanging drop method. Specifically, crystals were grown from a droplet containing a mixture of 0.5-2.0 μl of protein and 0.5-1.0 μl of the precipitant solution. Crystallization plates were incubated at 4° C.; rectangular rod crystals (0.1×0.1×0.3 mm) grew over 2-30 days.

Prior to data collection, crystals were washed with the reservoir solution of the crystallization setup and transferred into the same solution with 10% glycerol added. The crystals were then flash-cooled in a nitrogen stream at 95 K. X-ray diffraction was collected using a Riga generator equipped with a Praxis 4++ detector. Data were integrated and scaled using the HKL package.

Data Collection Statistics: Resolution 50.0-.20 Å No. of collected reflections 13234 No. of unique reflections (F >= 0)  4341 R-sym  6.2% Percent of theoretical (I/s >= 1) 84.8% Unit Cell a = 41.1 Å, b = 42.7 Å, c = 53.777 Å, α = β = γ = 90° Space Group P2₁2₁2₁ Asymmetric unit 1 molecule

The crystal structure was solved using molecular replacement using the search models 1YCQ and 1YCR from the PDB. Refinement was done using the program CNX. Theoretical number of reflections 5854 Resolution Limits 50.0-2.1 Å Number of unobserved reflections 1529 (26.1%) Number of reflections in working set 4325 (73.9%) Number of reflections in test set  197 (3.4%) Number of protein residues  87 Number of solvent atoms   0 R-factor   0.45 R-free   0.51 RMSD bond length     0.014 Å RMSD bond angles 1.97°

The structural coordinates for the above-described Hdm2 crystal are set forth below in Table 4. TABLE 4 1 2 3 4 5 6 7 8 9 10 11 ATOM 1 CB GLU 25 7.387 −0.822 5.902 1.00 31.40 C ATOM 2 CG GLU 25 7.019 −0.298 4.509 1.00 35.01 C ATOM 3 CD GLU 25 7.873 −0.972 3.442 1.00 37.01 C ATOM 4 OE1 GLU 25 7.321 −1.714 2.600 1.00 35.86 O ATOM 5 OE2 GLU 25 9.101 −0.744 3.437 1.00 38.68 O ATOM 6 C GLU 25 5.081 −0.176 6.662 1.00 30.27 C ATOM 7 O GLU 25 4.374 −1.161 6.879 1.00 31.21 O ATOM 8 N GLU 25 6.922 −0.708 8.375 1.00 29.47 N ATOM 9 CA GLU 25 6.567 −0.166 7.021 1.00 31.52 C ATOM 10 N THR 26 4.610 0.938 6.116 1.00 28.18 N ATOM 11 CA THR 26 3.217 1.047 5.711 1.00 24.93 C ATOM 12 CB THR 26 2.441 2.031 6.611 1.00 24.28 C ATOM 13 OG1 THR 26 2.654 1.706 7.990 1.00 23.56 O ATOM 14 CG2 THR 26 0.955 1.959 6.304 1.00 22.48 C ATOM 15 C THR 26 3.096 1.533 4.264 1.00 24.10 C ATOM 16 O THR 26 3.633 2.581 3.908 1.00 22.83 O ATOM 17 N LEU 27 2.405 0.760 3.431 1.00 19.92 N ATOM 18 CA LEU 27 2.177 1.160 2.047 1.00 20.55 C ATOM 19 CB LEU 27 2.052 −0.044 1.107 1.00 22.12 C ATOM 20 CG LEU 27 3.257 −0.991 1.005 1.00 24.55 C ATOM 21 CD1 LEU 27 2.945 −2.199 0.113 1.00 22.27 C ATOM 22 CD2 LEU 27 4.506 −0.259 0.513 1.00 22.59 C ATOM 23 C LEU 27 0.899 1.995 2.057 1.00 19.40 C ATOM 24 O LEU 27 −0.124 1.568 2.599 1.00 18.49 O ATOM 25 N VAL 28 0.956 3.190 1.476 1.00 20.26 N ATOM 26 CA VAL 28 −0.206 4.075 1.457 1.00 21.18 C ATOM 27 CB VAL 28 −0.090 5.200 2.523 1.00 19.01 C ATOM 28 CG1 VAL 28 0.094 4.599 3.897 1.00 19.71 C ATOM 29 CG2 VAL 28 1.057 6.125 2.183 1.00 20.08 C ATOM 30 C VAL 28 −0.481 4.741 0.118 1.00 21.98 C ATOM 31 O VAL 28 0.431 4.966 −0.679 1.00 23.19 O ATOM 32 N ARG 29 −1.755 5.042 −0.120 1.00 23.38 N ATOM 33 CA ARG 29 −2.188 5.722 −1.338 1.00 25.82 C ATOM 34 CB ARG 29 −3.239 4.904 −2.089 1.00 27.99 C ATOM 35 CG ARG 29 −2.761 3.515 −2.489 1.00 30.54 C ATOM 36 CD ARG 29 −3.838 2.738 −3.220 1.00 33.91 C ATOM 37 NE ARG 29 −3.398 1.395 −3.590 1.00 37.13 N ATOM 38 CZ ARG 29 −2.478 1.134 −4.511 1.00 39.21 C ATOM 39 NH1 ARG 29 −1.896 2.131 −5.168 1.00 41.39 N ATOM 40 NH2 ARG 29 −2.135 −0.122 −4.771 1.00 39.25 N ATOM 41 C ARG 29 −2.743 7.082 −0.905 1.00 26.04 C ATOM 42 O ARG 29 −3.723 7.163 −0.162 1.00 25.87 O ATOM 43 N PRO 30 −2.100 8.167 −1.358 1.00 25.80 N ATOM 44 CD PRO 30 −0.679 8.055 −1.738 1.00 24.67 C ATOM 45 CA PRO 30 −2.394 9.579 −1.111 1.00 22.90 C ATOM 46 CB PRO 30 −1.203 10.259 −1.751 1.00 22.35 C ATOM 47 CG PRO 30 −0.114 9.428 −1.255 1.00 26.65 C ATOM 48 C PRO 30 −3.699 10.094 −1.723 1.00 22.50 C ATOM 49 O PRO 30 −4.062 9.701 −2.835 1.00 21.62 O ATOM 50 N LYS 31 −4.411 10.954 −1.001 1.00 22.08 N ATOM 51 CA LYS 31 −5.593 11.574 −1.590 1.00 23.03 C ATOM 52 CB LYS 31 −6.451 12.381 −0.620 1.00 25.31 C ATOM 53 CG LYS 31 −7.122 11.655 0.501 1.00 27.67 C ATOM 54 CD LYS 31 −7.906 12.701 1.266 1.00 29.82 C ATOM 55 CE LYS 31 −8.654 12.122 2.423 1.00 30.22 C ATOM 56 NZ LYS 31 −9.401 13.196 3.133 1.00 31.71 N ATOM 57 C LYS 31 −5.065 12.527 −2.648 1.00 21.77 C ATOM 58 O LYS 31 −3.906 12.951 −2.590 1.00 21.83 O ATOM 59 N PRO 32 −5.909 12.873 −3.629 1.00 20.24 N ATOM 60 CD PRO 32 −7.253 12.301 −3.838 1.00 20.22 C ATOM 61 CA PRO 32 −5.608 13.770 −4.736 1.00 19.66 C ATOM 62 CB PRO 32 −6.996 14.120 −5.227 1.00 21.15 C ATOM 63 CG PRO 32 −7.598 12.787 −5.277 1.00 21.31 C ATOM 64 C PRO 32 −4.799 15.018 −4.348 1.00 18.96 C ATOM 65 O PRO 32 −3.832 15.368 −5.022 1.00 17.76 O ATOM 66 N LEU 33 −5.190 15.682 −3.263 1.00 20.65 N ATOM 67 CA LEU 33 −4.497 16.901 −2.853 1.00 22.91 C ATOM 68 CB LEU 33 −5.412 17.805 −2.025 1.00 27.03 C ATOM 69 CG LEU 33 −6.690 18.264 −2.733 1.00 30.44 C ATOM 70 CD1 LEU 33 −7.567 19.092 −1.796 1.00 32.45 C ATOM 71 CD2 LEU 33 −6.385 19.036 −4.014 1.00 31.10 C ATOM 72 C LEU 33 −3.172 16.659 −2.141 1.00 22.13 C ATOM 73 O LEU 33 −2.277 17.507 −2.169 1.00 20.13 O ATOM 74 N LEU 34 −3.041 15.500 −1.507 1.00 22.44 N ATOM 75 CA LEU 34 −1.788 15.170 −0.845 1.00 22.32 C ATOM 76 CB LEU 34 −1.967 14.032 0.158 1.00 22.46 C ATOM 77 CG LEU 34 −0.686 13.562 0.851 1.00 25.03 C ATOM 78 CD1 LEU 34 0.092 14.709 1.488 1.00 22.68 C ATOM 79 CD2 LEU 34 −0.984 12.449 1.846 1.00 25.15 C ATOM 80 C LEU 34 −0.833 14.775 −1.959 1.00 20.98 C ATOM 81 O LEU 34 0.370 15.027 −1.892 1.00 18.72 O ATOM 82 N LEU 35 −1.403 14.172 −2.996 1.00 22.16 N ATOM 83 CA LEU 35 −0.644 13.746 −4.158 1.00 22.50 C ATOM 84 CB LEU 35 −1.499 12.888 −5.086 1.00 21.79 C ATOM 85 CG LEU 35 −0.799 12.451 −6.371 1.00 21.31 C ATOM 86 CD1 LEU 35 0.509 11.738 −6.069 1.00 22.29 C ATOM 87 CD2 LEU 35 −1.709 11.605 −7.249 1.00 21.81 C ATOM 88 C LEU 35 −0.120 14.950 −4.913 1.00 23.62 C ATOM 89 O LEU 35 0.965 14.909 −5.489 1.00 24.50 O ATOM 90 N LYS 36 −0.892 16.029 −4.887 1.00 26.45 N ATOM 91 CA LYS 36 −0.517 17.247 −5.581 1.00 30.02 C ATOM 92 CB LYS 36 −1.739 18.156 −5.759 1.00 31.51 C ATOM 93 CG LYS 36 −1.468 19.454 −6.494 1.00 34.42 C ATOM 94 CD LYS 36 −2.742 20.280 −6.633 1.00 37.59 C ATOM 95 CE LYS 36 −2.483 21.584 −7.381 1.00 40.02 C ATOM 96 NZ LYS 36 −3.723 22.409 −7.540 1.00 42.11 N ATOM 97 C LYS 36 0.624 17.964 −4.864 1.00 30.99 C ATOM 98 O LYS 36 1.321 18.782 −5.460 1.00 32.96 O ATOM 99 N LEU 37 0.828 17.645 −3.590 1.00 31.87 N ATOM 100 CA LEU 37 1.909 18.274 −2.841 1.00 33.15 C ATOM 101 CB LEU 37 1.504 18.569 −1.395 1.00 34.78 C ATOM 102 CG LEU 37 0.316 19.498 −1.144 1.00 37.22 C ATOM 103 CD1 LEU 37 0.039 19.625 0.347 1.00 36.79 C ATOM 104 CD2 LEU 37 0.540 20.873 −1.760 1.00 38.28 C ATOM 105 C LEU 37 3.153 17.395 −2.866 1.00 32.75 C ATOM 106 O LEU 37 4.277 17.889 −2.747 1.00 31.66 O ATOM 107 N LEU 38 2.945 16.093 −3.040 1.00 30.45 N ATOM 108 CA LEU 38 4.054 15.155 −3.080 1.00 28.31 C ATOM 109 CB LEU 38 3.578 13.726 −2.805 1.00 27.70 C ATOM 110 CG LEU 38 2.878 13.360 −1.492 1.00 27.23 C ATOM 111 CD1 LEU 38 2.383 11.925 −1.547 1.00 27.09 C ATOM 112 CD2 LEU 38 3.750 13.597 −0.262 1.00 24.95 C ATOM 113 C LEU 38 4.713 15.230 −4.451 1.00 28.49 C ATOM 114 O LEU 38 5.888 14.897 −4.598 1.00 29.16 O ATOM 115 N LYS 39 3.956 15.684 −5.449 1.00 27.07 N ATOM 116 CA LYS 39 4.480 15.783 −6.806 1.00 28.73 C ATOM 117 CB LYS 39 3.373 15.754 −7.861 1.00 33.27 C ATOM 118 CG LYS 39 2.504 14.521 −7.920 1.00 37.75 C ATOM 119 CD LYS 39 1.487 14.719 −9.035 1.00 41.51 C ATOM 120 CE LYS 39 0.550 13.539 −9.187 1.00 45.31 C ATOM 121 NZ LYS 39 −0.430 13.767 −10.292 1.00 47.13 N ATOM 122 C LYS 39 5.304 17.036 −7.034 1.00 25.77 C ATOM 123 O LYS 39 6.154 17.062 −7.916 1.00 27.98 O ATOM 124 N SER 40 5.064 18.071 −6.240 1.00 24.34 N ATOM 125 CA SER 40 5.795 19.311 −6.427 1.00 23.75 C ATOM 126 CB SER 40 5.033 20.501 −5.845 1.00 24.25 C ATOM 127 OG SER 40 4.844 20.354 −4.451 1.00 24.47 O ATOM 128 C SER 40 7.180 19.229 −5.825 1.00 23.75 C ATOM 129 O SER 40 8.029 20.066 −6.099 1.00 26.76 O ATOM 130 N VAL 41 7.414 18.203 −5.018 1.00 26.35 N ATOM 131 CA VAL 41 8.701 18.055 −4.367 1.00 25.90 C ATOM 132 CB VAL 41 8.550 18.299 −2.846 1.00 26.80 C ATOM 133 CG1 VAL 41 7.800 17.139 −2.204 1.00 25.77 C ATOM 134 CG2 VAL 41 9.905 18.491 −2.202 1.00 28.50 C ATOM 135 C VAL 41 9.308 16.674 −4.597 1.00 26.12 C ATOM 136 O VAL 41 10.480 16.450 −4.300 1.00 28.42 O ATOM 137 N GLY 42 8.523 15.751 −5.144 1.00 24.94 N ATOM 138 CA GLY 42 9.049 14.416 −5.363 1.00 22.59 C ATOM 139 C GLY 42 8.438 13.615 −6.495 1.00 22.27 C ATOM 140 O GLY 42 7.720 14.143 −7.347 1.00 19.19 O ATOM 141 N ALA 43 8.740 12.321 −6.490 1.00 21.23 N ATOM 142 CA ALA 43 8.252 11.387 −7.491 1.00 23.12 C ATOM 143 CB ALA 43 8.939 10.043 −7.326 1.00 22.78 C ATOM 144 C ALA 43 6.740 11.202 −7.448 1.00 26.26 C ATOM 145 O ALA 43 6.137 11.093 −6.382 1.00 26.47 O ATOM 146 N GLN 44 6.144 11.182 −8.632 1.00 29.51 N ATOM 147 CA GLN 44 4.711 10.994 −8.814 1.00 34.61 C ATOM 148 CB GLN 44 4.254 11.798 −10.044 1.00 38.60 C ATOM 149 CG GLN 44 2.772 11.752 −10.418 1.00 44.52 C ATOM 150 CD GLN 44 2.343 10.341 −10.743 1.00 47.57 C ATOM 151 OE1 GLN 44 1.459 9.781 −10.093 1.00 50.77 O ATOM 152 NE2 GLN 44 2.959 9.760 −11.768 1.00 49.38 N ATOM 153 C GLN 44 4.452 9.486 −8.949 1.00 33.65 C ATOM 154 O GLN 44 4.970 8.844 −9.857 1.00 34.09 O ATOM 155 N LYS 45 3.660 8.925 −8.040 1.00 33.88 N ATOM 156 CA LYS 45 3.353 7.493 −8.071 1.00 34.47 C ATOM 157 CB LYS 45 4.586 6.652 −7.744 1.00 31.48 C ATOM 158 CG LYS 45 5.205 6.911 −6.388 1.00 28.37 C ATOM 159 CD LYS 45 6.411 6.017 −6.214 1.00 24.70 C ATOM 160 CE LYS 45 7.084 6.228 −4.883 1.00 24.73 C ATOM 161 NZ LYS 45 8.267 5.329 −4.749 1.00 24.48 N ATOM 162 C LYS 45 2.151 7.096 −7.218 1.00 36.41 C ATOM 163 O LYS 45 1.924 7.670 −6.157 1.00 36.79 O ATOM 164 N ASP 46 1.375 6.120 −7.693 1.00 39.70 N ATOM 165 CA ASP 46 0.178 5.678 −6.974 1.00 41.06 C ATOM 166 CB ASP 46 −0.641 4.672 −7.792 1.00 42.39 C ATOM 167 CG ASP 46 −1.137 5.241 −9.105 1.00 43.83 C ATOM 168 OD1 ASP 46 −0.864 4.624 −10.156 1.00 45.18 O ATOM 169 OD2 ASP 46 −1.799 6.301 −9.086 1.00 43.47 O ATOM 170 C ASP 46 0.391 5.118 −5.573 1.00 40.30 C ATOM 171 O ASP 46 −0.539 5.103 −4.769 1.00 40.91 O ATOM 172 N THR 47 1.605 4.671 −5.268 1.00 38.48 N ATOM 173 CA THR 47 1.868 4.100 −3.953 1.00 35.27 C ATOM 174 CB THR 47 1.860 2.564 −4.000 1.00 34.96 C ATOM 175 OG1 THR 47 0.592 2.115 −4.482 1.00 35.07 O ATOM 176 CG2 THR 47 2.083 1.986 −2.614 1.00 34.48 C ATOM 177 C THR 47 3.165 4.561 −3.312 1.00 33.33 C ATOM 178 O THR 47 4.224 4.569 −3.942 1.00 34.15 O ATOM 179 N TYR 48 3.055 4.951 −2.048 1.00 30.30 N ATOM 180 CA TYR 48 4.180 5.435 −1.256 1.00 27.10 C ATOM 181 CB TYR 48 4.048 6.925 −0.949 1.00 24.18 C ATOM 182 CG TYR 48 3.995 7.837 −2.150 1.00 21.88 C ATOM 183 CD1 TYR 48 5.152 8.418 −2.659 1.00 19.95 C ATOM 184 CE1 TYR 48 5.096 9.298 −3.727 1.00 20.60 C ATOM 185 CD2 TYR 48 2.782 8.153 −2.747 1.00 19.91 C ATOM 186 CE2 TYR 48 2.716 9.027 −3.812 1.00 20.90 C ATOM 187 CZ TYR 48 3.872 9.598 −4.298 1.00 20.62 C ATOM 188 OH TYR 48 3.795 10.481 −5.347 1.00 22.83 O ATOM 189 C TYR 48 4.269 4.685 0.061 1.00 26.72 C ATOM 190 O TYR 48 3.275 4.158 0.558 1.00 27.60 O ATOM 191 N THR 49 5.470 4.620 0.616 1.00 27.57 N ATOM 192 CA THR 49 5.647 4.001 1.916 1.00 27.42 C ATOM 193 CB THR 49 7.100 3.558 2.171 1.00 26.03 C ATOM 194 OG1 THR 49 7.953 4.708 2.191 1.00 24.83 O ATOM 195 CG2 THR 49 7.562 2.595 1.092 1.00 26.14 C ATOM 196 C THR 49 5.317 5.167 2.836 1.00 26.91 C ATOM 197 O THR 49 5.606 6.313 2.506 1.00 27.92 O ATOM 198 N MET 50 4.692 4.891 3.969 1.00 28.56 N ATOM 199 CA MET 50 4.345 5.953 4.905 1.00 30.04 C ATOM 200 CB MET 50 3.773 5.358 6.190 1.00 28.54 C ATOM 201 CG MET 50 3.355 6.367 7.246 1.00 30.69 C ATOM 202 SD MET 50 2.058 7.489 6.688 1.00 30.76 S ATOM 203 CE MET 50 2.888 9.022 6.804 1.00 31.08 C ATOM 204 C MET 50 5.605 6.746 5.233 1.00 30.79 C ATOM 205 O MET 50 5.546 7.896 5.664 1.00 31.44 O ATOM 206 N LYS 51 6.753 6.132 4.992 1.00 31.31 N ATOM 207 CA LYS 51 8.008 6.764 5.343 1.00 31.72 C ATOM 208 CB LYS 51 8.996 5.654 5.711 1.00 34.50 C ATOM 209 CG LYS 51 10.325 6.042 6.283 1.00 39.52 C ATOM 210 CD LYS 51 11.086 4.747 6.577 1.00 43.25 C ATOM 211 CE LYS 51 12.449 4.991 7.201 1.00 46.68 C ATOM 212 NZ LYS 51 12.318 5.719 8.503 1.00 47.10 N ATOM 213 C LYS 51 8.503 7.745 4.265 1.00 28.34 C ATOM 214 O LYS 51 9.297 8.637 4.559 1.00 25.46 O ATOM 215 N GLU 52 8.011 7.600 3.032 1.00 24.36 N ATOM 216 CA GLU 52 8.388 8.523 1.956 1.00 23.10 C ATOM 217 CB GLU 52 8.166 7.936 0.560 1.00 23.72 C ATOM 218 CG GLU 52 8.895 6.653 0.213 1.00 26.58 C ATOM 219 CD GLU 52 8.521 6.256 −1.209 1.00 25.01 C ATOM 220 OE1 GLU 52 7.629 5.400 −1.371 1.00 24.55 O ATOM 221 OE2 GLU 52 9.123 6.785 −2.164 1.00 25.12 O ATOM 222 C GLU 52 7.468 9.738 2.088 1.00 21.67 C ATOM 223 O GLU 52 7.843 10.860 1.740 1.00 18.74 O ATOM 224 N VAL 53 6.263 9.495 2.599 1.00 18.59 N ATOM 225 CA VAL 53 5.268 10.545 2.763 1.00 19.55 C ATOM 226 CB VAL 53 3.896 9.949 3.143 1.00 19.33 C ATOM 227 CG1 VAL 53 2.896 11.062 3.434 1.00 19.57 C ATOM 228 CG2 VAL 53 3.394 9.067 2.016 1.00 20.00 C ATOM 229 C VAL 53 5.703 11.518 3.841 1.00 19.68 C ATOM 230 O VAL 53 5.559 12.727 3.684 1.00 19.09 O ATOM 231 N LEU 54 6.253 10.983 4.926 1.00 21.56 N ATOM 232 CA LEU 54 6.732 11.811 6.022 1.00 24.05 C ATOM 233 CB LEU 54 7.118 10.949 7.227 1.00 25.58 C ATOM 234 CG LEU 54 5.962 10.130 7.805 1.00 27.53 C ATOM 235 CD1 LEU 54 6.406 9.184 8.917 1.00 27.26 C ATOM 236 CD2 LEU 54 4.854 11.055 8.278 1.00 27.23 C ATOM 237 C LEU 54 7.917 12.628 5.530 1.00 23.85 C ATOM 238 O LEU 54 8.066 13.800 5.876 1.00 24.62 O ATOM 239 N PHE 55 8.747 12.002 4.702 1.00 22.58 N ATOM 240 CA PHE 55 9.908 12.674 4.145 1.00 21.31 C ATOM 241 CB PHE 55 10.796 11.716 3.357 1.00 20.68 C ATOM 242 CG PHE 55 11.981 12.387 2.725 1.00 20.30 C ATOM 243 CD1 PHE 55 13.012 12.888 3.507 1.00 18.41 C ATOM 244 CD2 PHE 55 12.048 12.549 1.346 1.00 19.84 C ATOM 245 CE1 PHE 55 14.085 13.538 2.928 1.00 18.68 C ATOM 246 CE2 PHE 55 13.120 13.201 0.759 1.00 18.51 C ATOM 247 CZ PHE 55 14.140 13.696 1.552 1.00 19.56 C ATOM 248 C PHE 55 9.512 13.850 3.269 1.00 20.62 C ATOM 249 O PHE 55 9.963 14.971 3.493 1.00 23.48 O ATOM 250 N TYR 56 8.670 13.599 2.270 1.00 19.21 N ATOM 251 CA TYR 56 8.243 14.671 1.382 1.00 17.94 C ATOM 252 CB TYR 56 7.459 14.142 0.182 1.00 17.19 C ATOM 253 CG TYR 56 8.259 13.265 −0.752 1.00 17.01 C ATOM 254 CD1 TYR 56 9.447 13.726 −1.310 1.00 16.35 C ATOM 255 CE1 TYR 56 10.130 12.987 −2.251 1.00 15.96 C ATOM 256 CD2 TYR 56 7.781 12.024 −1.158 1.00 17.74 C ATOM 257 CE2 TYR 56 8.457 11.273 −2.105 1.00 18.06 C ATOM 258 CZ TYR 56 9.627 11.763 −2.651 1.00 18.15 C ATOM 259 OH TYR 56 10.268 11.055 −3.637 1.00 17.16 O ATOM 260 C TYR 56 7.506 15.830 2.034 1.00 18.40 C ATOM 261 O TYR 56 7.708 16.974 1.632 1.00 20.22 O ATOM 262 N LEU 57 6.666 15.559 3.034 1.00 18.61 N ATOM 263 CA LEU 57 5.964 16.652 3.699 1.00 19.85 C ATOM 264 CB LEU 57 4.869 16.162 4.655 1.00 20.61 C ATOM 265 CG LEU 57 3.644 15.424 4.115 1.00 23.15 C ATOM 266 CD1 LEU 57 2.757 14.911 5.243 1.00 23.67 C ATOM 267 CD2 LEU 57 2.843 16.320 3.162 1.00 21.07 C ATOM 268 C LEU 57 6.942 17.560 4.425 1.00 19.93 C ATOM 269 O LEU 57 6.778 18.777 4.429 1.00 20.07 O ATOM 270 N GLY 58 7.970 16.968 5.023 1.00 18.96 N ATOM 271 CA GLY 58 8.959 17.764 5.724 1.00 19.61 C ATOM 272 C GLY 58 9.735 18.612 4.736 1.00 20.66 C ATOM 273 O GLY 58 9.973 19.801 4.968 1.00 19.89 O ATOM 274 N GLN 59 10.132 18.003 3.622 1.00 21.02 N ATOM 275 CA GLN 59 10.873 18.730 2.600 1.00 22.78 C ATOM 276 CB GLN 59 11.519 17.776 1.599 1.00 22.59 C ATOM 277 CG GLN 59 12.505 16.839 2.250 1.00 25.03 C ATOM 278 CD GLN 59 13.576 17.674 2.912 1.00 26.69 C ATOM 279 OE1 GLN 59 13.877 17.502 4.090 1.00 28.42 O ATOM 280 NE2 GLN 59 14.139 18.612 2.160 1.00 27.94 N ATOM 281 C GLN 59 9.980 19.745 1.900 1.00 21.11 C ATOM 282 O GLN 59 10.458 20.730 1.342 1.00 20.60 O ATOM 283 N TYR 60 8.675 19.504 1.943 1.00 20.96 N ATOM 284 CA TYR 60 7.725 20.427 1.340 1.00 21.51 C ATOM 285 CB TYR 60 6.350 19.786 1.207 1.00 20.18 C ATOM 286 CG TYR 60 5.290 20.727 0.684 1.00 19.26 C ATOM 287 CD1 TYR 60 5.127 20.946 −0.677 1.00 18.65 C ATOM 288 CE1 TYR 60 4.145 21.796 −1.148 1.00 18.43 C ATOM 289 CD2 TYR 60 4.444 21.390 1.563 1.00 18.15 C ATOM 290 CE2 TYR 60 3.465 22.238 1.106 1.00 19.04 C ATOM 291 CZ TYR 60 3.314 22.437 −0.251 1.00 19.66 C ATOM 292 OH TYR 60 2.316 23.266 −0.705 1.00 17.66 O ATOM 293 C TYR 60 7.631 21.661 2.221 1.00 21.23 C ATOM 294 O TYR 60 7.592 22.793 1.737 1.00 21.02 O ATOM 295 N ILE 61 7.615 21.414 3.525 1.00 20.45 N ATOM 296 CA ILE 61 7.514 22.463 4.518 1.00 19.88 C ATOM 297 CB ILE 61 7.305 21.841 5.913 1.00 16.63 C ATOM 298 CG2 ILE 61 7.405 22.907 6.990 1.00 15.17 C ATOM 299 CG1 ILE 61 5.961 21.112 5.956 1.00 14.67 C ATOM 300 CD1 ILE 61 5.660 20.431 7.295 1.00 13.50 C ATOM 301 C ILE 61 8.789 23.293 4.518 1.00 24.11 C ATOM 302 O ILE 61 8.779 24.463 4.915 1.00 24.81 O ATOM 303 N MET 62 9.882 22.695 4.052 1.00 27.53 N ATOM 304 CA MET 62 11.158 23.399 4.010 1.00 31.34 C ATOM 305 CB MET 62 12.331 22.454 4.293 1.00 34.73 C ATOM 306 CG MET 62 12.295 21.791 5.665 1.00 41.21 C ATOM 307 SD MET 62 13.705 20.685 5.949 1.00 45.94 S ATOM 308 CE MET 62 15.034 21.883 6.155 1.00 46.15 C ATOM 309 C MET 62 11.394 24.154 2.710 1.00 30.78 C ATOM 310 O MET 62 11.975 25.236 2.723 1.00 31.93 O ATOM 311 N THR 63 10.929 23.607 1.591 1.00 30.29 N ATOM 312 CA THR 63 11.146 24.278 0.318 1.00 31.93 C ATOM 313 CB THR 63 10.913 23.331 −0.879 1.00 32.45 C ATOM 314 OG1 THR 63 11.653 22.121 −0.691 1.00 34.57 O ATOM 315 CG2 THR 63 11.383 23.992 −2.168 1.00 33.58 C ATOM 316 C THR 63 10.222 25.476 0.164 1.00 30.66 C ATOM 317 O THR 63 10.550 26.430 −0.535 1.00 32.12 O ATOM 318 N LYS 64 9.072 25.437 0.825 1.00 30.47 N ATOM 319 CA LYS 64 8.144 26.554 0.750 1.00 30.88 C ATOM 320 CB LYS 64 6.715 26.113 0.433 1.00 31.95 C ATOM 321 CG LYS 64 6.592 25.412 −0.903 1.00 33.47 C ATOM 322 CD LYS 64 5.163 25.021 −1.188 1.00 35.44 C ATOM 323 CE LYS 64 4.269 26.251 −1.223 1.00 35.32 C ATOM 324 NZ LYS 64 2.851 25.905 −1.507 1.00 36.49 N ATOM 325 C LYS 64 8.218 27.370 2.021 1.00 30.38 C ATOM 326 O LYS 64 7.504 28.356 2.190 1.00 31.61 O ATOM 327 N ARG 65 9.096 26.929 2.914 1.00 31.08 N ATOM 328 CA ARG 65 9.350 27.604 4.176 1.00 32.41 C ATOM 329 CB ARG 65 10.296 28.776 3.921 1.00 33.62 C ATOM 330 CG ARG 65 11.569 28.220 3.304 1.00 38.45 C ATOM 331 CD ARG 65 12.660 29.194 2.949 1.00 39.91 C ATOM 332 NE ARG 65 13.766 28.425 2.375 1.00 42.85 N ATOM 333 CZ ARG 65 14.793 28.944 1.713 1.00 43.34 C ATOM 334 NH1 ARG 65 14.878 30.255 1.530 1.00 45.53 N ATOM 335 NH2 ARG 65 15.729 28.146 1.221 1.00 43.64 N ATOM 336 C ARG 65 8.099 27.982 4.955 1.00 30.80 C ATOM 337 O ARG 65 7.856 29.145 5.259 1.00 28.75 O ATOM 338 N LEU 66 7.310 26.965 5.274 1.00 31.27 N ATOM 339 CA LEU 66 6.077 27.149 6.020 1.00 31.53 C ATOM 340 CB LEU 66 5.082 26.044 5.687 1.00 30.56 C ATOM 341 CG LEU 66 4.742 25.973 4.201 1.00 30.97 C ATOM 342 CD1 LEU 66 3.800 24.809 3.914 1.00 31.85 C ATOM 343 CD2 LEU 66 4.156 27.290 3.700 1.00 28.41 C ATOM 344 C LEU 66 6.391 27.171 7.507 1.00 32.00 C ATOM 345 O LEU 66 5.505 27.320 8.342 1.00 36.99 O ATOM 346 N TYR 67 7.669 27.018 7.822 1.00 32.16 N ATOM 347 CA TYR 67 8.147 27.010 9.196 1.00 29.34 C ATOM 348 CB TYR 67 9.300 26.023 9.365 1.00 30.19 C ATOM 349 CG TYR 67 10.505 26.362 8.517 1.00 30.32 C ATOM 350 CD1 TYR 67 11.362 27.393 8.877 1.00 31.21 C ATOM 351 CE1 TYR 67 12.453 27.726 8.097 1.00 31.23 C ATOM 352 CD2 TYR 67 10.775 25.668 7.348 1.00 31.49 C ATOM 353 CE2 TYR 67 11.867 25.995 6.559 1.00 31.76 C ATOM 354 CZ TYR 67 12.702 27.025 6.939 1.00 30.71 C ATOM 355 OH TYR 67 13.790 27.351 6.163 1.00 30.69 O ATOM 356 C TYR 67 8.584 28.410 9.599 1.00 26.76 C ATOM 357 O TYR 67 8.974 29.212 8.755 1.00 27.18 O ATOM 358 N ASP 68 8.505 28.710 10.887 1.00 26.00 N ATOM 359 CA ASP 68 8.931 30.012 11.376 1.00 24.98 C ATOM 360 CB ASP 68 8.536 30.213 12.832 1.00 24.44 C ATOM 361 CG ASP 68 8.916 31.581 13.354 1.00 25.82 C ATOM 362 OD1 ASP 68 8.229 32.064 14.280 1.00 27.13 O ATOM 363 OD2 ASP 68 9.876 32.189 12.829 1.00 23.05 O ATOM 364 C ASP 68 10.456 30.065 11.239 1.00 26.08 C ATOM 365 O ASP 68 11.171 29.230 11.809 1.00 20.81 O ATOM 366 N GLU 69 10.954 31.038 10.481 1.00 26.25 N ATOM 367 CA GLU 69 12.393 31.179 10.299 1.00 27.50 C ATOM 368 CB GLU 69 12.711 32.341 9.355 1.00 31.03 C ATOM 369 CG GLU 69 14.200 32.606 9.160 1.00 36.70 C ATOM 370 CD GLU 69 14.885 31.383 8.579 1.00 40.21 C ATOM 371 OE1 GLU 69 14.189 30.407 8.224 1.00 42.79 O ATOM 372 OE2 GLU 69 16.133 31.400 8.486 1.00 41.52 O ATOM 373 C GLU 69 13.155 31.330 11.617 1.00 25.94 C ATOM 374 O GLU 69 14.320 30.956 11.705 1.00 25.86 O ATOM 375 N LYS 70 12.493 31.856 12.645 1.00 23.46 N ATOM 376 CA LYS 70 13.141 32.048 13.937 1.00 23.45 C ATOM 377 CB LYS 70 12.882 33.449 14.490 1.00 26.70 C ATOM 378 CG LYS 70 13.362 34.567 13.582 1.00 28.84 C ATOM 379 CD LYS 70 14.858 34.477 13.329 1.00 31.67 C ATOM 380 CE LYS 70 15.327 35.607 12.415 1.00 33.30 C ATOM 381 NZ LYS 70 16.788 35.549 12.150 1.00 34.03 N ATOM 382 C LYS 70 12.762 30.989 14.965 1.00 22.06 C ATOM 383 O LYS 70 13.147 31.077 16.123 1.00 21.58 O ATOM 384 N GLN 71 11.995 29.993 14.541 1.00 21.15 N ATOM 385 CA GLN 71 11.588 28.913 15.436 1.00 20.20 C ATOM 386 CB GLN 71 10.497 29.383 16.407 1.00 20.24 C ATOM 387 CG GLN 71 10.110 28.357 17.460 1.00 20.50 C ATOM 388 CD GLN 71 9.029 28.928 18.363 1.00 20.46 C ATOM 389 OE1 GLN 71 8.365 29.908 18.019 1.00 24.60 O ATOM 390 NE2 GLN 71 8.865 28.330 19.535 1.00 18.17 N ATOM 391 C GLN 71 11.088 27.853 14.461 1.00 20.18 C ATOM 392 O GLN 71 9.880 27.643 14.280 1.00 20.12 O ATOM 393 N GLN 72 12.056 27.188 13.840 1.00 20.81 N ATOM 394 CA GLN 72 11.806 26.189 12.813 1.00 22.77 C ATOM 395 CB GLN 72 13.119 25.855 12.110 1.00 23.53 C ATOM 396 CG GLN 72 13.723 27.086 11.456 1.00 27.22 C ATOM 397 CD GLN 72 15.027 26.744 10.776 1.00 29.38 C ATOM 398 OE1 GLN 72 15.497 25.604 10.824 1.00 30.31 O ATOM 399 NE2 GLN 72 15.626 27.741 10.137 1.00 30.16 N ATOM 400 C GLN 72 11.028 24.940 13.195 1.00 21.80 C ATOM 401 O GLN 72 10.603 24.178 12.328 1.00 20.25 O ATOM 402 N HIS 73 10.829 24.737 14.488 1.00 20.18 N ATOM 403 CA HIS 73 10.076 23.585 14.949 1.00 21.21 C ATOM 404 CB HIS 73 10.627 23.080 16.287 1.00 22.75 C ATOM 405 CG HIS 73 10.662 24.117 17.366 1.00 24.88 C ATOM 406 CD2 HIS 73 11.670 24.911 17.801 1.00 25.16 C ATOM 407 ND1 HIS 73 9.565 24.435 18.136 1.00 26.05 N ATOM 408 CE1 HIS 73 9.895 25.378 19.001 1.00 27.37 C ATOM 409 NE2 HIS 73 11.167 25.684 18.818 1.00 27.33 N ATOM 410 C HIS 73 8.569 23.857 14.955 1.00 19.30 C ATOM 411 O HIS 73 7.762 23.018 15.353 1.00 15.05 O ATOM 412 N ILE 74 8.202 25.049 14.495 1.00 20.68 N ATOM 413 CA ILE 74 6.800 25.442 14.408 1.00 20.38 C ATOM 414 CB ILE 74 6.517 26.761 15.170 1.00 17.27 C ATOM 415 CG2 ILE 74 5.082 27.186 14.930 1.00 16.94 C ATOM 416 CG1 ILE 74 6.788 26.585 16.673 1.00 12.85 C ATOM 417 CD1 ILE 74 5.940 25.522 17.350 1.00 10.25 C ATOM 418 C ILE 74 6.433 25.631 12.931 1.00 22.21 C ATOM 419 O ILE 74 7.068 26.401 12.207 1.00 19.54 O ATOM 420 N VAL 75 5.406 24.914 12.489 1.00 22.66 N ATOM 421 CA VAL 75 4.968 24.994 11.106 1.00 20.85 C ATOM 422 CB VAL 75 4.656 23.596 10.552 1.00 19.84 C ATOM 423 CG1 VAL 75 4.268 23.697 9.081 1.00 17.74 C ATOM 424 CG2 VAL 75 5.870 22.678 10.745 1.00 19.97 C ATOM 425 C VAL 75 3.730 25.866 10.931 1.00 22.04 C ATOM 426 O VAL 75 2.682 25.605 11.523 1.00 19.88 O ATOM 427 N HIS 76 3.860 26.907 10.117 1.00 19.99 N ATOM 428 CA HIS 76 2.742 27.797 9.850 1.00 20.86 C ATOM 429 CB HIS 76 3.140 29.249 10.074 1.00 20.76 C ATOM 430 CG HIS 76 3.595 29.532 11.471 1.00 18.48 C ATOM 431 CD2 HIS 76 4.799 29.914 11.958 1.00 17.24 C ATOM 432 ND1 HIS 76 2.764 29.401 12.561 1.00 18.78 N ATOM 433 CE1 HIS 76 3.436 29.693 13.661 1.00 17.42 C ATOM 434 NE2 HIS 76 4.673 30.007 13.323 1.00 17.51 N ATOM 435 C HIS 76 2.250 27.541 8.429 1.00 22.01 C ATOM 436 O HIS 76 2.906 27.886 7.448 1.00 20.06 O ATOM 437 N CYS 77 1.076 26.934 8.333 1.00 25.10 N ATOM 438 CA CYS 77 0.503 26.582 7.049 1.00 27.53 C ATOM 439 CB CYS 77 0.499 25.055 6.882 1.00 26.53 C ATOM 440 SG CYS 77 −0.321 24.144 8.202 1.00 29.08 S ATOM 441 C CYS 77 −0.805 27.255 6.632 1.00 28.98 C ATOM 442 O CYS 77 −1.442 26.851 5.660 1.00 28.62 O ATOM 443 N SER 78 −1.206 28.283 7.377 1.00 31.46 N ATOM 444 CA SER 78 −2.404 29.043 7.035 1.00 34.18 C ATOM 445 CB SER 78 −2.859 29.936 8.186 1.00 32.67 C ATOM 446 OG SER 78 −1.858 30.878 8.515 1.00 32.54 O ATOM 447 C SER 78 −1.935 29.883 5.851 1.00 37.37 C ATOM 448 O SER 78 −0.941 30.602 5.966 1.00 40.89 O ATOM 449 N ASN 79 −2.637 29.782 4.725 1.00 38.16 N ATOM 450 CA ASN 79 −2.281 30.491 3.490 1.00 38.25 C ATOM 451 CB ASN 79 −1.490 31.788 3.729 1.00 41.43 C ATOM 452 CG ASN 79 −2.269 32.814 4.535 1.00 44.32 C ATOM 453 OD1 ASN 79 −1.804 33.293 5.568 1.00 47.01 O ATOM 454 ND2 ASN 79 −3.464 33.155 4.062 1.00 45.45 N ATOM 455 C ASN 79 −1.535 29.579 2.522 1.00 36.47 C ATOM 456 O ASN 79 −1.050 30.026 1.481 1.00 36.50 O ATOM 457 N ASP 80 −1.439 28.301 2.879 1.00 33.49 N ATOM 458 CA ASP 80 −0.782 27.304 2.038 1.00 30.65 C ATOM 459 CB ASP 80 0.597 26.908 2.567 1.00 28.08 C ATOM 460 CG ASP 80 1.300 25.894 1.666 1.00 27.51 C ATOM 461 OD1 ASP 80 2.347 26.248 1.088 1.00 28.18 O ATOM 462 OD2 ASP 80 0.818 24.749 1.528 1.00 24.49 O ATOM 463 C ASP 80 −1.696 26.089 1.926 1.00 30.18 C ATOM 464 O ASP 80 −2.399 25.750 2.876 1.00 32.29 O ATOM 465 N LEU 81 −1.701 25.447 0.763 1.00 29.44 N ATOM 466 CA LEU 81 −2.547 24.279 0.548 1.00 28.49 C ATOM 467 CB LEU 81 −2.242 23.632 −0.806 1.00 30.75 C ATOM 468 CG LEU 81 −3.069 22.396 −1.179 1.00 32.89 C ATOM 469 CD1 LEU 81 −4.564 22.720 −1.167 1.00 32.68 C ATOM 470 CD2 LEU 81 −2.658 21.821 −2.530 1.00 33.32 C ATOM 471 C LEU 81 −2.428 23.240 1.667 1.00 27.48 C ATOM 472 O LEU 81 −3.327 22.422 1.861 1.00 26.60 O ATOM 473 N LEU 82 −1.328 23.284 2.411 1.00 25.83 N ATOM 474 CA LEU 82 −1.121 22.326 3.485 1.00 25.93 C ATOM 475 CB LEU 82 0.335 22.334 3.953 1.00 27.37 C ATOM 476 CG LEU 82 0.714 21.341 5.051 1.00 26.40 C ATOM 477 CD1 LEU 82 0.391 19.918 4.617 1.00 28.04 C ATOM 478 CD2 LEU 82 2.183 21.459 5.440 1.00 25.48 C ATOM 479 C LEU 82 −2.075 22.622 4.640 1.00 26.61 C ATOM 480 O LEU 82 −2.394 21.736 5.434 1.00 24.04 O ATOM 481 N GLY 83 −2.539 23.870 4.713 1.00 25.97 N ATOM 482 CA GLY 83 −3.476 24.255 5.751 1.00 23.73 C ATOM 483 C GLY 83 −4.816 23.613 5.437 1.00 24.97 C ATOM 484 O GLY 83 −5.531 23.137 6.324 1.00 23.63 O ATOM 485 N ASP 84 −5.155 23.592 4.154 1.00 26.10 N ATOM 486 CA ASP 84 −6.404 22.994 3.705 1.00 28.17 C ATOM 487 CB ASP 84 −6.695 23.378 2.259 1.00 29.18 C ATOM 488 CG ASP 84 −6.829 24.868 2.065 1.00 31.27 C ATOM 489 OD1 ASP 84 −6.896 25.604 3.073 1.00 30.35 O ATOM 490 OD2 ASP 84 −6.856 25.298 0.891 1.00 33.57 O ATOM 491 C ASP 84 −6.345 21.477 3.817 1.00 28.68 C ATOM 492 O ASP 84 −7.369 20.818 3.992 1.00 29.33 O ATOM 493 N LEU 85 −5.138 20.931 3.728 1.00 28.47 N ATOM 494 CA LEU 85 −4.946 19.491 3.787 1.00 28.25 C ATOM 495 CB LEU 85 −3.572 19.113 3.231 1.00 29.46 C ATOM 496 CG LEU 85 −3.224 17.628 3.151 1.00 31.51 C ATOM 497 CD1 LEU 85 −4.226 16.913 2.258 1.00 31.47 C ATOM 498 CD2 LEU 85 −1.809 17.393 2.634 1.00 32.07 C ATOM 499 C LEU 85 −5.125 19.006 5.229 1.00 27.80 C ATOM 500 O LEU 85 −5.923 18.105 5.500 1.00 26.59 O ATOM 501 N PHE 86 −4.386 19.618 6.149 1.00 25.85 N ATOM 502 CA PHE 86 −4.466 19.262 7.561 1.00 25.42 C ATOM 503 CB PHE 86 −3.153 19.569 8.288 1.00 25.61 C ATOM 504 CG PHE 86 −1.984 18.745 7.833 1.00 24.56 C ATOM 505 CD1 PHE 86 −0.723 18.972 8.362 1.00 25.69 C ATOM 506 CD2 PHE 86 −2.158 17.687 6.955 1.00 25.22 C ATOM 507 CE1 PHE 86 0.343 18.158 8.033 1.00 24.12 C ATOM 508 CE2 PHE 86 −1.096 16.866 6.620 1.00 24.92 C ATOM 509 CZ PHE 86 0.156 17.100 7.161 1.00 25.70 C ATOM 510 C PHE 86 −5.626 19.871 8.342 1.00 25.22 C ATOM 511 O PHE 86 −5.984 19.374 9.403 1.00 27.68 O ATOM 512 N GLY 87 −6.220 20.936 7.821 1.00 25.48 N ATOM 513 CA GLY 87 −7.308 21.572 8.538 1.00 24.46 C ATOM 514 C GLY 87 −6.846 22.301 9.793 1.00 24.27 C ATOM 515 O GLY 87 −7.577 22.374 10.778 1.00 25.23 O ATOM 516 N VAL 88 −5.628 22.835 9.763 1.00 23.15 N ATOM 517 CA VAL 88 −5.067 23.582 10.892 1.00 21.50 C ATOM 518 CB VAL 88 −4.183 22.697 11.837 1.00 22.47 C ATOM 519 CG1 VAL 88 −5.014 21.573 12.444 1.00 23.92 C ATOM 520 CG2 VAL 88 −2.985 22.136 11.082 1.00 21.60 C ATOM 521 C VAL 88 −4.200 24.704 10.341 1.00 19.98 C ATOM 522 O VAL 88 −3.544 24.541 9.317 1.00 19.52 O ATOM 523 N PRO 89 −4.196 25.871 11.001 1.00 21.92 N ATOM 524 CD PRO 89 −4.796 26.279 12.289 1.00 20.40 C ATOM 525 CA PRO 89 −3.366 26.958 10.488 1.00 21.32 C ATOM 526 CB PRO 89 −4.009 28.164 11.135 1.00 21.47 C ATOM 527 CG PRO 89 −4.109 27.664 12.548 1.00 21.05 C ATOM 528 C PRO 89 −1.881 26.800 10.808 1.00 21.71 C ATOM 529 O PRO 89 −1.029 27.350 10.114 1.00 20.80 O ATOM 530 N SER 90 −1.579 26.025 11.845 1.00 22.01 N ATOM 531 CA SER 90 −0.197 25.803 12.257 1.00 24.39 C ATOM 532 CB SER 90 0.475 27.107 12.704 1.00 25.95 C ATOM 533 OG SER 90 −0.191 27.688 13.806 1.00 30.18 O ATOM 534 C SER 90 −0.076 24.728 13.329 1.00 23.46 C ATOM 535 O SER 90 −1.048 24.407 14.010 1.00 25.46 O ATOM 536 N PHE 91 1.119 24.161 13.462 1.00 23.68 N ATOM 537 CA PHE 91 1.375 23.126 14.463 1.00 22.17 C ATOM 538 CB PHE 91 0.869 21.755 14.002 1.00 22.00 C ATOM 539 CG PHE 91 1.527 21.265 12.739 1.00 23.50 C ATOM 540 CD1 PHE 91 1.133 21.751 11.497 1.00 23.67 C ATOM 541 CD2 PHE 91 2.575 20.360 12.798 1.00 21.96 C ATOM 542 CE1 PHE 91 1.775 21.342 10.339 1.00 22.42 C ATOM 543 CE2 PHE 91 3.220 19.949 11.645 1.00 23.74 C ATOM 544 CZ PHE 91 2.818 20.442 10.414 1.00 22.47 C ATOM 545 C PHE 91 2.862 23.032 14.812 1.00 21.03 C ATOM 546 O PHE 91 3.700 23.714 14.225 1.00 22.64 O ATOM 547 N SER 92 3.162 22.177 15.781 1.00 18.50 N ATOM 548 CA SER 92 4.517 21.909 16.234 1.00 17.97 C ATOM 549 CB SER 92 4.626 21.948 17.750 1.00 17.24 C ATOM 550 OG SER 92 5.941 21.622 18.147 1.00 15.01 O ATOM 551 C SER 92 4.938 20.538 15.718 1.00 19.41 C ATOM 552 O SER 92 4.134 19.607 15.711 1.00 16.66 O ATOM 553 N VAL 93 6.186 20.417 15.273 1.00 19.68 N ATOM 554 CA VAL 93 6.676 19.142 14.766 1.00 20.81 C ATOM 555 CB VAL 93 8.052 19.290 14.079 1.00 22.21 C ATOM 556 CG1 VAL 93 8.008 20.418 13.061 1.00 21.22 C ATOM 557 CG2 VAL 93 9.134 19.522 15.119 1.00 20.18 C ATOM 558 C VAL 93 6.819 18.131 15.897 1.00 21.81 C ATOM 559 O VAL 93 7.136 16.969 15.662 1.00 24.55 O ATOM 560 N LYS 94 6.579 18.568 17.127 1.00 22.80 N ATOM 561 CA LYS 94 6.696 17.670 18.267 1.00 23.16 C ATOM 562 CB LYS 94 7.400 18.364 19.431 1.00 25.99 C ATOM 563 CG LYS 94 6.681 19.571 19.966 1.00 29.97 C ATOM 564 CD LYS 94 7.486 20.206 21.088 1.00 34.85 C ATOM 565 CE LYS 94 8.855 20.641 20.553 1.00 34.82 C ATOM 566 NZ LYS 94 9.710 21.284 21.583 1.00 37.75 N ATOM 567 C LYS 94 5.343 17.088 18.669 1.00 20.95 C ATOM 568 O LYS 94 5.253 16.252 19.570 1.00 19.08 O ATOM 569 N GLU 95 4.297 17.538 17.983 1.00 19.27 N ATOM 570 CA GLU 95 2.937 17.055 18.212 1.00 18.96 C ATOM 571 CB GLU 95 1.919 18.145 17.873 1.00 18.81 C ATOM 572 CG GLU 95 2.046 19.387 18.743 1.00 21.00 C ATOM 573 CD GLU 95 1.017 20.418 18.319 1.00 22.03 C ATOM 574 OE1 GLU 95 −0.095 20.444 18.888 1.00 20.78 O ATOM 575 OE2 GLU 95 1.338 21.228 17.429 1.00 23.38 O ATOM 576 C GLU 95 2.751 15.823 17.334 1.00 18.97 C ATOM 577 O GLU 95 2.008 15.853 16.359 1.00 17.30 O ATOM 578 N HIS 96 3.426 14.735 17.698 1.00 20.49 N ATOM 579 CA HIS 96 3.374 13.503 16.919 1.00 22.53 C ATOM 580 CB HIS 96 4.357 12.468 17.460 1.00 22.80 C ATOM 581 CG HIS 96 5.778 12.924 17.429 1.00 22.99 C ATOM 582 CD2 HIS 96 6.331 14.078 16.987 1.00 24.26 C ATOM 583 ND1 HIS 96 6.818 12.157 17.903 1.00 22.37 N ATOM 584 CE1 HIS 96 7.952 12.818 17.754 1.00 25.34 C ATOM 585 NE2 HIS 96 7.683 13.987 17.200 1.00 25.87 N ATOM 586 C HIS 96 2.016 12.865 16.703 1.00 23.09 C ATOM 587 O HIS 96 1.741 12.375 15.611 1.00 25.80 O ATOM 588 N ARG 97 1.153 12.871 17.712 1.00 23.57 N ATOM 589 CA ARG 97 −0.145 12.253 17.509 1.00 22.11 C ATOM 590 CB ARG 97 −0.852 11.940 18.829 1.00 22.67 C ATOM 591 CG ARG 97 −2.215 11.295 18.608 1.00 25.29 C ATOM 592 CD ARG 97 −2.946 10.947 19.895 1.00 24.16 C ATOM 593 NE ARG 97 −4.238 10.344 19.586 1.00 25.87 N ATOM 594 CZ ARG 97 −5.067 9.819 20.481 1.00 25.09 C ATOM 595 NH1 ARG 97 −4.748 9.801 21.769 1.00 25.97 N ATOM 596 NH2 ARG 97 −6.236 9.339 20.086 1.00 24.37 N ATOM 597 C ARG 97 −1.019 13.095 16.596 1.00 20.82 C ATOM 598 O ARG 97 −1.837 12.563 15.849 1.00 22.99 O ATOM 599 N LYS 98 −0.833 14.409 16.638 1.00 19.91 N ATOM 600 CA LYS 98 −1.614 15.294 15.787 1.00 19.73 C ATOM 601 CB LYS 98 −1.487 16.749 16.228 1.00 20.60 C ATOM 602 CG LYS 98 −2.252 17.723 15.331 1.00 23.23 C ATOM 603 CD LYS 98 −2.091 19.164 15.794 1.00 23.00 C ATOM 604 CE LYS 98 −2.611 19.344 17.205 1.00 24.33 C ATOM 605 NZ LYS 98 −2.463 20.740 17.674 1.00 25.97 N ATOM 606 C LYS 98 −1.181 15.160 14.331 1.00 18.95 C ATOM 607 O LYS 98 −2.013 15.142 13.423 1.00 18.06 O ATOM 608 N ILE 99 0.126 15.047 14.120 1.00 16.71 N ATOM 609 CA ILE 99 0.664 14.935 12.777 1.00 18.14 C ATOM 610 CB ILE 99 2.205 15.049 12.794 1.00 18.88 C ATOM 611 CG2 ILE 99 2.764 14.887 11.382 1.00 17.52 C ATOM 612 CG1 ILE 99 2.612 16.408 13.372 1.00 16.52 C ATOM 613 CD1 ILE 99 4.102 16.610 13.445 1.00 18.05 C ATOM 614 C ILE 99 0.252 13.632 12.105 1.00 19.52 C ATOM 615 O ILE 99 −0.096 13.633 10.929 1.00 20.84 O ATOM 616 N TYR 100 0.278 12.520 12.836 1.00 21.34 N ATOM 617 CA TYR 100 −0.140 11.258 12.234 1.00 21.76 C ATOM 618 CB TYR 100 0.388 10.029 12.982 1.00 20.52 C ATOM 619 CG TYR 100 1.880 9.828 12.897 1.00 21.94 C ATOM 620 CD1 TYR 100 2.456 9.359 11.724 1.00 22.57 C ATOM 621 CE1 TYR 100 3.812 9.131 11.633 1.00 22.83 C ATOM 622 CD2 TYR 100 2.708 10.070 13.982 1.00 22.53 C ATOM 623 CE2 TYR 100 4.068 9.847 13.901 1.00 22.55 C ATOM 624 CZ TYR 100 4.613 9.374 12.724 1.00 22.83 C ATOM 625 OH TYR 100 5.962 9.125 12.642 1.00 24.71 O ATOM 626 C TYR 100 −1.637 11.164 12.051 1.00 22.16 C ATOM 627 O TYR 100 −2.120 10.375 11.240 1.00 20.79 O ATOM 628 N THR 101 −2.375 11.980 12.789 1.00 22.43 N ATOM 629 CA THR 101 −3.818 11.949 12.659 1.00 20.93 C ATOM 630 CB THR 101 −4.501 12.622 13.867 1.00 20.70 C ATOM 631 OG1 THR 101 −4.220 11.862 15.049 1.00 21.16 O ATOM 632 CG2 THR 101 −6.013 12.703 13.661 1.00 19.19 C ATOM 633 C THR 101 −4.176 12.684 11.382 1.00 20.33 C ATOM 634 O THR 101 −4.980 12.199 10.583 1.00 19.32 O ATOM 635 N MET 102 −3.551 13.843 11.186 1.00 20.81 N ATOM 636 CA MET 102 −3.803 14.664 10.006 1.00 21.77 C ATOM 637 CB MET 102 −3.128 16.031 10.119 1.00 22.96 C ATOM 638 CG MET 102 −3.563 16.875 11.305 1.00 25.26 C ATOM 639 SD MET 102 −2.691 18.457 11.303 1.00 26.02 S ATOM 640 CE MET 102 −1.054 17.961 11.843 1.00 25.10 C ATOM 641 C MET 102 −3.326 13.982 8.735 1.00 21.84 C ATOM 642 O MET 102 −3.959 14.101 7.689 1.00 22.57 O ATOM 643 N ILE 103 −2.215 13.259 8.828 1.00 20.60 N ATOM 644 CA ILE 103 −1.672 12.580 7.664 1.00 20.83 C ATOM 645 CB ILE 103 −0.220 12.115 7.937 1.00 21.14 C ATOM 646 CG2 ILE 103 0.262 11.190 6.832 1.00 20.31 C ATOM 647 CG1 ILE 103 0.685 13.350 8.046 1.00 20.27 C ATOM 648 CD1 ILE 103 2.144 13.056 8.323 1.00 20.70 C ATOM 649 C ILE 103 −2.568 11.414 7.248 1.00 20.54 C ATOM 650 O ILE 103 −2.897 11.288 6.072 1.00 20.36 O ATOM 651 N TYR 104 −2.974 10.569 8.194 1.00 20.06 N ATOM 652 CA TYR 104 −3.879 9.475 7.843 1.00 18.57 C ATOM 653 CB TYR 104 −4.007 8.411 8.939 1.00 17.25 C ATOM 654 CG TYR 104 −2.810 7.512 9.145 1.00 18.10 C ATOM 655 CD1 TYR 104 −2.836 6.214 8.649 1.00 19.08 C ATOM 656 CE1 TYR 104 −1.795 5.339 8.849 1.00 18.97 C ATOM 657 CD2 TYR 104 −1.688 7.920 9.851 1.00 17.72 C ATOM 658 CE2 TYR 104 −0.621 7.043 10.059 1.00 20.75 C ATOM 659 CZ TYR 104 −0.691 5.746 9.551 1.00 20.88 C ATOM 660 OH TYR 104 0.323 4.835 9.749 1.00 19.81 O ATOM 661 C TYR 104 −5.259 9.907 7.370 1.00 19.95 C ATOM 662 O TYR 104 −5.991 9.105 6.794 1.00 21.99 O ATOM 663 N ARG 105 −5.626 11.162 7.602 1.00 17.59 N ATOM 664 CA ARG 105 −6.915 11.623 7.121 1.00 17.20 C ATOM 665 CB ARG 105 −7.491 12.768 7.959 1.00 16.31 C ATOM 666 CG ARG 105 −7.847 12.404 9.383 1.00 17.10 C ATOM 667 CD ARG 105 −8.413 13.609 10.125 1.00 16.21 C ATOM 668 NE ARG 105 −8.799 13.284 11.495 1.00 16.48 N ATOM 669 CZ ARG 105 −9.313 14.159 12.358 1.00 19.13 C ATOM 670 NH1 ARG 105 −9.495 15.427 12.003 1.00 17.52 N ATOM 671 NH2 ARG 105 −9.676 13.760 13.572 1.00 19.14 N ATOM 672 C ARG 105 −6.798 12.023 5.663 1.00 17.20 C ATOM 673 O ARG 105 −7.789 12.336 5.021 1.00 16.63 O ATOM 674 N ASN 106 −5.574 11.989 5.147 1.00 19.37 N ATOM 675 CA ASN 106 −5.302 12.366 3.766 1.00 20.38 C ATOM 676 CB ASN 106 −4.507 13.663 3.704 1.00 20.43 C ATOM 677 CG ASN 106 −5.251 14.812 4.339 1.00 20.58 C ATOM 678 OD1 ASN 106 −6.143 15.390 3.723 1.00 23.31 O ATOM 679 ND2 ASN 106 −4.885 15.160 5.562 1.00 17.80 N ATOM 680 C ASN 106 −4.659 11.281 2.919 1.00 21.95 C ATOM 681 O ASN 106 −4.027 11.558 1.896 1.00 20.86 O ATOM 682 N LEU 107 −4.823 10.042 3.361 1.00 21.77 N ATOM 683 CA LEU 107 −4.264 8.899 2.666 1.00 21.73 C ATOM 684 CB LEU 107 −2.737 8.860 2.832 1.00 20.40 C ATOM 685 CG LEU 107 −2.118 8.762 4.235 1.00 19.18 C ATOM 686 CD1 LEU 107 −2.558 7.498 4.968 1.00 18.29 C ATOM 687 CD2 LEU 107 −0.602 8.811 4.171 1.00 16.48 C ATOM 688 C LEU 107 −4.943 7.622 3.150 1.00 24.57 C ATOM 689 O LEU 107 −5.476 7.574 4.261 1.00 26.59 O ATOM 690 N VAL 108 −4.950 6.604 2.300 1.00 24.85 N ATOM 691 CA VAL 108 −5.535 5.314 2.637 1.00 23.27 C ATOM 692 CB VAL 108 −6.585 4.884 1.594 1.00 25.05 C ATOM 693 CG1 VAL 108 −6.727 3.374 1.592 1.00 26.97 C ATOM 694 CG2 VAL 108 −7.923 5.523 1.917 1.00 23.65 C ATOM 695 C VAL 108 −4.435 4.259 2.704 1.00 22.36 C ATOM 696 O VAL 108 −3.534 4.240 1.866 1.00 23.25 O ATOM 697 N VAL 109 −4.494 3.397 3.714 1.00 21.67 N ATOM 698 CA VAL 109 −3.504 2.336 3.865 1.00 20.80 C ATOM 699 CB VAL 109 −3.455 1.801 5.316 1.00 19.45 C ATOM 700 CG1 VAL 109 −2.544 0.583 5.389 1.00 17.84 C ATOM 701 CG2 VAL 109 −2.941 2.892 6.256 1.00 18.14 C ATOM 702 C VAL 109 −3.787 1.173 2.910 1.00 21.74 C ATOM 703 O VAL 109 −4.915 0.696 2.811 1.00 22.57 O ATOM 704 N VAL 110 −2.754 0.739 2.195 1.00 22.61 N ATOM 705 CA VAL 110 −2.871 −0.365 1.249 1.00 23.79 C ATOM 706 CB VAL 110 −1.791 −0.279 0.158 1.00 22.99 C ATOM 707 CG1 VAL 110 −1.997 −1.377 −0.864 1.00 23.58 C ATOM 708 CG2 VAL 110 −1.828 1.081 −0.495 1.00 24.01 C ATOM 709 C VAL 110 −2.722 −1.703 1.961 1.00 24.53 C ATOM 710 O VAL 110 −3.639 −2.521 1.944 1.00 28.90 O ATOM 711 OH2 WAT 901 6.275 31.112 15.565 1.00 15.47 O ATOM 712 OH2 WAT 902 0.081 30.036 10.221 1.00 17.32 O ATOM 713 OH2 WAT 903 0.127 15.519 19.408 1.00 7.93 O ATOM 714 OH2 WAT 904 7.030 2.992 5.951 1.00 1.12 O ATOM 715 OH2 WAT 905 −8.260 9.003 4.793 1.00 16.56 O ATOM 716 OH2 WAT 906 −0.287 23.410 17.398 1.00 20.45 O ATOM 717 OH2 WAT 907 11.907 15.641 5.635 1.00 12.75 O ATOM 718 OH2 WAT 908 6.231 3.121 −2.803 1.00 30.59 O ATOM 719 OH2 WAT 909 14.427 27.473 −1.777 1.00 32.06 O ATOM 720 OH2 WAT 910 1.367 29.323 5.015 1.00 30.79 O ATOM 721 OH2 WAT 911 −3.588 −4.814 0.678 1.00 24.03 O ATOM 722 OH2 WAT 912 3.828 6.836 −11.268 1.00 35.90 O ATOM 723 OH2 WAT 913 8.152 2.609 8.906 1.00 34.73 O ATOM 724 OH2 WAT 914 2.691 4.733 10.966 1.00 33.58 O ATOM 725 OH2 WAT 916 −5.458 26.444 7.758 1.00 45.56 O ATOM 726 OH2 WAT 917 −8.076 13.274 16.506 1.00 48.77 O ATOM 727 OH2 WAT 918 −7.491 17.267 10.217 1.00 40.88 O ATOM 728 OH2 WAT 919 −3.101 7.362 −4.725 1.00 53.52 O ATOM 729 OH2 WAT 920 1.887 19.751 −8.003 1.00 32.67 O ATOM 730 OH2 WAT 921 −8.379 15.505 −1.840 1.00 19.94 O ATOM 731 OH2 WAT 922 12.181 19.059 −4.016 1.00 25.92 O ATOM 732 OH2 WAT 923 −8.305 16.544 7.450 1.00 29.31 O ATOM 733 OH2 WAT 924 −10.379 14.823 6.843 1.00 19.67 O ATOM 734 C1 SCH 999 14.935 15.343 10.195 1.00 58.18 C ATOM 735 C2 SCH 999 13.897 15.023 11.252 1.00 58.15 C ATOM 736 O1 SCH 999 14.212 14.616 12.373 1.00 58.19 O ATOM 737 N1 SCH 999 12.629 15.230 10.832 1.00 57.26 N ATOM 738 C3 SCH 999 11.571 15.353 11.839 1.00 54.45 C ATOM 739 C4 SCH 999 10.855 14.032 12.129 1.00 55.03 C ATOM 740 O2 SCH 999 11.268 12.976 11.642 1.00 55.46 O ATOM 741 N2 SCH 999 9.780 14.154 12.934 1.00 56.28 N ATOM 742 C5 SCH 999 9.102 12.951 13.392 1.00 58.10 C ATOM 743 C6 SCH 999 10.025 12.199 14.360 1.00 59.43 C ATOM 744 O3 SCH 999 10.530 11.115 14.068 1.00 59.32 O ATOM 745 N3 SCH 999 10.203 12.847 15.527 1.00 61.53 N ATOM 746 C7 SCH 999 11.400 12.542 16.310 1.00 62.93 C ATOM 747 C8 SCH 999 11.113 11.660 17.534 1.00 62.40 C ATOM 748 O4 SCH 999 11.912 11.709 18.416 1.00 60.48 O ATOM 749 O5 SCH 999 10.616 10.479 17.100 1.00 62.41 O ATOM 750 C9 SCH 999 10.586 16.476 11.453 1.00 49.76 C ATOM 751 C10 SCH 999 12.105 13.839 16.718 1.00 64.21 C ATOM 752 C11 SCH 999 13.629 13.756 16.707 1.00 65.67 C ATOM 753 C12 SCH 999 14.196 14.646 17.803 1.00 66.24 C ATOM 754 O6 SCH 999 14.526 15.775 17.594 1.00 66.36 O ATOM 755 O7 SCH 999 14.290 14.052 19.016 1.00 65.17 O ATOM 756 C13 SCH 999 9.685 16.072 10.295 1.00 46.19 C ATOM 757 C14 SCH 999 8.313 16.472 10.068 1.00 43.66 C ATOM 758 C15 SCH 999 7.872 15.829 8.846 1.00 42.20 C ATOM 759 N4 SCH 999 8.951 15.079 8.368 1.00 43.85 N ATOM 760 C16 SCH 999 10.006 15.227 9.219 1.00 44.78 C ATOM 761 C17 SCH 999 7.411 17.318 10.780 1.00 43.03 C ATOM 762 C18 SCH 999 6.085 17.525 10.294 1.00 39.51 C ATOM 763 C19 SCH 999 5.651 16.887 9.095 1.00 39.12 C ATOM 764 C20 SCH 999 6.542 16.041 8.370 1.00 40.06 C ATOM 765 CL1 SCH 999 4.034 17.133 8.522 1.00 34.69 CL ATOM 766 C21 SCH 999 8.779 12.041 12.203 1.00 57.67 C ATOM 767 C22 SCH 999 7.820 13.335 14.135 1.00 58.12 C ATOM 768 C23 SCH 999 6.793 13.968 13.201 1.00 56.83 C ATOM 769 C24 SCH 999 7.749 12.676 11.271 1.00 57.14 C ATOM 770 C25 SCH 999 6.477 13.064 12.015 1.00 56.55 C END

The present invention is not to be limited in scope by the specific embodiments describe herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties. 

1. A polypeptide comprising the amino acid sequence of SEQ ID NO: 4; wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 conservative amino acid substitutions that are not at one of the seven variable positions of SEQ ID NO:
 4. 2. The polypeptide according to claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12; wherein any one of said amino acid sequences optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of said conservative amino acid substitutions.
 3. The polypeptide according to claim 2, wherein said polypeptide optionally comprises 1, 2, or 3 of said conservative amino acid substitutions.
 4. The polypeptide according to claim 3, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO:
 12. 5. The polypeptide according to claim 4, wherein said polypeptide consists of the amino acid sequence of selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO:
 10. 6. A nucleic acid encoding the polypeptide according to claim
 1. 7. The nucleic acid according to claim 6 comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO:
 11. 8. An expression vector comprising the nucleic acid according to claim 7, wherein said expression vector further comprises a transcriptional control sequence operatively linked to the nucleic acid.
 9. A host cell comprising the expression vector according to claim
 8. 10. A method for producing a modified Hdm2 protein, comprising culturing the host cell according to claim 9 in a culture medium under conditions in which the nucleic acid encoding the modified Hdm2 protein is expressed.
 11. The method according to claim 10 wherein the host cell is an E. coli cell.
 12. A method of obtaining a purified modified Hdm2 protein, comprising purifying the modified Hdm2 protein produced by the method according to claim 10 from the culture medium.
 13. A method for identifying an agent for use as an inhibitor of Hdm2 comprising: (a) contacting the potential agent with the polypeptide according to claim 1 and a p53 substrate; and (b) determining the ability of the polypeptide to bind to the p53 substrate; wherein a potential agent is identified as an agent that inhibits Hdm2 when there is a decrease in the binding of the polypeptide and the p53 substrate in the presence of the agent relative to in its absence.
 14. A compound selected from the group consisting of and


15. A polypeptide-compound complex comprising the compound according to claim 14 and a polypeptide complexed to it, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4, wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 conservative amino acid substitutions that are not at one of the seven variable positions of SEQ ID NO:
 4. 16. A crystal comprising a polypeptide, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4, wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 conservative amino acid substitutions that are not at one of the seven variable positions of SEQ ID NO:
 4. 17. The crystal according to claim 16, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12; wherein any one of said amino acid sequences optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 of said conservative amino acid substitutions.
 18. The crystal according to claim 17, wherein said polypeptide optionally comprises 1, 2, or 3 of said conservative amino acid substitutions.
 19. The crystal according to claim 18, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO:
 12. 20. The crystal according to claim 19, wherein said polypeptide consists essentially of the amino acid sequence of selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO:
 10. 21. The crystal according to either of claims 16 or 20, wherein said crystal effectively diffracts X-rays to a resolution of greater than 5.0 Å.
 22. The crystal according to claim 21, wherein said crystal effectively diffracts X-rays to a resolution of greater than 2.5 Å.
 23. The crystal according to claim 22, wherein said crystal effectively diffracts X-rays to a resolution of greater than 1.5 Å.
 24. The crystal according to either of claims 16 or 20, wherein said polypeptide is complexed to a compound that binds said polypeptide and forms a polypeptide-compound complex.
 25. The crystal according to claim 24, wherein said compound is selected from the group consisting of a peptide derived from p53, SCH549128, Ac-^(6Cl)WAC_(3c)E and Ac-^(6Br)WAC_(3c)E.
 26. The crystal according to claim 16, wherein said polypeptide consists of the amino acid of SEQ ID NO: 10 and said crystal has the structural coordinates as set forth in Table
 3. 27. The crystal according to claim 16, wherein said polypeptide consists of the amino acid of SEQ ID NO: 6 and said crystal has the structural coordinates as set forth in Table
 4. 28. A crystal comprising a polypeptide, wherein said polypeptide is characterized by structure coordinates comprising a root mean square deviation (RMSD) of conserved residue backbone atoms of less than about 2.0 Å when superimposed on backbone atoms described by structural coordinates of Table 3 or Table
 4. 29. The crystal according to claim 28, wherein-said-RMSD is less than about 1.5 Å.
 30. The crystal according to claim 29, wherein said RMSD is less than about 1.0 Å.
 31. The crystal according to claim 30, wherein said RMSD is less than about 0.5 Å.
 32. The crystal according to claim 28, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 4, wherein at least one of the seven variable positions of SEQ ID NO: 4 has an amino acid residue that differs from that of the corresponding wild-type Hdm2(17-125) amino acid sequence (SEQ ID NO: 2); and wherein said polypeptide optionally comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 conservative amino acid substitutions that are not at one of the seven variable positions of SEQ ID NO:
 4. 33. The crystal according to claim 32, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO:
 12. 34. A method for producing a crystal comprising the polypeptide according to claim 1, comprising a) providing said polypeptide; and b) incubating said polypeptide under conditions in which a crystal of said polypeptide is formed.
 35. The method according to claim 34, wherein said providing comprises providing a solution comprising said polypeptide; and said incubating comprises (i) mixing said solution with a precipitant to produce a polypeptide-precipitant mixture; and (ii) incubating said mixture in a sealed container in close proximity to a reservoir of said precipitant under conditions in which a crystal of said polypeptide is formed.
 36. The method according to claim 35, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO:
 12. 37. The method according to claim 36, wherein said polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO:
 10. 38. The method according to claim 35, wherein said mixing further comprises mixing a compound that binds said polypeptide with said polypeptide and said mixing forms a polypeptide-compound complex.
 39. The method according to claim 38, wherein said compound is selected from the group consisting of a peptide derived from p53, SCH549128, Ac-^(6Cl)WAC_(3c)E and AC-^(6Br)WAC_(3c)E.
 40. A computer for producing a three-dimensional representation of the polypeptide according to claim 1 or a polypeptide-compound complex that comprises said polypeptide complexed with a compound that binds said polypeptide, wherein said polypeptide or said polypeptide-compound complex has a root mean square deviation from the backbone atoms of Table 3 or 4 of less than about 2.0 Å, wherein said computer comprises: (a) a machine-readable data storage medium comprising a data storage material encoded with machine-readable data, wherein said data comprises the structure coordinates of Table 3 or 4; (b) a working memory for storing instructions for processing said machine-readable data; (c) a central-processing unit coupled to said working memory and to said machine-readable data storage medium for processing said machine readable data into said three-dimensional representation; and (d) a display unit coupled to said central-processing unit for displaying said three-dimensional representation.
 41. The computer according to claim 40, wherein the root mean square deviation between the homologue and the structure coordinates set forth in Table 3 or 4 is less than about 1.5 Å.
 42. The computer according to claim 41, wherein the root mean-square deviation between the homologue and the structure coordinates set forth in Table 3 or 4 is less than about 1.0 Å.
 43. The computer according to claim 42, wherein the root mean square deviation between the homologue and the structure coordinates set forth in Table 3 or 4 is less than about 0.5 Å.
 44. The computer according to claim 40, wherein said polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO:
 12. 45. The computer according to claim 44, wherein said polypeptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NO:
 10. 46. The computer according to claim 40, wherein said polypeptide compound complex comprises a compound selected from the group consisting of a peptide derived from p53, SCH549128, Ac-^(6Cl)WAC_(3c)E and Ac-^(6Br)WAC_(3c)E.
 47. The computer according to claim 40, wherein the display unit is displaying the three dimensional representation.
 48. A method for obtaining structural information concerning a molecule of unknown structure, comprising generating X-ray diffraction data from a crystallized form of the molecule, and applying crystallographic phases derived from at least a portion of structure coordinates set forth in Table 3 or 4 to said X-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule.
 49. A method for designing, selecting and/or optimizing a potential inhibitor of the polypeptide according to claim 1, comprising (a) providing the structure coordinates of said polypeptide or of a polypeptide-compound complex comprising said polypeptide complexed to a compound on a computer comprising the means for generating three-dimensional structural information from said structural coordinates; and (b) designing, selecting and/or optimizing said potential inhibitor by performing a fitting operation between said potential inhibitor and said three-dimensional structural information of said polypeptide or said polypeptide-compound complex.
 50. The method according to claim 49, wherein said structure coordinates are set forth in Table 3 or 4 or comprise a root mean square deviation (RMSD) of conserved residue backbone atoms of less than about 1.5 Å when superimposed on backbone atoms described by structural coordinates of Table 3 or Table
 4. 51. The method according to claim 50, wherein said RMSD is less than about 1.0 Å.
 52. The crystal according to claim 51, wherein said RMSD is less than about 0.5 Å.
 53. The crystal according to claim 52, wherein said RMSD is less than about 0.1 Å.
 54. The method according to claim 50, further comprising after step (b), (c) providing or synthesizing said potential inhibitor; (d) contacting said potential inhibitor with said polypeptide; and (e) determining whether the potential inhibitor binds to said polypeptide and inhibits its activity.
 55. A method for evaluating the ability of a potential inhibitor to associate with the polypeptide according to claim 1 or of a polypeptide-compound complex comprising said polypeptide complexed to a compound, comprising (a) employing computational means to perform a fitting operation between the structure coordinates of the potential inhibitor and the structure coordinates of the polypeptide or polypeptide-compound complex; and (b) analyzing the results of said fitting operation to quantitate the association between the potential inhibitor and the polypeptide or polypeptide-compound complex.
 56. The method according to claim 55, further comprising generating a three-dimensional graphical representation of the polypeptide or polypeptide-compound complex prior to (a).
 57. The method according to claim 55, wherein said structure coordinates are set forth in Table 3 or 4 or comprise a root mean square deviation (RMSD) of conserved residue backbone atoms of less than about 2.0 Å when superimposed on backbone atoms described by structural coordinates of Table 3 or Table
 4. 